메뉴 건너뛰기




Volumn , Issue , 2012, Pages 1097-1121

Human immunodeficiency virus vaccines

Author keywords

[No Author keywords available]

Indexed keywords


EID: 84879100564     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00054-9     Document Type: Chapter
Times cited : (5)

References (867)
  • 1
    • 2442689092 scopus 로고    scopus 로고
    • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies
    • Haigwood N.L., Montefiori D.C., Sutton W.F., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004, 78:5983-5995.
    • (2004) J Virol , vol.78 , pp. 5983-5995
    • Haigwood, N.L.1    Montefiori, D.C.2    Sutton, W.F.3
  • 2
    • 84902046259 scopus 로고    scopus 로고
    • The Thai VaxGen Trial: What have we learned?
    • Horizon Press, Norkfolk, UK, W. Koff, P. Kahn, I. Gust (Eds.)
    • Beyrer C. The Thai VaxGen Trial: What have we learned?. AIDS Vaccine Development: Challenges and Opportunities 2007, 111-116. Horizon Press, Norkfolk, UK. W. Koff, P. Kahn, I. Gust (Eds.).
    • (2007) AIDS Vaccine Development: Challenges and Opportunities , pp. 111-116
    • Beyrer, C.1
  • 3
    • 79952445068 scopus 로고    scopus 로고
    • Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
    • Rolland M., Tovanabutra S., Decamp A.C., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371.
    • (2011) Nat Med , vol.17 , pp. 366-371
    • Rolland, M.1    Tovanabutra, S.2    Decamp, A.C.3
  • 4
    • 77955517683 scopus 로고    scopus 로고
    • HIV vaccines: lessons learned and the way forward
    • Kim J.H., Rerks-Ngarm S., Excler J.L., et al. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010, 5:428-434.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 428-434
    • Kim, J.H.1    Rerks-Ngarm, S.2    Excler, J.L.3
  • 5
    • 79953019952 scopus 로고    scopus 로고
    • Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials
    • Gilbert P.B., Berger J.O., Stablein D., et al. Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011, 203:969-975.
    • (2011) J Infect Dis , vol.203 , pp. 969-975
    • Gilbert, P.B.1    Berger, J.O.2    Stablein, D.3
  • 6
    • 77949263061 scopus 로고    scopus 로고
    • Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
    • Barouch D.H., O'Brien K.L., Simmons N.L., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
    • (2010) Nat Med , vol.16 , pp. 319-323
    • Barouch, D.H.1    O'Brien, K.L.2    Simmons, N.L.3
  • 7
    • 67649338409 scopus 로고    scopus 로고
    • Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
    • Gudmundsdotter L., Nilsson C., Brave A., et al. Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27:4468-4474.
    • (2009) Vaccine , vol.27 , pp. 4468-4474
    • Gudmundsdotter, L.1    Nilsson, C.2    Brave, A.3
  • 8
    • 44749088148 scopus 로고    scopus 로고
    • EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
    • McCormack S., Stohr W., Barber T., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.
    • (2008) Vaccine , vol.26 , pp. 3162-3174
    • McCormack, S.1    Stohr, W.2    Barber, T.3
  • 9
    • 78650311033 scopus 로고    scopus 로고
    • Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine
    • Papagno L., Alter G., Assoumou L., et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011, 25:27-36.
    • (2011) AIDS , vol.25 , pp. 27-36
    • Papagno, L.1    Alter, G.2    Assoumou, L.3
  • 10
    • 77955067596 scopus 로고    scopus 로고
    • The renaissance in HIV vaccine development: future directions
    • Koff W.C., Berkley S.F. The renaissance in HIV vaccine development: future directions. N Engl J Med 2010, 363:e7.
    • (2010) N Engl J Med , vol.363
    • Koff, W.C.1    Berkley, S.F.2
  • 11
    • 0019782357 scopus 로고
    • Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency
    • Gottlieb M.S., Schroff R., Schanker H.M., et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
    • (1981) N Engl J Med , vol.305 , pp. 1425-1431
    • Gottlieb, M.S.1    Schroff, R.2    Schanker, H.M.3
  • 12
    • 0019774135 scopus 로고
    • An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction
    • Masur H., Michelis M.A., Greene J.B., et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
    • (1981) N Engl J Med , vol.305 , pp. 1431-1438
    • Masur, H.1    Michelis, M.A.2    Greene, J.B.3
  • 13
    • 0032546969 scopus 로고    scopus 로고
    • The science of AIDS: a tale of two worlds
    • Piot P. The science of AIDS: a tale of two worlds. Science 1998, 280:1844-1845.
    • (1998) Science , vol.280 , pp. 1844-1845
    • Piot, P.1
  • 14
    • 78349233841 scopus 로고    scopus 로고
    • Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission
    • Weber J., Tatoud R., Fidler S. Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. AIDS 2010, 24(suppl. 4):S27-S39.
    • (2010) AIDS , vol.24 , Issue.SUPPL.. 4
    • Weber, J.1    Tatoud, R.2    Fidler, S.3
  • 15
    • 28444460441 scopus 로고    scopus 로고
    • Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial
    • Auvert B., Taljaard D., Lagarde E., et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005, 2:e298.
    • (2005) PLoS Med , vol.2
    • Auvert, B.1    Taljaard, D.2    Lagarde, E.3
  • 16
    • 58749101526 scopus 로고    scopus 로고
    • Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics
    • Warner L., Ghanem K.G., Newman D.R., et al. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis 2009, 199:59-65.
    • (2009) J Infect Dis , vol.199 , pp. 59-65
    • Warner, L.1    Ghanem, K.G.2    Newman, D.R.3
  • 17
    • 77955930318 scopus 로고    scopus 로고
    • Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    • Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
    • (2010) Science , vol.329 , pp. 1168-1174
    • Abdool Karim, Q.1    Abdool Karim, S.S.2    Frohlich, J.A.3
  • 18
    • 34249792153 scopus 로고    scopus 로고
    • Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure
    • CD002835
    • Young T.N., Arens F.J., Kennedy G.E., et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev 2007, 1. CD002835.
    • (2007) Cochrane Database Syst Rev , vol.1
    • Young, T.N.1    Arens, F.J.2    Kennedy, G.E.3
  • 19
    • 77956403366 scopus 로고    scopus 로고
    • Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination
    • Sellier P., Mannioui A., Bourry O., et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One 2010, 5:e10570.
    • (2010) PLoS One , vol.5
    • Sellier, P.1    Mannioui, A.2    Bourry, O.3
  • 20
    • 77953293984 scopus 로고    scopus 로고
    • Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    • Donnell D., Baeten J.M., Kiarie J., et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010, 375:2092-2098.
    • (2010) Lancet , vol.375 , pp. 2092-2098
    • Donnell, D.1    Baeten, J.M.2    Kiarie, J.3
  • 21
    • 78650549662 scopus 로고    scopus 로고
    • Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    • Grant R.M., Lama J.R., Anderson P.L., et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599.
    • (2010) N Engl J Med , vol.363 , pp. 2587-2599
    • Grant, R.M.1    Lama, J.R.2    Anderson, P.L.3
  • 22
    • 41849117498 scopus 로고    scopus 로고
    • Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection
    • CD003510
    • Volmink J., Siegfried N.L., van der Merwe L., et al. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007, 1. CD003510.
    • (2007) Cochrane Database Syst Rev , vol.1
    • Volmink, J.1    Siegfried, N.L.2    van der Merwe, L.3
  • 23
    • 34247872923 scopus 로고    scopus 로고
    • Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection
    • Suksomboon N., Poolsup N., Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther 2007, 32:293-311.
    • (2007) J Clin Pharm Ther , vol.32 , pp. 293-311
    • Suksomboon, N.1    Poolsup, N.2    Ket-Aim, S.3
  • 24
    • 34548398653 scopus 로고    scopus 로고
    • Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach
    • Tonwe-Gold B., Ekouevi D.K., Viho I., et al. Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. PLoS Med 2007, 4:e257.
    • (2007) PLoS Med , vol.4
    • Tonwe-Gold, B.1    Ekouevi, D.K.2    Viho, I.3
  • 25
    • 77953723667 scopus 로고    scopus 로고
    • Maternal or infant antiretroviral drugs to reduce HIV-1 transmission
    • Chasela C.S., Hudgens M.G., Jamieson D.J., et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010, 362:2271-2281.
    • (2010) N Engl J Med , vol.362 , pp. 2271-2281
    • Chasela, C.S.1    Hudgens, M.G.2    Jamieson, D.J.3
  • 26
    • 0035834497 scopus 로고    scopus 로고
    • HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda
    • Ahmed S., Lutalo T., Wawer M., et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS 2001, 15:2171-2179.
    • (2001) AIDS , vol.15 , pp. 2171-2179
    • Ahmed, S.1    Lutalo, T.2    Wawer, M.3
  • 27
    • 27644524761 scopus 로고    scopus 로고
    • HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir
    • Chun T.W., Nickle D.C., Justement J.S., et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005, 115:3250-3255.
    • (2005) J Clin Invest , vol.115 , pp. 3250-3255
    • Chun, T.W.1    Nickle, D.C.2    Justement, J.S.3
  • 28
    • 28044456980 scopus 로고    scopus 로고
    • The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years
    • Gallo R.C. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 2005, 366:1894-1898.
    • (2005) Lancet , vol.366 , pp. 1894-1898
    • Gallo, R.C.1
  • 29
    • 33644822414 scopus 로고    scopus 로고
    • Pathogenesis of HIV infection: what the virus spares is as important as what it destroys
    • Grossman Z., Meier-Schellersheim M., Paul W.E., et al. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.
    • (2006) Nat Med , vol.12 , pp. 289-295
    • Grossman, Z.1    Meier-Schellersheim, M.2    Paul, W.E.3
  • 30
    • 0034699512 scopus 로고    scopus 로고
    • Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
    • Allen T.M., O'Connor D.H., Jing P., et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000, 407:386-390.
    • (2000) Nature , vol.407 , pp. 386-390
    • Allen, T.M.1    O'Connor, D.H.2    Jing, P.3
  • 31
    • 0036181249 scopus 로고    scopus 로고
    • Viral persistence: HIV's strategies of immune system evasion
    • Johnson W.E., Desrosiers R.C. Viral persistence: HIV's strategies of immune system evasion. Annu Rev Med 2002, 53:499-518.
    • (2002) Annu Rev Med , vol.53 , pp. 499-518
    • Johnson, W.E.1    Desrosiers, R.C.2
  • 32
    • 0037389643 scopus 로고    scopus 로고
    • Rapid evolution of the neutralizing antibody response to HIV type 1 infection
    • Richman D.D., Wrin T., Little S.J., et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003, 100:4144-4149.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 4144-4149
    • Richman, D.D.1    Wrin, T.2    Little, S.J.3
  • 33
    • 2342540480 scopus 로고    scopus 로고
    • HIV escape: there and back again
    • Altman J.D., Feinberg M.B. HIV escape: there and back again. Nat Med 2004, 10:229-230.
    • (2004) Nat Med , vol.10 , pp. 229-230
    • Altman, J.D.1    Feinberg, M.B.2
  • 34
    • 3543078012 scopus 로고    scopus 로고
    • HIV and SIV CTL escape: implications for vaccine design
    • Goulder P.J., Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 2004, 4:630-640.
    • (2004) Nat Rev Immunol , vol.4 , pp. 630-640
    • Goulder, P.J.1    Watkins, D.I.2
  • 35
    • 67449147145 scopus 로고    scopus 로고
    • The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    • Goonetilleke N., Liu M.K., Salazar-Gonzalez J.F., et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206:1253-1272.
    • (2009) J Exp Med , vol.206 , pp. 1253-1272
    • Goonetilleke, N.1    Liu, M.K.2    Salazar-Gonzalez, J.F.3
  • 36
    • 0029875421 scopus 로고    scopus 로고
    • Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
    • Schwartz O., Marechal V., Le Gall S., et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996, 2:338-342.
    • (1996) Nat Med , vol.2 , pp. 338-342
    • Schwartz, O.1    Marechal, V.2    Le Gall, S.3
  • 37
    • 0032556872 scopus 로고    scopus 로고
    • HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
    • Collins K.L., Chen B.K., Kalams S.A., et al. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998, 391:397-401.
    • (1998) Nature , vol.391 , pp. 397-401
    • Collins, K.L.1    Chen, B.K.2    Kalams, S.A.3
  • 38
    • 0035885920 scopus 로고    scopus 로고
    • Dressed to kill? a review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection
    • Lieberman J., Shankar P., Manjunath N., et al. Dressed to kill? a review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001, 98:1667-1677.
    • (2001) Blood , vol.98 , pp. 1667-1677
    • Lieberman, J.1    Shankar, P.2    Manjunath, N.3
  • 39
    • 0034600786 scopus 로고    scopus 로고
    • HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
    • Appay V., Nixon D.F., Donahoe S.M., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000, 192:63-75.
    • (2000) J Exp Med , vol.192 , pp. 63-75
    • Appay, V.1    Nixon, D.F.2    Donahoe, S.M.3
  • 40
    • 0035130059 scopus 로고    scopus 로고
    • Functional impairment of simian immunodeficiency virus-specific CD8 + T cells during the chronic phase of infection
    • Vogel T.U., Allen T.M., Altman J.D., et al. Functional impairment of simian immunodeficiency virus-specific CD8 + T cells during the chronic phase of infection. J Virol 2001, 75:2458-2461.
    • (2001) J Virol , vol.75 , pp. 2458-2461
    • Vogel, T.U.1    Allen, T.M.2    Altman, J.D.3
  • 41
    • 33646163652 scopus 로고    scopus 로고
    • A review of vaccine research and development: the human immunodeficiency virus (HIV)
    • Girard M.P., Osmanov S.K., Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24:4062-4081.
    • (2006) Vaccine , vol.24 , pp. 4062-4081
    • Girard, M.P.1    Osmanov, S.K.2    Kieny, M.P.3
  • 42
    • 36148973173 scopus 로고    scopus 로고
    • HIV/AIDS vaccines: 2007
    • Robinson H.L. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 2007, 82:686-893.
    • (2007) Clin Pharmacol Ther , vol.82 , pp. 686-893
    • Robinson, H.L.1
  • 43
    • 57449098504 scopus 로고    scopus 로고
    • HIV/AIDS vaccines: a need for new concepts?
    • Girard M.P., Bansal G.P. HIV/AIDS vaccines: a need for new concepts?. Int Rev Immunol 2008, 27:447-471.
    • (2008) Int Rev Immunol , vol.27 , pp. 447-471
    • Girard, M.P.1    Bansal, G.P.2
  • 45
    • 79952787740 scopus 로고    scopus 로고
    • Human immunodeficiency virus-1 vaccine design: where do we go now?
    • Wijesundara D.K., Jackson R.J., Ramshaw I.A., et al. Human immunodeficiency virus-1 vaccine design: where do we go now?. Immunol Cell Biol 2011, 89:367-374.
    • (2011) Immunol Cell Biol , vol.89 , pp. 367-374
    • Wijesundara, D.K.1    Jackson, R.J.2    Ramshaw, I.A.3
  • 46
    • 77952311370 scopus 로고    scopus 로고
    • The role of antibodies in HIV vaccines
    • Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010, 28:413-444.
    • (2010) Annu Rev Immunol , vol.28 , pp. 413-444
    • Mascola, J.R.1    Montefiori, D.C.2
  • 47
    • 77951918976 scopus 로고    scopus 로고
    • Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference
    • Ross A.L., Brave A., Scarlatti G., et al. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis 2010, 10:305-316.
    • (2010) Lancet Infect Dis , vol.10 , pp. 305-316
    • Ross, A.L.1    Brave, A.2    Scarlatti, G.3
  • 48
    • 77958490167 scopus 로고    scopus 로고
    • Induction of immunity to human immunodeficiency virus type-1 by vaccination
    • McElrath M.J., Haynes B.F. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 2010, 33:542-554.
    • (2010) Immunity , vol.33 , pp. 542-554
    • McElrath, M.J.1    Haynes, B.F.2
  • 49
    • 80051564046 scopus 로고    scopus 로고
    • Vaccine. Human immunodeficiency virus (HIV) vaccine development: a review
    • Girard M., Osmanov S., Assossou O., et al. Vaccine. Human immunodeficiency virus (HIV) vaccine development: a review. Vaccine 2011, 29:6191-6218.
    • (2011) Vaccine , vol.29 , pp. 6191-6218
    • Girard, M.1    Osmanov, S.2    Assossou, O.3
  • 50
    • 73349094086 scopus 로고    scopus 로고
    • Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    • Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
    • (2009) N Engl J Med , vol.361 , pp. 2209-2220
    • Rerks-Ngarm, S.1    Pitisuttithum, P.2    Nitayaphan, S.3
  • 51
    • 76749132657 scopus 로고    scopus 로고
    • Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances
    • Bansal G.P., Malaspina A., Flores J. Future paths for HIV vaccine research: exploiting results from recent clinical trials and current scientific advances. Curr Opin Mol Ther 2010, 12:39-46.
    • (2010) Curr Opin Mol Ther , vol.12 , pp. 39-46
    • Bansal, G.P.1    Malaspina, A.2    Flores, J.3
  • 52
    • 0020596551 scopus 로고
    • Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)
    • Barre-Sinoussi F., Chermann J.C., Rey F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
    • (1983) Science , vol.220 , pp. 868-871
    • Barre-Sinoussi, F.1    Chermann, J.C.2    Rey, F.3
  • 53
    • 0021237243 scopus 로고
    • Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
    • Popovic M., Sarngadharan M.G., Read E., et al. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224:497-500.
    • (1984) Science , vol.224 , pp. 497-500
    • Popovic, M.1    Sarngadharan, M.G.2    Read, E.3
  • 54
    • 0021150629 scopus 로고
    • Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS
    • Levy J.A., Hoffman A.D., Kramer S.M., et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984, 225:840-842.
    • (1984) Science , vol.225 , pp. 840-842
    • Levy, J.A.1    Hoffman, A.D.2    Kramer, S.M.3
  • 55
    • 0023272187 scopus 로고
    • Human immunodeficiency virus type 2 infection associated with AIDS in West Africa
    • Clavel F., Mansinho K., Chamaret S., et al. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med 1987, 316:1180-1185.
    • (1987) N Engl J Med , vol.316 , pp. 1180-1185
    • Clavel, F.1    Mansinho, K.2    Chamaret, S.3
  • 56
    • 84881194271 scopus 로고    scopus 로고
    • Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus
    • Briggs J.A., Johnson M.C., Simon M.N., et al. Cryo-electron microscopy reveals conserved and divergent features of gag packing in immature particles of Rous sarcoma virus and human immunodeficiency virus. J Mol Biol 2006, 355:157-168.
    • (2006) J Mol Biol , vol.355 , pp. 157-168
    • Briggs, J.A.1    Johnson, M.C.2    Simon, M.N.3
  • 57
    • 0036133058 scopus 로고    scopus 로고
    • Directed egress of animal viruses promotes cell-to-cell spread
    • Johnson D.C., Huber M.T. Directed egress of animal viruses promotes cell-to-cell spread. J Virol 2002, 76:1-8.
    • (2002) J Virol , vol.76 , pp. 1-8
    • Johnson, D.C.1    Huber, M.T.2
  • 58
    • 0038025223 scopus 로고    scopus 로고
    • Recruitment of HIV and its receptors to dendritic cell-T cell junctions
    • McDonald D., Wu L., Bohks S.M., et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297.
    • (2003) Science , vol.300 , pp. 1295-1297
    • McDonald, D.1    Wu, L.2    Bohks, S.M.3
  • 59
    • 1642540589 scopus 로고    scopus 로고
    • HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse
    • Jolly C., Kashefi K., Hollinshead M., et al. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med 2004, 199:283-293.
    • (2004) J Exp Med , vol.199 , pp. 283-293
    • Jolly, C.1    Kashefi, K.2    Hollinshead, M.3
  • 60
    • 77955781209 scopus 로고    scopus 로고
    • 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells
    • Felts R.L., Narayan K., Estes J.D., et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A 2010, 107:13336-13341.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 13336-13341
    • Felts, R.L.1    Narayan, K.2    Estes, J.D.3
  • 61
    • 36049037370 scopus 로고    scopus 로고
    • Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses
    • Chen P., Hubner W., Spinelli M.A., et al. Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses. J Virol 2007, 81:12582-12595.
    • (2007) J Virol , vol.81 , pp. 12582-12595
    • Chen, P.1    Hubner, W.2    Spinelli, M.A.3
  • 62
    • 77950845174 scopus 로고    scopus 로고
    • SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse
    • Gonzalez N., Bermejo M., Calonge E., et al. SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell-T-cell infectious synapse. J Virol 2010, 84:4341-4351.
    • (2010) J Virol , vol.84 , pp. 4341-4351
    • Gonzalez, N.1    Bermejo, M.2    Calonge, E.3
  • 63
    • 0035220578 scopus 로고    scopus 로고
    • Gp120: Biologic aspects of structural features
    • Poignard P., Saphire E.O., Parren P.W., et al. gp120: Biologic aspects of structural features. Annu Rev Immunol 2001, 19:253-274.
    • (2001) Annu Rev Immunol , vol.19 , pp. 253-274
    • Poignard, P.1    Saphire, E.O.2    Parren, P.W.3
  • 64
    • 51349162563 scopus 로고    scopus 로고
    • Molecular architecture of native HIV-1 gp120 trimers
    • Liu J., Bartesaghi A., Borgnia M.J., et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
    • (2008) Nature , vol.455 , pp. 109-113
    • Liu, J.1    Bartesaghi, A.2    Borgnia, M.J.3
  • 65
    • 33745203490 scopus 로고    scopus 로고
    • Distribution and three-dimensional structure of AIDS virus envelope spikes
    • Zhu P., Liu J., Bess J., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006, 441:847-852.
    • (2006) Nature , vol.441 , pp. 847-852
    • Zhu, P.1    Liu, J.2    Bess, J.3
  • 66
    • 0242268511 scopus 로고    scopus 로고
    • + T lymphocytes by favoring cytosolic delivery of viral material
    • + T lymphocytes by favoring cytosolic delivery of viral material. J Virol 2003, 77:12299-12309.
    • (2003) J Virol , vol.77 , pp. 12299-12309
    • Tardif, M.R.1    Tremblay, M.J.2
  • 67
    • 0030962180 scopus 로고    scopus 로고
    • Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization
    • Rizzuto C.D., Sodroski J.G. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol 1997, 71:4847-4851.
    • (1997) J Virol , vol.71 , pp. 4847-4851
    • Rizzuto, C.D.1    Sodroski, J.G.2
  • 68
    • 0029836852 scopus 로고    scopus 로고
    • Cytoskeletal proteins inside human immunodeficiency virus type 1 virions
    • Ott D.E., Coren L.V., Kane B.P., et al. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J Virol 1996, 70:7734-7743.
    • (1996) J Virol , vol.70 , pp. 7734-7743
    • Ott, D.E.1    Coren, L.V.2    Kane, B.P.3
  • 69
    • 33646457944 scopus 로고    scopus 로고
    • Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity
    • Keckesova Z., Ylinen L.M., Towers G.J. Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. J Virol 2006, 80:4683-4690.
    • (2006) J Virol , vol.80 , pp. 4683-4690
    • Keckesova, Z.1    Ylinen, L.M.2    Towers, G.J.3
  • 70
    • 54949126675 scopus 로고    scopus 로고
    • TRIM family proteins and their emerging roles in innate immunity
    • Ozato K., Shin D.M., Chang T.H. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008, 8:849-860.
    • (2008) Nat Rev Immunol , vol.8 , pp. 849-860
    • Ozato, K.1    Shin, D.M.2    Chang, T.H.3
  • 71
    • 77956832938 scopus 로고    scopus 로고
    • TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species
    • Kirmaier A., Wu F., Newman R.M., et al. TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 2010, 8.
    • (2010) PLoS Biol , vol.8
    • Kirmaier, A.1    Wu, F.2    Newman, R.M.3
  • 72
    • 79951669703 scopus 로고    scopus 로고
    • Tripartite-motif proteins and innate immune regulation
    • McNab F.W., Rajsbaum R., Stoye J.P., et al. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol 2011, 23:46-56.
    • (2011) Curr Opin Immunol , vol.23 , pp. 46-56
    • McNab, F.W.1    Rajsbaum, R.2    Stoye, J.P.3
  • 73
    • 77954165325 scopus 로고    scopus 로고
    • Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys
    • Lim S.Y., Chan T., Gelman R.S., et al. Contributions of Mamu-A*01 status and TRIM5 allele expression, but not CCL3L copy number variation, to the control of SIVmac251 replication in Indian-origin rhesus monkeys. PLoS Genet 2010, 6:e1000997.
    • (2010) PLoS Genet , vol.6
    • Lim, S.Y.1    Chan, T.2    Gelman, R.S.3
  • 74
    • 0030005423 scopus 로고    scopus 로고
    • Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates
    • Otteken A., Earl P.L., Moss B. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol 1996, 70:3407-3415.
    • (1996) J Virol , vol.70 , pp. 3407-3415
    • Otteken, A.1    Earl, P.L.2    Moss, B.3
  • 75
    • 0032546844 scopus 로고    scopus 로고
    • The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens
    • Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
    • (1998) Science , vol.280 , pp. 1884-1888
    • Wyatt, R.1    Sodroski, J.2
  • 76
    • 40849136223 scopus 로고    scopus 로고
    • The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
    • Montero M., van Houten N.E., Wang X., et al. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72:54-84.
    • (2008) Microbiol Mol Biol Rev , vol.72 , pp. 54-84
    • Montero, M.1    van Houten, N.E.2    Wang, X.3
  • 77
    • 39449098115 scopus 로고    scopus 로고
    • HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
    • Arthos J., Cicala C., Martinelli E., et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008, 9:301-309.
    • (2008) Nat Immunol , vol.9 , pp. 301-309
    • Arthos, J.1    Cicala, C.2    Martinelli, E.3
  • 78
    • 69249153068 scopus 로고    scopus 로고
    • Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection
    • Kader M., Wang X., Piatak M., et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009, 2:439-449.
    • (2009) Mucosal Immunol , vol.2 , pp. 439-449
    • Kader, M.1    Wang, X.2    Piatak, M.3
  • 79
    • 73949112038 scopus 로고    scopus 로고
    • The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1
    • Cicala C., Martinelli E., McNally J.P., et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A 2009, 106:20877-20882.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 20877-20882
    • Cicala, C.1    Martinelli, E.2    McNally, J.P.3
  • 80
    • 56849129238 scopus 로고    scopus 로고
    • Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection
    • Yu H., Tudor D., Alfsen A., et al. Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. Retrovirology 2008, 5:93.
    • (2008) Retrovirology , vol.5 , pp. 93
    • Yu, H.1    Tudor, D.2    Alfsen, A.3
  • 81
    • 38049031709 scopus 로고    scopus 로고
    • The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent
    • Yu H., Alfsen A., Tudor D., et al. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent. Cell Calcium 2008, 43:73-82.
    • (2008) Cell Calcium , vol.43 , pp. 73-82
    • Yu, H.1    Alfsen, A.2    Tudor, D.3
  • 82
    • 23244434512 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    • Li M., Gao F., Mascola J.R., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125.
    • (2005) J Virol , vol.79 , pp. 10108-10125
    • Li, M.1    Gao, F.2    Mascola, J.R.3
  • 83
    • 0037456827 scopus 로고    scopus 로고
    • Antibody neutralization and escape by HIV-1
    • Wei X., Decker J.M., Wang S., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312.
    • (2003) Nature , vol.422 , pp. 307-312
    • Wei, X.1    Decker, J.M.2    Wang, S.3
  • 84
    • 0031761965 scopus 로고    scopus 로고
    • Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine
    • Arthur L.O., Bess J.W., Chertova E.N., et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses 1998, 14(suppl. 3):S311-S319.
    • (1998) AIDS Res Hum Retroviruses , vol.14 , Issue.SUPPL.. 3
    • Arthur, L.O.1    Bess, J.W.2    Chertova, E.N.3
  • 85
    • 20144387029 scopus 로고    scopus 로고
    • Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins
    • Morcock D.R., Thomas J.A., Gagliardi T.D., et al. Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins. J Virol 2005, 79:1533-1542.
    • (2005) J Virol , vol.79 , pp. 1533-1542
    • Morcock, D.R.1    Thomas, J.A.2    Gagliardi, T.D.3
  • 86
    • 0032546817 scopus 로고    scopus 로고
    • HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology
    • Emerman M., Malim M.H. HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 1998, 280:1880-1884.
    • (1998) Science , vol.280 , pp. 1880-1884
    • Emerman, M.1    Malim, M.H.2
  • 87
    • 0033587718 scopus 로고    scopus 로고
    • Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
    • Gallo R.C. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci U S A 1999, 96:8324-8326.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 8324-8326
    • Gallo, R.C.1
  • 88
    • 20144389726 scopus 로고    scopus 로고
    • The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters
    • Rezza G., Fiorelli V., Dorrucci M., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005, 191:1321-1324.
    • (2005) J Infect Dis , vol.191 , pp. 1321-1324
    • Rezza, G.1    Fiorelli, V.2    Dorrucci, M.3
  • 89
    • 2342595835 scopus 로고    scopus 로고
    • Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis
    • Wadia J.S., Stan R.V., Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004, 10:310-315.
    • (2004) Nat Med , vol.10 , pp. 310-315
    • Wadia, J.S.1    Stan, R.V.2    Dowdy, S.F.3
  • 90
    • 0026561508 scopus 로고
    • Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency
    • Pomerantz R.J., Seshamma T., Trono D. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol 1992, 66:1809-1813.
    • (1992) J Virol , vol.66 , pp. 1809-1813
    • Pomerantz, R.J.1    Seshamma, T.2    Trono, D.3
  • 91
    • 0035128420 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX
    • Renkema G.H., Manninen A., Saksela K. Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX. J Virol 2001, 75:2154-2160.
    • (2001) J Virol , vol.75 , pp. 2154-2160
    • Renkema, G.H.1    Manninen, A.2    Saksela, K.3
  • 92
    • 0037089651 scopus 로고    scopus 로고
    • HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells
    • Manninen A., Saksela K. HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells. J Exp Med 2002, 195:1023-1032.
    • (2002) J Exp Med , vol.195 , pp. 1023-1032
    • Manninen, A.1    Saksela, K.2
  • 93
    • 0038342442 scopus 로고    scopus 로고
    • HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection
    • Swingler S., Brichacek B., Jacque J.M., et al. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003, 424:213-219.
    • (2003) Nature , vol.424 , pp. 213-219
    • Swingler, S.1    Brichacek, B.2    Jacque, J.M.3
  • 94
    • 0043198081 scopus 로고    scopus 로고
    • Nefarious abuse
    • Pope M. Nefarious abuse. Nat Immunol 2003, 4:729-730.
    • (2003) Nat Immunol , vol.4 , pp. 729-730
    • Pope, M.1
  • 95
    • 1542317632 scopus 로고    scopus 로고
    • + T cells for apoptosis by interacting with CXCR4 surface receptors
    • + T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004, 78:3099-3109.
    • (2004) J Virol , vol.78 , pp. 3099-3109
    • James, C.O.1    Huang, M.B.2    Khan, M.3
  • 97
    • 0142060865 scopus 로고    scopus 로고
    • CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 Nef protein in pediatric AIDS progression
    • Casartelli N., Di Matteo G., Potesta M., et al. CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 Nef protein in pediatric AIDS progression. J Virol 2003, 77:11536-11545.
    • (2003) J Virol , vol.77 , pp. 11536-11545
    • Casartelli, N.1    Di Matteo, G.2    Potesta, M.3
  • 98
    • 0842347716 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity
    • Alexander M., Bor Y.C., Ravichandran K.S., et al. Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity. J Virol 2004, 78:1685-1696.
    • (2004) J Virol , vol.78 , pp. 1685-1696
    • Alexander, M.1    Bor, Y.C.2    Ravichandran, K.S.3
  • 99
    • 0036201092 scopus 로고    scopus 로고
    • Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease
    • Simard M.C., Chrobak P., Kay D.G., et al. Expression of simian immunodeficiency virus nef in immune cells of transgenic mice leads to a severe AIDS-like disease. J Virol 2002, 76:3981-3995.
    • (2002) J Virol , vol.76 , pp. 3981-3995
    • Simard, M.C.1    Chrobak, P.2    Kay, D.G.3
  • 100
    • 70349272209 scopus 로고    scopus 로고
    • Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes
    • Hanna Z., Priceputu E., Chrobak P., et al. Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes. J Virol 2009, 83:9743-9758.
    • (2009) J Virol , vol.83 , pp. 9743-9758
    • Hanna, Z.1    Priceputu, E.2    Chrobak, P.3
  • 101
    • 0027043276 scopus 로고
    • Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
    • Daniel M.D., Kirchhoff F., Czajak S.C., et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992, 258:1938-1941.
    • (1992) Science , vol.258 , pp. 1938-1941
    • Daniel, M.D.1    Kirchhoff, F.2    Czajak, S.C.3
  • 102
    • 0031550781 scopus 로고    scopus 로고
    • Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa
    • Cranage M.P., Whatmore A.M., Sharpe S.A., et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997, 229:143-154.
    • (1997) Virology , vol.229 , pp. 143-154
    • Cranage, M.P.1    Whatmore, A.M.2    Sharpe, S.A.3
  • 103
    • 0032849066 scopus 로고    scopus 로고
    • Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
    • Wyand M.S., Manson K., Montefiori D.C., et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999, 73:8356-8363.
    • (1999) J Virol , vol.73 , pp. 8356-8363
    • Wyand, M.S.1    Manson, K.2    Montefiori, D.C.3
  • 104
    • 0037227694 scopus 로고    scopus 로고
    • A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication
    • Chakrabarti L.A., Metzner K.J., Ivanovic T., et al. A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Deltanef increases viral replication. J Virol 2003, 77:1245-1256.
    • (2003) J Virol , vol.77 , pp. 1245-1256
    • Chakrabarti, L.A.1    Metzner, K.J.2    Ivanovic, T.3
  • 105
    • 29244474887 scopus 로고    scopus 로고
    • HIV vaccine design: insights from live attenuated SIV vaccines
    • Koff W.C., Johnson P.R., Watkins D.I., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7:19-23.
    • (2006) Nat Immunol , vol.7 , pp. 19-23
    • Koff, W.C.1    Johnson, P.R.2    Watkins, D.I.3
  • 106
    • 33645767939 scopus 로고    scopus 로고
    • Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr
    • Ardon O., Zimmerman E.S., Andersen J.L., et al. Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr. J Virol 2006, 80:3694-3700.
    • (2006) J Virol , vol.80 , pp. 3694-3700
    • Ardon, O.1    Zimmerman, E.S.2    Andersen, J.L.3
  • 107
    • 33644764832 scopus 로고    scopus 로고
    • The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest
    • Sakai K., Dimas J., Lenardo M.J. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci U S A 2006, 103:3369-3374.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 3369-3374
    • Sakai, K.1    Dimas, J.2    Lenardo, M.J.3
  • 108
    • 38549095979 scopus 로고    scopus 로고
    • Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    • Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
    • (2008) Nature , vol.451 , pp. 425-430
    • Neil, S.J.1    Zang, T.2    Bieniasz, P.D.3
  • 109
    • 61449243774 scopus 로고    scopus 로고
    • Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants
    • McNatt M.W., Zang T., Hatziioannou T., et al. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 2009, 5:e1000300.
    • (2009) PLoS Pathog , vol.5
    • McNatt, M.W.1    Zang, T.2    Hatziioannou, T.3
  • 110
    • 67249114758 scopus 로고    scopus 로고
    • Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2
    • Jia B., Serra-Moreno R., Neidermyer W., et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009, 5:e1000429.
    • (2009) PLoS Pathog , vol.5
    • Jia, B.1    Serra-Moreno, R.2    Neidermyer, W.3
  • 111
    • 78650646751 scopus 로고    scopus 로고
    • The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses
    • Schmokel J., Sauter D., Schindler M., et al. The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. J Virol 2011, 85:742-752.
    • (2011) J Virol , vol.85 , pp. 742-752
    • Schmokel, J.1    Sauter, D.2    Schindler, M.3
  • 112
    • 71749105713 scopus 로고    scopus 로고
    • Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains
    • Sauter D., Schindler M., Specht A., et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6(5):409-421.
    • (2009) Cell Host Microbe , vol.6 , Issue.5 , pp. 409-421
    • Sauter, D.1    Schindler, M.2    Specht, A.3
  • 113
    • 80053375827 scopus 로고    scopus 로고
    • Lack of adaptation to human tetherin in HIV-1 group O and P
    • Yang S.J., Lopez L.A., Exline C.M., et al. Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 2011, 8:78.
    • (2011) Retrovirology , vol.8 , pp. 78
    • Yang, S.J.1    Lopez, L.A.2    Exline, C.M.3
  • 114
    • 0025029028 scopus 로고
    • Origin of vpx in lentiviruses
    • Tristem M., Marshall C., Karpas A., et al. Origin of vpx in lentiviruses. Nature 1990, 347:341-342.
    • (1990) Nature , vol.347 , pp. 341-342
    • Tristem, M.1    Marshall, C.2    Karpas, A.3
  • 115
    • 0038681023 scopus 로고    scopus 로고
    • Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
    • Mangeat B., Turelli P., Caron G., et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
    • (2003) Nature , vol.424 , pp. 99-103
    • Mangeat, B.1    Turelli, P.2    Caron, G.3
  • 116
    • 13844309367 scopus 로고    scopus 로고
    • Editing at the crossroad of innate and adaptive immunity
    • Turelli P., Trono D. Editing at the crossroad of innate and adaptive immunity. Science 2005, 307:1061-1065.
    • (2005) Science , vol.307 , pp. 1061-1065
    • Turelli, P.1    Trono, D.2
  • 117
    • 31944438580 scopus 로고    scopus 로고
    • Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity
    • Peng G., Lei K.J., Jin W., et al. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med 2006, 203:41-46.
    • (2006) J Exp Med , vol.203 , pp. 41-46
    • Peng, G.1    Lei, K.J.2    Jin, W.3
  • 118
    • 0242578406 scopus 로고    scopus 로고
    • Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex
    • Yu X., Yu Y., Liu B., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
    • (2003) Science , vol.302 , pp. 1056-1060
    • Yu, X.1    Yu, Y.2    Liu, B.3
  • 119
    • 3442876111 scopus 로고    scopus 로고
    • APOBEC-mediated editing of viral RNA
    • Bishop K.N., Holmes R.K., Sheehy A.M., et al. APOBEC-mediated editing of viral RNA. Science 2004, 305:645.
    • (2004) Science , vol.305 , pp. 645
    • Bishop, K.N.1    Holmes, R.K.2    Sheehy, A.M.3
  • 120
    • 33646443637 scopus 로고    scopus 로고
    • Monomeric APOBEC3G is catalytically active and has antiviral activity
    • Opi S., Takeuchi H., Kao S., et al. Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 2006, 80:4673-4682.
    • (2006) J Virol , vol.80 , pp. 4673-4682
    • Opi, S.1    Takeuchi, H.2    Kao, S.3
  • 121
    • 37349006127 scopus 로고    scopus 로고
    • Mucosal innate immunity as a determinant of HIV susceptibility
    • Iqbal S.M., Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am J Reprod Immunol 2008, 59:44-54.
    • (2008) Am J Reprod Immunol , vol.59 , pp. 44-54
    • Iqbal, S.M.1    Kaul, R.2
  • 122
    • 58249095268 scopus 로고    scopus 로고
    • Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells
    • Wang Y., Bergmeier L.A., Stebbings R., et al. Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine 2009, 27:870-881.
    • (2009) Vaccine , vol.27 , pp. 870-881
    • Wang, Y.1    Bergmeier, L.A.2    Stebbings, R.3
  • 123
    • 58149502601 scopus 로고    scopus 로고
    • Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G
    • Trapp S., Derby N.R., Singer R., et al. Double-stranded RNA analog poly(I:C) inhibits human immunodeficiency virus amplification in dendritic cells via type I interferon-mediated activation of APOBEC3G. J Virol 2009, 83:884-895.
    • (2009) J Virol , vol.83 , pp. 884-895
    • Trapp, S.1    Derby, N.R.2    Singer, R.3
  • 124
    • 77957673112 scopus 로고    scopus 로고
    • Innate immunity against HIV: a priority target for HIV prevention research
    • Borrow P., Shattock R.J., Vyakarnam A. Innate immunity against HIV: a priority target for HIV prevention research. Retrovirology 2010, 7:84.
    • (2010) Retrovirology , vol.7 , pp. 84
    • Borrow, P.1    Shattock, R.J.2    Vyakarnam, A.3
  • 125
    • 78049433762 scopus 로고    scopus 로고
    • Innate immunity in resistance to HIV infection
    • Biasin M., Clerici M., Piacentini L. Innate immunity in resistance to HIV infection. J Infect Dis 2010, 202(suppl. 3):S361-S365.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 3
    • Biasin, M.1    Clerici, M.2    Piacentini, L.3
  • 126
    • 77953118149 scopus 로고    scopus 로고
    • Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques
    • Sui Y., Zhu Q., Gagnon S., et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 2010, 107:9843-9848.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 9843-9848
    • Sui, Y.1    Zhu, Q.2    Gagnon, S.3
  • 127
    • 0037237790 scopus 로고    scopus 로고
    • Syndecan captures, protects, and transmits HIV to T lymphocytes
    • Bobardt M.D., Saphire A.C., Hung H.C., et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003, 18:27-39.
    • (2003) Immunity , vol.18 , pp. 27-39
    • Bobardt, M.D.1    Saphire, A.C.2    Hung, H.C.3
  • 128
    • 0034598905 scopus 로고    scopus 로고
    • DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
    • Geijtenbeek T.B., Kwon D.S., Torensma R., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
    • (2000) Cell , vol.100 , pp. 587-597
    • Geijtenbeek, T.B.1    Kwon, D.S.2    Torensma, R.3
  • 129
    • 31444453892 scopus 로고    scopus 로고
    • Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection
    • Wiley R.D., Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 2006, 103:738-743.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 738-743
    • Wiley, R.D.1    Gummuluru, S.2
  • 130
    • 0021720872 scopus 로고
    • T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
    • Klatzmann D., Champagne E., Chamaret S., et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984, 312:767-768.
    • (1984) Nature , vol.312 , pp. 767-768
    • Klatzmann, D.1    Champagne, E.2    Chamaret, S.3
  • 131
    • 0037007670 scopus 로고    scopus 로고
    • HIV preferentially infects HIV-specific CD4+ T cells
    • Douek D.C., Brenchley J.M., Betts M.R., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
    • (2002) Nature , vol.417 , pp. 95-98
    • Douek, D.C.1    Brenchley, J.M.2    Betts, M.R.3
  • 132
    • 0027411206 scopus 로고
    • Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor
    • Fantini J., Cook D.G., Nathanson N., et al. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc Natl Acad Sci U S A 1993, 90:2700-2704.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 2700-2704
    • Fantini, J.1    Cook, D.G.2    Nathanson, N.3
  • 133
    • 0034482696 scopus 로고    scopus 로고
    • Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
    • Kwong P.D., Wyatt R., Majeed S., et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8:1329-1339.
    • (2000) Structure , vol.8 , pp. 1329-1339
    • Kwong, P.D.1    Wyatt, R.2    Majeed, S.3
  • 134
    • 0032543307 scopus 로고    scopus 로고
    • Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    • Kwong P.D., Wyatt R., Robinson J., et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
    • (1998) Nature , vol.393 , pp. 648-659
    • Kwong, P.D.1    Wyatt, R.2    Robinson, J.3
  • 135
    • 0037069682 scopus 로고    scopus 로고
    • HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites
    • Kwong P.D., Doyle M.L., Casper D.J., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682.
    • (2002) Nature , vol.420 , pp. 678-682
    • Kwong, P.D.1    Doyle, M.L.2    Casper, D.J.3
  • 136
    • 13844302894 scopus 로고    scopus 로고
    • Structure of an unliganded simian immunodeficiency virus gp120 core
    • Chen B., Vogan E.M., Gong H., et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841.
    • (2005) Nature , vol.433 , pp. 834-841
    • Chen, B.1    Vogan, E.M.2    Gong, H.3
  • 137
    • 0141521564 scopus 로고    scopus 로고
    • Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1
    • Labrijn A.F., Poignard P., Raja A., et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77:10557-10565.
    • (2003) J Virol , vol.77 , pp. 10557-10565
    • Labrijn, A.F.1    Poignard, P.2    Raja, A.3
  • 138
    • 0035884899 scopus 로고    scopus 로고
    • Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks
    • Resch W., Hoffman N., Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001, 288:51-62.
    • (2001) Virology , vol.288 , pp. 51-62
    • Resch, W.1    Hoffman, N.2    Swanstrom, R.3
  • 139
    • 27744597054 scopus 로고    scopus 로고
    • Structure of a V3-containing HIV-1 gp120 core
    • Huang C.C., Tang M., Zhang M.Y., et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005, 310:1025-1028.
    • (2005) Science , vol.310 , pp. 1025-1028
    • Huang, C.C.1    Tang, M.2    Zhang, M.Y.3
  • 141
    • 0026785547 scopus 로고
    • Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein
    • Freed E.O., Myers D.J. Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 1992, 66:5472-5478.
    • (1992) J Virol , vol.66 , pp. 5472-5478
    • Freed, E.O.1    Myers, D.J.2
  • 142
    • 5644229850 scopus 로고    scopus 로고
    • The many mechanisms of viral membrane fusion proteins
    • Earp L.J., Delos S.E., Park H.E., et al. The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol 2005, 285:25-66.
    • (2005) Curr Top Microbiol Immunol , vol.285 , pp. 25-66
    • Earp, L.J.1    Delos, S.E.2    Park, H.E.3
  • 143
    • 26944466459 scopus 로고    scopus 로고
    • Mechanism of membrane fusion by viral envelope proteins
    • Harrison S.C. Mechanism of membrane fusion by viral envelope proteins. Adv Virus Res 2005, 64:231-261.
    • (2005) Adv Virus Res , vol.64 , pp. 231-261
    • Harrison, S.C.1
  • 144
    • 0030970693 scopus 로고    scopus 로고
    • Core structure of gp41 from the HIV envelope glycoprotein
    • Chan D.C., Fass D., Berger J.M., et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997, 89:263-273.
    • (1997) Cell , vol.89 , pp. 263-273
    • Chan, D.C.1    Fass, D.2    Berger, J.M.3
  • 145
    • 0030962291 scopus 로고    scopus 로고
    • Atomic structure of the ectodomain from HIV-1 gp41
    • Weissenhorn W., Dessen A., Harrison S.C., et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997, 387:426-430.
    • (1997) Nature , vol.387 , pp. 426-430
    • Weissenhorn, W.1    Dessen, A.2    Harrison, S.C.3
  • 146
    • 0033563698 scopus 로고    scopus 로고
    • The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution
    • Yang Z.N., Mueser T.C., Kaufman J., et al. The crystal structure of the SIV gp41 ectodomain at 1.47 A resolution. J Struct Biol 1999, 126:131-144.
    • (1999) J Struct Biol , vol.126 , pp. 131-144
    • Yang, Z.N.1    Mueser, T.C.2    Kaufman, J.3
  • 147
    • 0032577550 scopus 로고    scopus 로고
    • HIV entry and its inhibition
    • Chan D.C., Kim P.S. HIV entry and its inhibition. Cell 1998, 93:681-684.
    • (1998) Cell , vol.93 , pp. 681-684
    • Chan, D.C.1    Kim, P.S.2
  • 148
    • 46449100666 scopus 로고    scopus 로고
    • Viral membrane fusion
    • Harrison S.C. Viral membrane fusion. Nat Struct Mol Biol 2008, 15:690-698.
    • (2008) Nat Struct Mol Biol , vol.15 , pp. 690-698
    • Harrison, S.C.1
  • 149
    • 2442629758 scopus 로고    scopus 로고
    • Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation
    • Swalley S.E., Baker B.M., Calder L.J., et al. Full-length influenza hemagglutinin HA2 refolds into the trimeric low-pH-induced conformation. Biochemistry 2004, 43:5902-5911.
    • (2004) Biochemistry , vol.43 , pp. 5902-5911
    • Swalley, S.E.1    Baker, B.M.2    Calder, L.J.3
  • 150
    • 0032431055 scopus 로고    scopus 로고
    • Coiled coils in both intracellular vesicle and viral membrane fusion
    • Skehel J.J., Wiley D.C. Coiled coils in both intracellular vesicle and viral membrane fusion. Cell 1998, 95:871-874.
    • (1998) Cell , vol.95 , pp. 871-874
    • Skehel, J.J.1    Wiley, D.C.2
  • 151
    • 33646185493 scopus 로고    scopus 로고
    • Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells
    • Yang X., Kurteva S., Ren X., et al. Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol 2006, 80:4388-4395.
    • (2006) J Virol , vol.80 , pp. 4388-4395
    • Yang, X.1    Kurteva, S.2    Ren, X.3
  • 152
    • 78649861760 scopus 로고    scopus 로고
    • Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
    • Frey G., Chen J., Rits-Volloch S., et al. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol 2010, 17:1486-1491.
    • (2010) Nat Struct Mol Biol , vol.17 , pp. 1486-1491
    • Frey, G.1    Chen, J.2    Rits-Volloch, S.3
  • 153
    • 0742325043 scopus 로고    scopus 로고
    • The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection
    • Moore J.P., Kitchen S.G., Pugach P., et al. The CCR5 and CXCR4 coreceptors: central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 2004, 20:111-126.
    • (2004) AIDS Res Hum Retroviruses , vol.20 , pp. 111-126
    • Moore, J.P.1    Kitchen, S.G.2    Pugach, P.3
  • 154
    • 0026600926 scopus 로고
    • Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population
    • Schuitemaker H., Koot M., Kootstra N.A., et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360.
    • (1992) J Virol , vol.66 , pp. 1354-1360
    • Schuitemaker, H.1    Koot, M.2    Kootstra, N.A.3
  • 155
    • 0031058480 scopus 로고    scopus 로고
    • Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239
    • Marcon L., Choe H., Martin K.A., et al. Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol 1997, 71:2522-2527.
    • (1997) J Virol , vol.71 , pp. 2522-2527
    • Marcon, L.1    Choe, H.2    Martin, K.A.3
  • 156
    • 0029909461 scopus 로고    scopus 로고
    • Participants in HIV Study: correction
    • Dean M., Carrington M., Goedert J., et al. Participants in HIV Study: correction. Science 1996, 274:1069a.
    • (1996) Science , vol.274
    • Dean, M.1    Carrington, M.2    Goedert, J.3
  • 157
    • 15844388931 scopus 로고    scopus 로고
    • Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
    • Liu R., Paxton W.A., Choe S., et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996, 86:367-377.
    • (1996) Cell , vol.86 , pp. 367-377
    • Liu, R.1    Paxton, W.A.2    Choe, S.3
  • 158
    • 16044367526 scopus 로고    scopus 로고
    • The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
    • Huang Y., Paxton W.A., Wolinsky S.M., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
    • (1996) Nat Med , vol.2 , pp. 1240-1243
    • Huang, Y.1    Paxton, W.A.2    Wolinsky, S.M.3
  • 159
    • 0031455968 scopus 로고    scopus 로고
    • Novel alleles of the chemokine-receptor gene CCR5
    • Carrington M., Kissner T., Gerrard B., et al. Novel alleles of the chemokine-receptor gene CCR5. Am J Hum Genet 1997, 61:1261-1267.
    • (1997) Am J Hum Genet , vol.61 , pp. 1261-1267
    • Carrington, M.1    Kissner, T.2    Gerrard, B.3
  • 160
    • 0036139926 scopus 로고    scopus 로고
    • Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression
    • Tang J., Shelton B., Makhatadze N.J., et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002, 76:662-672.
    • (2002) J Virol , vol.76 , pp. 662-672
    • Tang, J.1    Shelton, B.2    Makhatadze, N.J.3
  • 161
    • 2642563503 scopus 로고    scopus 로고
    • Human genes that limit AIDS
    • O'Brien S.J., Nelson G.W. Human genes that limit AIDS. Nat Genet 2004, 36:565-574.
    • (2004) Nat Genet , vol.36 , pp. 565-574
    • O'Brien, S.J.1    Nelson, G.W.2
  • 162
    • 16044373004 scopus 로고    scopus 로고
    • Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
    • Samson M., Libert F., Doranz B.J., et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
    • (1996) Nature , vol.382 , pp. 722-725
    • Samson, M.1    Libert, F.2    Doranz, B.J.3
  • 163
    • 21344467949 scopus 로고    scopus 로고
    • Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons
    • Hummel S., Schmidt D., Kremeyer B., et al. Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes Immun 2005, 6:371-374.
    • (2005) Genes Immun , vol.6 , pp. 371-374
    • Hummel, S.1    Schmidt, D.2    Kremeyer, B.3
  • 164
    • 78049445213 scopus 로고    scopus 로고
    • Genomic approaches to the study of HIV-1 acquisition
    • Telenti A., McLaren P. Genomic approaches to the study of HIV-1 acquisition. J Infect Dis 2010, 202(suppl. 3):S382-S386.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 3
    • Telenti, A.1    McLaren, P.2
  • 165
    • 0031051739 scopus 로고    scopus 로고
    • HIV-1 infection in an individual homozygous for the CCR5 deletion allele
    • Biti R., Ffrench R., Young J., et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997, 3:252-253.
    • (1997) Nat Med , vol.3 , pp. 252-253
    • Biti, R.1    Ffrench, R.2    Young, J.3
  • 166
    • 33746610538 scopus 로고    scopus 로고
    • Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics
    • Suresh P., Wanchu A. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics. J Postgrad Med 2006, 52:210-217.
    • (2006) J Postgrad Med , vol.52 , pp. 210-217
    • Suresh, P.1    Wanchu, A.2
  • 167
    • 34248578768 scopus 로고    scopus 로고
    • Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1)
    • Reiche E.M., Bonametti A.M., Voltarelli J.C., et al. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007, 14:1325-1334.
    • (2007) Curr Med Chem , vol.14 , pp. 1325-1334
    • Reiche, E.M.1    Bonametti, A.M.2    Voltarelli, J.C.3
  • 169
    • 18244361800 scopus 로고    scopus 로고
    • HIV pathogenesis: the first cut is the deepest
    • Picker L.J., Watkins D.I. HIV pathogenesis: the first cut is the deepest. Nat Immunol 2005, 6:430-432.
    • (2005) Nat Immunol , vol.6 , pp. 430-432
    • Picker, L.J.1    Watkins, D.I.2
  • 170
    • 0033986873 scopus 로고    scopus 로고
    • Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo
    • Veazey R.S., Tham I.C., Mansfield K.G., et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J l 2000, 74:57-64.
    • (2000) J l , vol.74 , pp. 57-64
    • Veazey, R.S.1    Tham, I.C.2    Mansfield, K.G.3
  • 171
    • 79251555316 scopus 로고    scopus 로고
    • Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques
    • Ansari A.A., Reimann K.A., Mayne A.E., et al. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011, 186:1044-1059.
    • (2011) J Immunol , vol.186 , pp. 1044-1059
    • Ansari, A.A.1    Reimann, K.A.2    Mayne, A.E.3
  • 172
    • 40549092339 scopus 로고    scopus 로고
    • Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
    • Chun T.W., Nickle D.C., Justement J.S., et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008, 197:714-720.
    • (2008) J Infect Dis , vol.197 , pp. 714-720
    • Chun, T.W.1    Nickle, D.C.2    Justement, J.S.3
  • 173
    • 78149417719 scopus 로고    scopus 로고
    • Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy
    • Yukl S.A., Gianella S., Sinclair E., et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010, 202:1553-1561.
    • (2010) J Infect Dis , vol.202 , pp. 1553-1561
    • Yukl, S.A.1    Gianella, S.2    Sinclair, E.3
  • 174
    • 77949409948 scopus 로고    scopus 로고
    • Targeting early infection to prevent HIV-1 mucosal transmission
    • Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
    • (2010) Nature , vol.464 , pp. 217-223
    • Haase, A.T.1
  • 175
    • 44649102135 scopus 로고    scopus 로고
    • Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    • Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008, 105:7552-7557.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 7552-7557
    • Keele, B.F.1    Giorgi, E.E.2    Salazar-Gonzalez, J.F.3
  • 176
    • 66049139947 scopus 로고    scopus 로고
    • Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    • Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009, 206:1273-1289.
    • (2009) J Exp Med , vol.206 , pp. 1273-1289
    • Salazar-Gonzalez, J.F.1    Salazar, M.G.2    Keele, B.F.3
  • 177
    • 59249096215 scopus 로고    scopus 로고
    • Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
    • Haaland R.E., Hawkins P.A., Salazar-Gonzalez J., et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009, 5:e1000274.
    • (2009) PLoS Pathog , vol.5
    • Haaland, R.E.1    Hawkins, P.A.2    Salazar-Gonzalez, J.3
  • 178
    • 77953784170 scopus 로고    scopus 로고
    • A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251
    • Stone M., Keele B.F., Ma Z.M., et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010, 84:7083-7095.
    • (2010) J Virol , vol.84 , pp. 7083-7095
    • Stone, M.1    Keele, B.F.2    Ma, Z.M.3
  • 179
    • 77957569793 scopus 로고    scopus 로고
    • HIV-1 transmission biology: selection and characteristics of infecting viruses
    • Sagar M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis 2010, 202(suppl. 2):S289-S296.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 2
    • Sagar, M.1
  • 180
    • 0030162644 scopus 로고    scopus 로고
    • On the nature of virus quasispecies
    • Eigen M. On the nature of virus quasispecies. Trends Microbiol 1996, 4:216-218.
    • (1996) Trends Microbiol , vol.4 , pp. 216-218
    • Eigen, M.1
  • 181
    • 77957901912 scopus 로고    scopus 로고
    • Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing
    • Fischer W., Ganusov V.V., Giorgi E.E., et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 2010, 5:e12303.
    • (2010) PLoS ONE , vol.5
    • Fischer, W.1    Ganusov, V.V.2    Giorgi, E.E.3
  • 182
    • 77952678708 scopus 로고    scopus 로고
    • Wide variation in the multiplicity of HIV-1 infection among injection drug users
    • Bar K.J., Li H., Chamberland A., et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010, 84:6241-6247.
    • (2010) J Virol , vol.84 , pp. 6241-6247
    • Bar, K.J.1    Li, H.2    Chamberland, A.3
  • 183
    • 33845532053 scopus 로고    scopus 로고
    • Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    • Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
    • (2006) Nat Med , vol.12 , pp. 1365-1371
    • Brenchley, J.M.1    Price, D.A.2    Schacker, T.W.3
  • 184
    • 39349104176 scopus 로고    scopus 로고
    • Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection
    • Li Q., Estes J.D., Duan L., et al. Simian immunodeficiency virus-induced intestinal cell apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J Infect Dis 2008, 197:420-429.
    • (2008) J Infect Dis , vol.197 , pp. 420-429
    • Li, Q.1    Estes, J.D.2    Duan, L.3
  • 185
    • 38949134533 scopus 로고    scopus 로고
    • Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis
    • Gori A., Tincati C., Rizzardini G., et al. Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol 2008, 46:757-758.
    • (2008) J Clin Microbiol , vol.46 , pp. 757-758
    • Gori, A.1    Tincati, C.2    Rizzardini, G.3
  • 186
    • 77950267769 scopus 로고    scopus 로고
    • Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections
    • Nowroozalizadeh S., Mansson F., da Silva Z., et al. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Infect Dis 2010, 201:1150-1154.
    • (2010) J Infect Dis , vol.201 , pp. 1150-1154
    • Nowroozalizadeh, S.1    Mansson, F.2    da Silva, Z.3
  • 187
    • 33749338938 scopus 로고    scopus 로고
    • PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
    • Petrovas C., Casazza J.P., Brenchley J.M., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203:2281-2292.
    • (2006) J Exp Med , vol.203 , pp. 2281-2292
    • Petrovas, C.1    Casazza, J.P.2    Brenchley, J.M.3
  • 188
    • 33748947326 scopus 로고    scopus 로고
    • PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
    • Day C.L., Kaufmann D.E., Kiepiela P., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
    • (2006) Nature , vol.443 , pp. 350-354
    • Day, C.L.1    Kaufmann, D.E.2    Kiepiela, P.3
  • 189
    • 38949102301 scopus 로고    scopus 로고
    • Chronic innate immune activation as a cause of HIV-1 immunopathogenesis
    • Boasso A., Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008, 126:235-242.
    • (2008) Clin Immunol , vol.126 , pp. 235-242
    • Boasso, A.1    Shearer, G.M.2
  • 190
    • 77950525439 scopus 로고    scopus 로고
    • Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
    • Said E.A., Dupuy F.P., Trautmann L., et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010, 16:452-459.
    • (2010) Nat Med , vol.16 , pp. 452-459
    • Said, E.A.1    Dupuy, F.P.2    Trautmann, L.3
  • 191
    • 0027220025 scopus 로고
    • Programmed cell death in AIDS-related HIV and SIV infections
    • Gougeon M.L., Garcia S., Heeney J., et al. Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses 1993, 9:553-563.
    • (1993) AIDS Res Hum Retroviruses , vol.9 , pp. 553-563
    • Gougeon, M.L.1    Garcia, S.2    Heeney, J.3
  • 192
    • 0029062573 scopus 로고
    • Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein
    • Li C.J., Friedman D.J., Wang C., et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995, 268:429-431.
    • (1995) Science , vol.268 , pp. 429-431
    • Li, C.J.1    Friedman, D.J.2    Wang, C.3
  • 193
    • 0028912254 scopus 로고
    • Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes
    • Finkel T.H., Tudor-Williams G., Banda N.K., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 1:129-134.
    • (1995) Nat Med , vol.1 , pp. 129-134
    • Finkel, T.H.1    Tudor-Williams, G.2    Banda, N.K.3
  • 194
    • 0028074885 scopus 로고
    • Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections
    • Estaquier J., Idziorek T., de Bels F., et al. Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A 1994, 91:9431-9435.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 9431-9435
    • Estaquier, J.1    Idziorek, T.2    de Bels, F.3
  • 195
    • 33749009709 scopus 로고    scopus 로고
    • Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
    • Trautmann L., Janbazian L., Chomont N., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12:1198-1202.
    • (2006) Nat Med , vol.12 , pp. 1198-1202
    • Trautmann, L.1    Janbazian, L.2    Chomont, N.3
  • 196
    • 41849142985 scopus 로고    scopus 로고
    • Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut
    • Raffatellu M., Santos R.L., Verhoeven D.E., et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med 2008, 14:421-428.
    • (2008) Nat Med , vol.14 , pp. 421-428
    • Raffatellu, M.1    Santos, R.L.2    Verhoeven, D.E.3
  • 197
    • 61449115882 scopus 로고    scopus 로고
    • Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection
    • Favre D., Lederer S., Kanwar B., et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog 2009, 5:e1000295.
    • (2009) PLoS Pathog , vol.5
    • Favre, D.1    Lederer, S.2    Kanwar, B.3
  • 198
    • 77749295656 scopus 로고    scopus 로고
    • Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection
    • El Hed A., Khaitan A., Kozhaya L., et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis 2010, 201:843-854.
    • (2010) J Infect Dis , vol.201 , pp. 843-854
    • El Hed, A.1    Khaitan, A.2    Kozhaya, L.3
  • 199
  • 200
    • 76949098433 scopus 로고    scopus 로고
    • Th17 cells and HIV infection
    • Elhed A., Unutmaz D. Th17 cells and HIV infection. Curr Opin HIV AIDS 2010, 5:146-150.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 146-150
    • Elhed, A.1    Unutmaz, D.2
  • 201
    • 76949099874 scopus 로고    scopus 로고
    • Th17 cells in natural SIV hosts
    • Paiardini M. Th17 cells in natural SIV hosts. Curr Opin HIV AIDS 2010, 5:166-172.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 166-172
    • Paiardini, M.1
  • 202
    • 37349126294 scopus 로고    scopus 로고
    • Natural regulatory T cells and persistent viral infection
    • Li S., Gowans E.J., Chougnet C., et al. Natural regulatory T cells and persistent viral infection. J Virol 2008, 82:21-30.
    • (2008) J Virol , vol.82 , pp. 21-30
    • Li, S.1    Gowans, E.J.2    Chougnet, C.3
  • 203
    • 67650711146 scopus 로고    scopus 로고
    • Lessons learned from the natural hosts of HIV-related viruses
    • Paiardini M., Pandrea I., Apetrei C., et al. Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med 2009, 60:485-495.
    • (2009) Annu Rev Med , vol.60 , pp. 485-495
    • Paiardini, M.1    Pandrea, I.2    Apetrei, C.3
  • 204
    • 76949108202 scopus 로고    scopus 로고
    • Th17 and regulatory T cells: implications for AIDS pathogenesis
    • Kanwar B., Favre D., McCune J.M. Th17 and regulatory T cells: implications for AIDS pathogenesis. Curr Opin HIV AIDS 2010, 5:151-157.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 151-157
    • Kanwar, B.1    Favre, D.2    McCune, J.M.3
  • 205
  • 207
    • 0036129320 scopus 로고    scopus 로고
    • AIDS vaccine models: challenging challenge viruses
    • Feinberg M.B., Moore J.P. AIDS vaccine models: challenging challenge viruses. Nat Med 2002, 8:207-210.
    • (2002) Nat Med , vol.8 , pp. 207-210
    • Feinberg, M.B.1    Moore, J.P.2
  • 208
    • 78650358966 scopus 로고    scopus 로고
    • The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection
    • Ling B., Mohan M., Lackner A.A., et al. The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J Infect Dis 2010, 202:1846-1854.
    • (2010) J Infect Dis , vol.202 , pp. 1846-1854
    • Ling, B.1    Mohan, M.2    Lackner, A.A.3
  • 209
    • 78649431227 scopus 로고    scopus 로고
    • HIV-1 continues to replicate and evolve in patients with natural control of HIV infection
    • Mens H., Kearney M., Wiegand A., et al. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol 2010, 84:12971-12981.
    • (2010) J Virol , vol.84 , pp. 12971-12981
    • Mens, H.1    Kearney, M.2    Wiegand, A.3
  • 210
    • 0030891167 scopus 로고    scopus 로고
    • Escape of human immunodeficiency virus from immune control
    • McMichael A.J., Phillips R.E. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997, 15:271-296.
    • (1997) Annu Rev Immunol , vol.15 , pp. 271-296
    • McMichael, A.J.1    Phillips, R.E.2
  • 211
    • 0035862326 scopus 로고    scopus 로고
    • Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection
    • Goulder P.J., Altfeld M.A., Rosenberg E.S., et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med 2001, 193:181-194.
    • (2001) J Exp Med , vol.193 , pp. 181-194
    • Goulder, P.J.1    Altfeld, M.A.2    Rosenberg, E.S.3
  • 212
    • 0037122796 scopus 로고    scopus 로고
    • Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
    • Barouch D.H., Kunstman J., Kuroda M.J., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002, 415:335-339.
    • (2002) Nature , vol.415 , pp. 335-339
    • Barouch, D.H.1    Kunstman, J.2    Kuroda, M.J.3
  • 213
    • 0037791747 scopus 로고    scopus 로고
    • Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys
    • Barouch D.H., Kunstman J., Glowczwskie J., et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003, 77:7367-7375.
    • (2003) J Virol , vol.77 , pp. 7367-7375
    • Barouch, D.H.1    Kunstman, J.2    Glowczwskie, J.3
  • 214
    • 0036113306 scopus 로고    scopus 로고
    • Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection
    • O'Connor D.H., Allen T.M., Vogel T.U., et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 2002, 8:493-499.
    • (2002) Nat Med , vol.8 , pp. 493-499
    • O'Connor, D.H.1    Allen, T.M.2    Vogel, T.U.3
  • 215
    • 1642264887 scopus 로고    scopus 로고
    • Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States
    • Nwanegbo E., Vardas E., Gao W., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004, 11:351-357.
    • (2004) Clin Diagn Lab Immunol , vol.11 , pp. 351-357
    • Nwanegbo, E.1    Vardas, E.2    Gao, W.3
  • 216
    • 1842741699 scopus 로고    scopus 로고
    • HIV evolution: CTL escape mutation and reversion after transmission
    • Leslie A.J., Pfafferott K.J., Chetty P., et al. HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004, 10:282-289.
    • (2004) Nat Med , vol.10 , pp. 282-289
    • Leslie, A.J.1    Pfafferott, K.J.2    Chetty, P.3
  • 217
    • 20144384850 scopus 로고    scopus 로고
    • Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection
    • Betts M.R., Exley B., Price D.A., et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 2005, 102:4512-4517.
    • (2005) Proc Natl Acad Sci U S A , vol.102 , pp. 4512-4517
    • Betts, M.R.1    Exley, B.2    Price, D.A.3
  • 218
    • 43549109265 scopus 로고    scopus 로고
    • Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients
    • Goepfert P.A., Lumm W., Farmer P., et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J Exp Med 2008, 205:1009-1017.
    • (2008) J Exp Med , vol.205 , pp. 1009-1017
    • Goepfert, P.A.1    Lumm, W.2    Farmer, P.3
  • 219
    • 33645240933 scopus 로고    scopus 로고
    • Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1
    • Martinez-Picado J., Prado J.G., Fry E.E., et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 2006, 80:3617-3623.
    • (2006) J Virol , vol.80 , pp. 3617-3623
    • Martinez-Picado, J.1    Prado, J.G.2    Fry, E.E.3
  • 220
    • 36048949732 scopus 로고    scopus 로고
    • Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication
    • Schneidewind A., Brockman M.A., Yang R., et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J Virol 2007, 81:12382-12393.
    • (2007) J Virol , vol.81 , pp. 12382-12393
    • Schneidewind, A.1    Brockman, M.A.2    Yang, R.3
  • 221
    • 77957560654 scopus 로고    scopus 로고
    • Viral evolution and escape during acute HIV-1 infection
    • Boutwell C.L., Rolland M.M., Herbeck J.T., et al. Viral evolution and escape during acute HIV-1 infection. J Infect Dis 2010, 202(suppl. 2):S309-S314.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 2
    • Boutwell, C.L.1    Rolland, M.M.2    Herbeck, J.T.3
  • 222
    • 0031041375 scopus 로고    scopus 로고
    • In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues
    • Wong J.K., Ignacio C.C., Torriani F., et al. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997, 71:2059-2071.
    • (1997) J Virol , vol.71 , pp. 2059-2071
    • Wong, J.K.1    Ignacio, C.C.2    Torriani, F.3
  • 223
    • 0028874048 scopus 로고
    • Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
    • Ho D.D., Neumann A.U., Perelson A.S., et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
    • (1995) Nature , vol.373 , pp. 123-126
    • Ho, D.D.1    Neumann, A.U.2    Perelson, A.S.3
  • 224
    • 0028811974 scopus 로고
    • Viral dynamics in human immunodeficiency virus type 1 infection
    • Wei X., Ghosh S.K., Taylor M.E., et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
    • (1995) Nature , vol.373 , pp. 117-122
    • Wei, X.1    Ghosh, S.K.2    Taylor, M.E.3
  • 225
    • 0028952146 scopus 로고
    • HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy
    • Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267:483-489.
    • (1995) Science , vol.267 , pp. 483-489
    • Coffin, J.M.1
  • 226
    • 0029967721 scopus 로고    scopus 로고
    • HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
    • Perelson A.S., Neumann A.U., Markowitz M., et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582-1586.
    • (1996) Science , vol.271 , pp. 1582-1586
    • Perelson, A.S.1    Neumann, A.U.2    Markowitz, M.3
  • 227
    • 0025938499 scopus 로고
    • A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease
    • Watanabe M., Ringler D.J., Fultz P.N., et al. A chimpanzee-passaged human immunodeficiency virus isolate is cytopathic for chimpanzee cells but does not induce disease. J Virol 1991, 65:3344-3348.
    • (1991) J Virol , vol.65 , pp. 3344-3348
    • Watanabe, M.1    Ringler, D.J.2    Fultz, P.N.3
  • 228
    • 84902052511 scopus 로고    scopus 로고
    • The role of broad HIV-1 neutralising antibodies and vaccine protection from heterologous HIV-1 infection in chimpanzees
    • Bogers W., Koornstra W., Bjömdal Å., et al. The role of broad HIV-1 neutralising antibodies and vaccine protection from heterologous HIV-1 infection in chimpanzees. Immunol Lett 1997, 56(pt 2):292.
    • (1997) Immunol Lett , vol.56 , Issue.PART 2 , pp. 292
    • Bogers, W.1    Koornstra, W.2    Bjömdal, A.3
  • 229
    • 2342660749 scopus 로고    scopus 로고
    • What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?
    • Hirsch V.M. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS?. AIDS Rev 2004, 6:40-53.
    • (2004) AIDS Rev , vol.6 , pp. 40-53
    • Hirsch, V.M.1
  • 230
    • 36048968755 scopus 로고    scopus 로고
    • Understanding the benign nature of SIV infection in natural hosts
    • Silvestri G., Paiardini M., Pandrea I., et al. Understanding the benign nature of SIV infection in natural hosts. J Clin Invest 2007, 117:3148-3154.
    • (2007) J Clin Invest , vol.117 , pp. 3148-3154
    • Silvestri, G.1    Paiardini, M.2    Pandrea, I.3
  • 231
    • 49849088558 scopus 로고    scopus 로고
    • Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts
    • Pandrea I., Sodora D.L., Silvestri G., et al. Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol 2008, 29:419-428.
    • (2008) Trends Immunol , vol.29 , pp. 419-428
    • Pandrea, I.1    Sodora, D.L.2    Silvestri, G.3
  • 232
    • 59649097925 scopus 로고    scopus 로고
    • African non human primates infected by SIV: why don't they get sick? lessons from studies on the early phase of non-pathogenic SIV infection
    • Liovat A.S., Jacquelin B., Ploquin M.J., et al. African non human primates infected by SIV: why don't they get sick? lessons from studies on the early phase of non-pathogenic SIV infection. Curr HIV Res 2009, 7:39-50.
    • (2009) Curr HIV Res , vol.7 , pp. 39-50
    • Liovat, A.S.1    Jacquelin, B.2    Ploquin, M.J.3
  • 233
    • 68349157582 scopus 로고    scopus 로고
    • Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts
    • Sodora D.L., Allan J.S., Apetrei C., et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009, 15:861-865.
    • (2009) Nat Med , vol.15 , pp. 861-865
    • Sodora, D.L.1    Allan, J.S.2    Apetrei, C.3
  • 234
    • 0037343278 scopus 로고    scopus 로고
    • Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia
    • Silvestri G., Sodora D.L., Koup R.A., et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003, 18:441-452.
    • (2003) Immunity , vol.18 , pp. 441-452
    • Silvestri, G.1    Sodora, D.L.2    Koup, R.A.3
  • 235
    • 33646452400 scopus 로고    scopus 로고
    • Comparison of simian immunodeficiency virus SIVagmVer replication and CD4+ T-cell dynamics in vervet and sabaeus African green monkeys
    • Goldstein S., Brown C.R., Ourmanov I., et al. Comparison of simian immunodeficiency virus SIVagmVer replication and CD4+ T-cell dynamics in vervet and sabaeus African green monkeys. J Virol 2006, 80:4868-4877.
    • (2006) J Virol , vol.80 , pp. 4868-4877
    • Goldstein, S.1    Brown, C.R.2    Ourmanov, I.3
  • 236
    • 33745945059 scopus 로고    scopus 로고
    • Simian immunodeficiency viruses replication dynamics in African non-human primate hosts: common patterns and species-specific differences
    • Pandrea I., Silvestri G., Onanga R., et al. Simian immunodeficiency viruses replication dynamics in African non-human primate hosts: common patterns and species-specific differences. J Med Primatol 2006, 35:194-201.
    • (2006) J Med Primatol , vol.35 , pp. 194-201
    • Pandrea, I.1    Silvestri, G.2    Onanga, R.3
  • 237
    • 33745627473 scopus 로고    scopus 로고
    • The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus
    • Dunham R., Pagliardini P., Gordon S., et al. The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus. Blood 2006, 108:209-217.
    • (2006) Blood , vol.108 , pp. 209-217
    • Dunham, R.1    Pagliardini, P.2    Gordon, S.3
  • 238
    • 77953901782 scopus 로고    scopus 로고
    • Nonprogressive and progressive primate immunodeficiency lentivirus infections
    • Brenchley J.M., Silvestri G., Douek D.C. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 2010, 32:737-742.
    • (2010) Immunity , vol.32 , pp. 737-742
    • Brenchley, J.M.1    Silvestri, G.2    Douek, D.C.3
  • 239
    • 36048989052 scopus 로고    scopus 로고
    • Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence
    • Pandrea I.V., Gautam R., Ribeiro R.M., et al. Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007, 179:3035-3046.
    • (2007) J Immunol , vol.179 , pp. 3035-3046
    • Pandrea, I.V.1    Gautam, R.2    Ribeiro, R.M.3
  • 240
    • 53549129725 scopus 로고    scopus 로고
    • Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy
    • Marchetti G., Bellistri G.M., Borghi E., et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS 2008, 22:2035-2038.
    • (2008) AIDS , vol.22 , pp. 2035-2038
    • Marchetti, G.1    Bellistri, G.M.2    Borghi, E.3
  • 241
    • 53449093632 scopus 로고    scopus 로고
    • Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections
    • Brenchley J.M., Paiardini M., Knox K.S., et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008, 112:2826-2835.
    • (2008) Blood , vol.112 , pp. 2826-2835
    • Brenchley, J.M.1    Paiardini, M.2    Knox, K.S.3
  • 242
    • 39349088126 scopus 로고    scopus 로고
    • Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    • Hunt P.W., Brenchley J., Sinclair E., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008, 197:126-133.
    • (2008) J Infect Dis , vol.197 , pp. 126-133
    • Hunt, P.W.1    Brenchley, J.2    Sinclair, E.3
  • 243
    • 79251480064 scopus 로고    scopus 로고
    • Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue
    • Doitsh G., Cavrois M., Lassen K.G., et al. Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue. Cell 2010, 143:789-801.
    • (2010) Cell , vol.143 , pp. 789-801
    • Doitsh, G.1    Cavrois, M.2    Lassen, K.G.3
  • 244
    • 0034988648 scopus 로고    scopus 로고
    • AIDS: an immune response against the immune system: role of a precise tridimensional molecular mimicry
    • Serres P.F. AIDS: an immune response against the immune system: role of a precise tridimensional molecular mimicry. J Autoimmun 2001, 16:287-291.
    • (2001) J Autoimmun , vol.16 , pp. 287-291
    • Serres, P.F.1
  • 245
    • 0028873681 scopus 로고
    • Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression
    • Borrow P., Evans C.F., Oldstone M.B. Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol 1995, 69:1059-1070.
    • (1995) J Virol , vol.69 , pp. 1059-1070
    • Borrow, P.1    Evans, C.F.2    Oldstone, M.B.3
  • 246
    • 26444522325 scopus 로고    scopus 로고
    • HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway
    • Ji J., Sahu G.K., Braciale V.L., et al. HIV-1 induces IL-10 production in human monocytes via a CD4-independent pathway. Int Immunol 2005, 17:729-736.
    • (2005) Int Immunol , vol.17 , pp. 729-736
    • Ji, J.1    Sahu, G.K.2    Braciale, V.L.3
  • 247
    • 0025787430 scopus 로고
    • Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure
    • Odermatt B., Eppler M., Leist T.P., et al. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc Natl Acad Sci U S A 1991, 88:8252-8256.
    • (1991) Proc Natl Acad Sci U S A , vol.88 , pp. 8252-8256
    • Odermatt, B.1    Eppler, M.2    Leist, T.P.3
  • 248
    • 0028825476 scopus 로고
    • Follicular dendritic cells and human immunodeficiency virus infectivity
    • Heath S.L., Tew J.G., Szakal A.K. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995, 377:740-744.
    • (1995) Nature , vol.377 , pp. 740-744
    • Heath, S.L.1    Tew, J.G.2    Szakal, A.K.3
  • 249
    • 0026333671 scopus 로고
    • Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?
    • Matsuyama T., Kobayashi N., Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?. AIDS 1991, 5:1405-1417.
    • (1991) AIDS , vol.5 , pp. 1405-1417
    • Matsuyama, T.1    Kobayashi, N.2    Yamamoto, N.3
  • 250
    • 20244368227 scopus 로고    scopus 로고
    • Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai
    • Wawer M.J., Gray R.H., Sewankambo N.K., et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai. Uganda. J Infect Dis 2005, 191:1403-1409.
    • (2005) Uganda. J Infect Dis , vol.191 , pp. 1403-1409
    • Wawer, M.J.1    Gray, R.H.2    Sewankambo, N.K.3
  • 252
    • 41849127131 scopus 로고    scopus 로고
    • The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
    • Cohen M.S., Hellmann N., Levy J.A., et al. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J Clin Invest 2008, 118:1244-1254.
    • (2008) J Clin Invest , vol.118 , pp. 1244-1254
    • Cohen, M.S.1    Hellmann, N.2    Levy, J.A.3
  • 253
    • 77953614032 scopus 로고    scopus 로고
    • An overview of the relative risks of different sexual behaviours on HIV transmission
    • Dosekun O., Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. Curr Opin HIV AIDS 2010, 5:291-297.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 291-297
    • Dosekun, O.1    Fox, J.2
  • 254
    • 0028181261 scopus 로고
    • HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study
    • Kroner B.L., Rosenberg P.S., Aledort L.M., et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994, 7:279-286.
    • (1994) J Acquir Immune Defic Syndr , vol.7 , pp. 279-286
    • Kroner, B.L.1    Rosenberg, P.S.2    Aledort, L.M.3
  • 255
    • 0030590749 scopus 로고    scopus 로고
    • Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
    • Fowke K.R., Nagelkerke N.J., Kimani J., et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 1996, 348:1347-1351.
    • (1996) Lancet , vol.348 , pp. 1347-1351
    • Fowke, K.R.1    Nagelkerke, N.J.2    Kimani, J.3
  • 256
    • 78049442075 scopus 로고    scopus 로고
    • Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us?
    • Shearer G., Clerici M. Historical perspective on HIV-exposed seronegative individuals: has nature done the experiment for us?. J Infect Dis 2010, 202(suppl. 3):S329-S332.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 3
    • Shearer, G.1    Clerici, M.2
  • 257
    • 0033773876 scopus 로고    scopus 로고
    • Understanding the genetic diversity of HIV-1
    • McCutchan F.E. Understanding the genetic diversity of HIV-1. AIDS 2000, 14(suppl. 3):S31-S44.
    • (2000) AIDS , vol.14 , Issue.SUPPL.. 3
    • McCutchan, F.E.1
  • 258
    • 0023052240 scopus 로고
    • Isolation of a new human retrovirus from West African patients with AIDS
    • Clavel F., Guetard D., Brun-Vezinet F., et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986, 233:343-346.
    • (1986) Science , vol.233 , pp. 343-346
    • Clavel, F.1    Guetard, D.2    Brun-Vezinet, F.3
  • 259
    • 0028116919 scopus 로고
    • Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group
    • Charneau P., Borman A.M., Quillent C., et al. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 1994, 205:247-253.
    • (1994) Virology , vol.205 , pp. 247-253
    • Charneau, P.1    Borman, A.M.2    Quillent, C.3
  • 260
    • 0031695516 scopus 로고    scopus 로고
    • Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
    • Simon F., Mauclere P., Roques P., et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998, 4:1032-1037.
    • (1998) Nat Med , vol.4 , pp. 1032-1037
    • Simon, F.1    Mauclere, P.2    Roques, P.3
  • 261
    • 68349125395 scopus 로고    scopus 로고
    • A new human immunodeficiency virus derived from gorillas
    • Plantier J.C., Leoz M., Dickerson J.E., et al. A new human immunodeficiency virus derived from gorillas. Nat Med 2009, 15:871-872.
    • (2009) Nat Med , vol.15 , pp. 871-872
    • Plantier, J.C.1    Leoz, M.2    Dickerson, J.E.3
  • 262
    • 74049090141 scopus 로고    scopus 로고
    • Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun
    • Vessiere A., Rousset D., Kfutwah A., et al. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun. J Acquir Immune Defic Syndr 2010, 53:107-110.
    • (2010) J Acquir Immune Defic Syndr , vol.53 , pp. 107-110
    • Vessiere, A.1    Rousset, D.2    Kfutwah, A.3
  • 263
    • 78651387208 scopus 로고    scopus 로고
    • Confirmation of putative HIV-1 group P in Cameroon
    • Vallari A., Holzmayer V., Harris B., et al. Confirmation of putative HIV-1 group P in Cameroon. J Virol 2011, 85:1403-1407.
    • (2011) J Virol , vol.85 , pp. 1403-1407
    • Vallari, A.1    Holzmayer, V.2    Harris, B.3
  • 264
    • 0035162494 scopus 로고    scopus 로고
    • Evolutionary and immunological implications of contemporary HIV-1 variation
    • Korber B., Gaschen B., Yusim K., et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
    • (2001) Br Med Bull , vol.58 , pp. 19-42
    • Korber, B.1    Gaschen, B.2    Yusim, K.3
  • 265
    • 79952414942 scopus 로고    scopus 로고
    • Global trends in molecular epidemiology of HIV-1 during 2000-2007
    • Hemelaar J., Gouws E., Ghys P.D., et al. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
    • (2011) AIDS , vol.25 , pp. 679-689
    • Hemelaar, J.1    Gouws, E.2    Ghys, P.D.3
  • 266
    • 77954589754 scopus 로고    scopus 로고
    • Late for the epidemic: HIV/AIDS in Eastern Europe
    • Cohen J. Late for the epidemic: HIV/AIDS in Eastern Europe. Science 2010, 329:160-164.
    • (2010) Science , vol.329 , pp. 160-164
    • Cohen, J.1
  • 268
    • 0028947028 scopus 로고
    • Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans
    • Artenstein A.W., VanCott T.C., Mascola J.R., et al. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis 1995, 171:805-810.
    • (1995) J Infect Dis , vol.171 , pp. 805-810
    • Artenstein, A.W.1    VanCott, T.C.2    Mascola, J.R.3
  • 269
    • 0031776457 scopus 로고    scopus 로고
    • A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1
    • Gao F., Robertson D.L., Carruthers C.D., et al. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J Virol 1998, 72:5680-5698.
    • (1998) J Virol , vol.72 , pp. 5680-5698
    • Gao, F.1    Robertson, D.L.2    Carruthers, C.D.3
  • 270
    • 0033840552 scopus 로고    scopus 로고
    • Biological considerations in the development of a human immunodeficiency virus vaccine
    • Nathanson N., Mathieson B.J. Biological considerations in the development of a human immunodeficiency virus vaccine. J Infect Dis 2000, 182:579-589.
    • (2000) J Infect Dis , vol.182 , pp. 579-589
    • Nathanson, N.1    Mathieson, B.J.2
  • 271
    • 0036310370 scopus 로고    scopus 로고
    • Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users
    • Ramos A., Hu D.J., Nguyen L., et al. Intersubtype human immunodeficiency virus type 1 superinfection following seroconversion to primary infection in two injection drug users. J Virol 2002, 76:7444-7452.
    • (2002) J Virol , vol.76 , pp. 7444-7452
    • Ramos, A.1    Hu, D.J.2    Nguyen, L.3
  • 272
    • 33750085591 scopus 로고    scopus 로고
    • Lack of neutralizing antibody response to HIV-1 predisposes to superinfection
    • Smith D.M., Strain M.C., Frost S.D., et al. Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology 2006, 355:1-5.
    • (2006) Virology , vol.355 , pp. 1-5
    • Smith, D.M.1    Strain, M.C.2    Frost, S.D.3
  • 274
    • 19944427052 scopus 로고    scopus 로고
    • Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein
    • Gao F., Weaver E.A., Lu Z., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005, 79:1154-1163.
    • (2005) J Virol , vol.79 , pp. 1154-1163
    • Gao, F.1    Weaver, E.A.2    Lu, Z.3
  • 275
    • 23844468382 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope
    • Doria-Rose N.A., Learn G.H., Rodrigo A.G., et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005, 79:11214-11224.
    • (2005) J Virol , vol.79 , pp. 11214-11224
    • Doria-Rose, N.A.1    Learn, G.H.2    Rodrigo, A.G.3
  • 276
    • 23644454804 scopus 로고    scopus 로고
    • Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use
    • Thomson S.A., Jaramillo A.B., Shoobridge M., et al. Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005, 23:4647-4657.
    • (2005) Vaccine , vol.23 , pp. 4647-4657
    • Thomson, S.A.1    Jaramillo, A.B.2    Shoobridge, M.3
  • 277
    • 38949176103 scopus 로고    scopus 로고
    • Centralized HIV-1 envelope immunogens and neutralizing antibodies
    • Gao F., Liao H.X., Hahn B.H., et al. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 2007, 5:572-577.
    • (2007) Curr HIV Res , vol.5 , pp. 572-577
    • Gao, F.1    Liao, H.X.2    Hahn, B.H.3
  • 278
    • 69249211230 scopus 로고    scopus 로고
    • T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces
    • Korber B.T., Letvin N.L., Haynes B.F. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol 2009, 83:8300-8314.
    • (2009) J Virol , vol.83 , pp. 8300-8314
    • Korber, B.T.1    Letvin, N.L.2    Haynes, B.F.3
  • 279
    • 33846111016 scopus 로고    scopus 로고
    • Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
    • Fischer W., Perkins S., Theiler J., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13:100-106.
    • (2007) Nat Med , vol.13 , pp. 100-106
    • Fischer, W.1    Perkins, S.2    Theiler, J.3
  • 280
    • 77749233746 scopus 로고    scopus 로고
    • HIV vaccines: mosaic approach to virus diversity
    • Corey L., McElrath M.J. HIV vaccines: mosaic approach to virus diversity. Nat Med 2010, 16:268-270.
    • (2010) Nat Med , vol.16 , pp. 268-270
    • Corey, L.1    McElrath, M.J.2
  • 281
    • 77955517246 scopus 로고    scopus 로고
    • Novel adenovirus vector-based vaccines for HIV-1
    • Barouch D.H. Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 2010, 5:386-390.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 386-390
    • Barouch, D.H.1
  • 282
    • 77949264937 scopus 로고    scopus 로고
    • Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys
    • Santra S., Liao H.X., Zhang R., et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010, 16:324-328.
    • (2010) Nat Med , vol.16 , pp. 324-328
    • Santra, S.1    Liao, H.X.2    Zhang, R.3
  • 283
    • 0034723385 scopus 로고    scopus 로고
    • AIDS as a zoonosis: scientific and public health implications
    • Hahn B.H., Shaw G.M., De Cock K.M. AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
    • (2000) Science , vol.287 , pp. 607-614
    • Hahn, B.H.1    Shaw, G.M.2    De Cock, K.M.3
  • 284
    • 33745059199 scopus 로고    scopus 로고
    • Chimpanzee reservoirs of pandemic and nonpandemic HIV-1
    • Keele B.F., Van Heuverswyn F., Li Y., et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
    • (2006) Science , vol.313 , pp. 523-526
    • Keele, B.F.1    Van Heuverswyn, F.2    Li, Y.3
  • 285
    • 0034625771 scopus 로고    scopus 로고
    • Timing the ancestor of the HIV-1 pandemic strains
    • Korber B., Muldoon M., Theiler J., et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000, 288:1789-1796.
    • (2000) Science , vol.288 , pp. 1789-1796
    • Korber, B.1    Muldoon, M.2    Theiler, J.3
  • 286
    • 67049119333 scopus 로고    scopus 로고
    • Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2
    • Wertheim J.O., Worobey M. Dating the age of the SIV lineages that gave rise to HIV-1 and HIV-2. PLoS Comput Biol 2009, 5:e1000377.
    • (2009) PLoS Comput Biol , vol.5
    • Wertheim, J.O.1    Worobey, M.2
  • 288
    • 0033521911 scopus 로고    scopus 로고
    • Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes
    • Gao F., Bailes E., Robertson D.L., et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397:436-441.
    • (1999) Nature , vol.397 , pp. 436-441
    • Gao, F.1    Bailes, E.2    Robertson, D.L.3
  • 290
    • 73949151602 scopus 로고    scopus 로고
    • Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas
    • Neel C., Etienne L., Li Y., et al. Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas. J Virol 2010, 84:1464-1476.
    • (2010) J Virol , vol.84 , pp. 1464-1476
    • Neel, C.1    Etienne, L.2    Li, Y.3
  • 291
    • 30844450364 scopus 로고    scopus 로고
    • Widely varying SIV prevalence rates in naturally infected primate species from Cameroon
    • Aghokeng A.F., Liu W., Bibollet-Ruche F., et al. Widely varying SIV prevalence rates in naturally infected primate species from Cameroon. Virology 2006, 345:174-189.
    • (2006) Virology , vol.345 , pp. 174-189
    • Aghokeng, A.F.1    Liu, W.2    Bibollet-Ruche, F.3
  • 292
    • 78149375894 scopus 로고    scopus 로고
    • Les variants des groupes N, O et P du virus de l'immunodéficience humaine de type 1
    • Vessière A., Simon F., Plantier J.C. Les variants des groupes N, O et P du virus de l'immunodéficience humaine de type 1. Virologie 2010, 14:334-348.
    • (2010) Virologie , vol.14 , pp. 334-348
    • Vessière, A.1    Simon, F.2    Plantier, J.C.3
  • 293
    • 0028043670 scopus 로고
    • Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild
    • Jin M.J., Rogers J., Phillips-Conroy J.E., et al. Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild. J Virol 1994, 68:8454-8460.
    • (1994) J Virol , vol.68 , pp. 8454-8460
    • Jin, M.J.1    Rogers, J.2    Phillips-Conroy, J.E.3
  • 294
    • 0038047665 scopus 로고    scopus 로고
    • Hybrid origin of SIV in chimpanzees
    • Bailes E., Gao F., Bibollet-Ruche F., et al. Hybrid origin of SIV in chimpanzees. Science 2003, 300:1713.
    • (2003) Science , vol.300 , pp. 1713
    • Bailes, E.1    Gao, F.2    Bibollet-Ruche, F.3
  • 295
    • 77956685623 scopus 로고    scopus 로고
    • Island biogeography reveals the deep history of SIV
    • Worobey M., Telfer P., Souquiere S., et al. Island biogeography reveals the deep history of SIV. Science 2010, 329:1487.
    • (2010) Science , vol.329 , pp. 1487
    • Worobey, M.1    Telfer, P.2    Souquiere, S.3
  • 296
    • 53349127137 scopus 로고    scopus 로고
    • Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960
    • Worobey M., Gemmel M., Teuwen D.E., et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455:661-664.
    • (2008) Nature , vol.455 , pp. 661-664
    • Worobey, M.1    Gemmel, M.2    Teuwen, D.E.3
  • 297
    • 3843100510 scopus 로고    scopus 로고
    • The molecular population genetics of HIV-1 group O
    • Lemey P., Pybus O.G., Rambaut A., et al. The molecular population genetics of HIV-1 group O. Genetics 2004, 167:1059-1068.
    • (2004) Genetics , vol.167 , pp. 1059-1068
    • Lemey, P.1    Pybus, O.G.2    Rambaut, A.3
  • 298
    • 77956316616 scopus 로고    scopus 로고
    • High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains
    • De Sousa J.D., Müller V., Lemey P., et al. High GUD incidence in the early 20 century created a particularly permissive time window for the origin and initial spread of epidemic HIV strains. PLoS One 2010, 5:e9936.
    • (2010) PLoS One , vol.5
    • De Sousa, J.D.1    Müller, V.2    Lemey, P.3
  • 299
    • 0036093398 scopus 로고    scopus 로고
    • Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat
    • Peeters M., Courgnaud V., Abela B., et al. Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat. Emerg Infect Dis 2002, 8:451-457.
    • (2002) Emerg Infect Dis , vol.8 , pp. 451-457
    • Peeters, M.1    Courgnaud, V.2    Abela, B.3
  • 300
    • 77951092393 scopus 로고    scopus 로고
    • Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions
    • Aghokeng A.F., Ayouba A., Mpoudi-Ngole E., et al. Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions. Infect Genet Evol 2010, 10:386-396.
    • (2010) Infect Genet Evol , vol.10 , pp. 386-396
    • Aghokeng, A.F.1    Ayouba, A.2    Mpoudi-Ngole, E.3
  • 301
    • 32044468934 scopus 로고    scopus 로고
    • Amplified HIV transmission during early-stage infection
    • Hayes R.J., White R.G. Amplified HIV transmission during early-stage infection. J Infect Dis 2006, 193:604-606.
    • (2006) J Infect Dis , vol.193 , pp. 604-606
    • Hayes, R.J.1    White, R.G.2
  • 302
    • 33947375214 scopus 로고    scopus 로고
    • High rates of forward transmission events after acute/early HIV-1 infection
    • Brenner B.G., Roger M., Routy J.P., et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007, 195:951-959.
    • (2007) J Infect Dis , vol.195 , pp. 951-959
    • Brenner, B.G.1    Roger, M.2    Routy, J.P.3
  • 303
    • 34447527370 scopus 로고    scopus 로고
    • How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?
    • Pinkerton S.D. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission?. AIDS 2007, 21:1625-1629.
    • (2007) AIDS , vol.21 , pp. 1625-1629
    • Pinkerton, S.D.1
  • 304
    • 63149127441 scopus 로고    scopus 로고
    • High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection
    • Ma Z.M., Stone M., Piatak M., et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009, 83:3288-3297.
    • (2009) J Virol , vol.83 , pp. 3288-3297
    • Ma, Z.M.1    Stone, M.2    Piatak, M.3
  • 305
    • 77957569460 scopus 로고    scopus 로고
    • Acute HIV-1 infection: what's new? where are we going?
    • D'Souza M.P., Axten K.L., Hecht F.M. Acute HIV-1 infection: what's new? where are we going?. J Infect Dis 2010, 202(suppl. 2):S267-S269.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 2
    • D'Souza, M.P.1    Axten, K.L.2    Hecht, F.M.3
  • 306
    • 70449371426 scopus 로고    scopus 로고
    • Circumcision and risk of HIV infection in Australian homosexual men
    • Templeton D.J., Jin F., Mao L., et al. Circumcision and risk of HIV infection in Australian homosexual men. AIDS 2009, 23:2347-2351.
    • (2009) AIDS , vol.23 , pp. 2347-2351
    • Templeton, D.J.1    Jin, F.2    Mao, L.3
  • 307
    • 84855902980 scopus 로고    scopus 로고
    • Determinants of per-coital-act HIV-1 infectivity among African HIV-1 serodiscordant couples
    • Hughes J.P., Baeten J.M., Lingappa J.R., et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1 serodiscordant couples. J Infect Dis 2012, 205:358-365.
    • (2012) J Infect Dis , vol.205 , pp. 358-365
    • Hughes, J.P.1    Baeten, J.M.2    Lingappa, J.R.3
  • 308
    • 77951065603 scopus 로고    scopus 로고
    • UNAIDS, Joint United Nations Programme on HIV/AIDS, Geneva
    • UNAIDS AIDS Epidemic Update 2009 2009, Joint United Nations Programme on HIV/AIDS, Geneva.
    • (2009) AIDS Epidemic Update 2009
  • 309
    • 77954572785 scopus 로고    scopus 로고
    • Tracing the regional rise of HIV
    • Cohen J. Tracing the regional rise of HIV. Science 2010, 329:161.
    • (2010) Science , vol.329 , pp. 161
    • Cohen, J.1
  • 310
    • 77949583044 scopus 로고    scopus 로고
    • AIDS in America: forgotten but not gone
    • El-Sadr W.M., Mayer K.H., Hodder S.L. AIDS in America: forgotten but not gone. N Engl J Med 2010, 362:967-970.
    • (2010) N Engl J Med , vol.362 , pp. 967-970
    • El-Sadr, W.M.1    Mayer, K.H.2    Hodder, S.L.3
  • 311
    • 48749117983 scopus 로고    scopus 로고
    • Estimation of HIV incidence in the United States
    • Hall H.I., Song R., Rhodes P., et al. Estimation of HIV incidence in the United States. JAMA 2008, 300:520-529.
    • (2008) JAMA , vol.300 , pp. 520-529
    • Hall, H.I.1    Song, R.2    Rhodes, P.3
  • 312
    • 79953773356 scopus 로고    scopus 로고
    • Why is HIV ravaging D.C.?
    • McEnery R. Why is HIV ravaging D.C.?. IAVI Rep 2010, 14:10-13.
    • (2010) IAVI Rep , vol.14 , pp. 10-13
    • McEnery, R.1
  • 313
    • 67651049000 scopus 로고    scopus 로고
    • Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk
    • Magnus M., Kuo I., Shelley K., et al. Risk factors driving the emergence of a generalized heterosexual HIV epidemic in Washington, District of Columbia networks at risk. AIDS 2009, 23:1277-1284.
    • (2009) AIDS , vol.23 , pp. 1277-1284
    • Magnus, M.1    Kuo, I.2    Shelley, K.3
  • 315
    • 4043060710 scopus 로고    scopus 로고
    • Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know
    • Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10:806-810.
    • (2004) Nat Med , vol.10 , pp. 806-810
    • Pantaleo, G.1    Koup, R.A.2
  • 316
    • 42049102821 scopus 로고    scopus 로고
    • Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus
    • Friedrich T.C., Watkins D.I. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr Opin HIV AIDS 2008, 3:393-398.
    • (2008) Curr Opin HIV AIDS , vol.3 , pp. 393-398
    • Friedrich, T.C.1    Watkins, D.I.2
  • 317
    • 78650598765 scopus 로고    scopus 로고
    • The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors
    • Koup R.A., Graham B.S., Douek D.C. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 2011, 11:65-70.
    • (2011) Nat Rev Immunol , vol.11 , pp. 65-70
    • Koup, R.A.1    Graham, B.S.2    Douek, D.C.3
  • 318
    • 57349127300 scopus 로고    scopus 로고
    • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
    • Tomaras G.D., Yates N.L., Liu P., et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008, 82:12449-12463.
    • (2008) J Virol , vol.82 , pp. 12449-12463
    • Tomaras, G.D.1    Yates, N.L.2    Liu, P.3
  • 319
    • 49149118421 scopus 로고    scopus 로고
    • Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection
    • Bunnik E.M., Pisas L., van Nuenen A.C., et al. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008, 82:7932-7941.
    • (2008) J Virol , vol.82 , pp. 7932-7941
    • Bunnik, E.M.1    Pisas, L.2    van Nuenen, A.C.3
  • 320
    • 37848999666 scopus 로고    scopus 로고
    • The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen
    • Ching L.K., Vlachogiannis G., Bosch K.A., et al. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen. J Virol 2008, 82:949-956.
    • (2008) J Virol , vol.82 , pp. 949-956
    • Ching, L.K.1    Vlachogiannis, G.2    Bosch, K.A.3
  • 321
    • 0141788494 scopus 로고    scopus 로고
    • Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate
    • Srivastava I.K., Stamatatos L., Kan E., et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003, 77:11244-11259.
    • (2003) J Virol , vol.77 , pp. 11244-11259
    • Srivastava, I.K.1    Stamatatos, L.2    Kan, E.3
  • 322
    • 0025071687 scopus 로고
    • Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant
    • LaRosa G.J., Davide J.P., Weinhold K., et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249:932-935.
    • (1990) Science , vol.249 , pp. 932-935
    • LaRosa, G.J.1    Davide, J.P.2    Weinhold, K.3
  • 323
    • 0026361459 scopus 로고
    • The role of the V3 loop of gp120 in HIV infection
    • Moore J.P., Nara P.L. The role of the V3 loop of gp120 in HIV infection. AIDS 1991, 5(suppl. 2):S21-S33.
    • (1991) AIDS , vol.5 , Issue.SUPPL.. 2
    • Moore, J.P.1    Nara, P.L.2
  • 324
    • 16244419386 scopus 로고    scopus 로고
    • Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles
    • Gorny M.K., Stamatatos L., Volsky B., et al. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol 2005, 79:5232-5237.
    • (2005) J Virol , vol.79 , pp. 5232-5237
    • Gorny, M.K.1    Stamatatos, L.2    Volsky, B.3
  • 325
    • 33846556067 scopus 로고    scopus 로고
    • Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence
    • Honnen W.J., Krachmarov C., Kayman S.C., et al. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J Virol 2007, 81:1424-1432.
    • (2007) J Virol , vol.81 , pp. 1424-1432
    • Honnen, W.J.1    Krachmarov, C.2    Kayman, S.C.3
  • 326
    • 38949186531 scopus 로고    scopus 로고
    • Roles of HIV-1 Env variable regions in viral neutralization and vaccine development
    • Pinter A. Roles of HIV-1 Env variable regions in viral neutralization and vaccine development. Curr HIV Res 2007, 5:542-553.
    • (2007) Curr HIV Res , vol.5 , pp. 542-553
    • Pinter, A.1
  • 327
  • 328
    • 33646146379 scopus 로고    scopus 로고
    • GP120: target for neutralizing HIV-1 antibodies
    • Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006, 24:739-769.
    • (2006) Annu Rev Immunol , vol.24 , pp. 739-769
    • Pantophlet, R.1    Burton, D.R.2
  • 329
    • 56449131391 scopus 로고    scopus 로고
    • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
    • Binley J.M., Lybarger E.A., Crooks E.T., et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668.
    • (2008) J Virol , vol.82 , pp. 11651-11668
    • Binley, J.M.1    Lybarger, E.A.2    Crooks, E.T.3
  • 330
    • 70349887757 scopus 로고    scopus 로고
    • Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    • Walker L.M., Phogat S.K., Chan-Hui P.Y., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
    • (2009) Science , vol.326 , pp. 285-289
    • Walker, L.M.1    Phogat, S.K.2    Chan-Hui, P.Y.3
  • 331
    • 58149517700 scopus 로고    scopus 로고
    • Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    • Li Y., Svehla K., Louder M.K., et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059.
    • (2009) J Virol , vol.83 , pp. 1045-1059
    • Li, Y.1    Svehla, K.2    Louder, M.K.3
  • 332
    • 73949084963 scopus 로고    scopus 로고
    • Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables
    • Doria-Rose N.A., Klein R.M., Daniels M.G., et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010, 84:1631-1636.
    • (2010) J Virol , vol.84 , pp. 1631-1636
    • Doria-Rose, N.A.1    Klein, R.M.2    Daniels, M.G.3
  • 333
    • 63849131879 scopus 로고    scopus 로고
    • Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    • Scheid J.F., Mouquet H., Feldhahn N., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
    • (2009) Nature , vol.458 , pp. 636-640
    • Scheid, J.F.1    Mouquet, H.2    Feldhahn, N.3
  • 334
    • 79551518897 scopus 로고    scopus 로고
    • Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    • Mikell I., Sather D.N., Kalams S.A., et al. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011, 7:e1001251.
    • (2011) PLoS Pathog , vol.7
    • Mikell, I.1    Sather, D.N.2    Kalams, S.A.3
  • 335
    • 58149487645 scopus 로고    scopus 로고
    • Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    • Sather D.N., Armann J., Ching L.K., et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009, 83:757-769.
    • (2009) J Virol , vol.83 , pp. 757-769
    • Sather, D.N.1    Armann, J.2    Ching, L.K.3
  • 336
    • 69149083668 scopus 로고    scopus 로고
    • Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
    • Stamatatos L., Morris L., Burton D.R., et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. Nat Med 2009, 15:866-870.
    • (2009) Nat Med , vol.15 , pp. 866-870
    • Stamatatos, L.1    Morris, L.2    Burton, D.R.3
  • 337
    • 70349298392 scopus 로고    scopus 로고
    • Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression
    • Piantadosi A., Panteleeff D., Blish C.A., et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J Virol 2009, 83:10269-10274.
    • (2009) J Virol , vol.83 , pp. 10269-10274
    • Piantadosi, A.1    Panteleeff, D.2    Blish, C.A.3
  • 338
    • 58149399396 scopus 로고    scopus 로고
    • Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies
    • Doria-Rose N.A., Klein R.M., Manion M.M., et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009, 83:188-199.
    • (2009) J Virol , vol.83 , pp. 188-199
    • Doria-Rose, N.A.1    Klein, R.M.2    Manion, M.M.3
  • 339
    • 77957573505 scopus 로고    scopus 로고
    • The humoral response to HIV-1: new insights, renewed focus
    • Alter G., Moody M.A. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis 2010, 202(suppl. 2):S315-S322.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 2
    • Alter, G.1    Moody, M.A.2
  • 340
    • 67650453747 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
    • Simek M.D., Rida W., Priddy F.H., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 2009, 83:7337-7348.
    • (2009) J Virol , vol.83 , pp. 7337-7348
    • Simek, M.D.1    Rida, W.2    Priddy, F.H.3
  • 341
    • 77949411309 scopus 로고    scopus 로고
    • Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4
    • Robinson J.E., Franco K., Elliott D.H., et al. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 2010, 84:3443-3453.
    • (2010) J Virol , vol.84 , pp. 3443-3453
    • Robinson, J.E.1    Franco, K.2    Elliott, D.H.3
  • 342
    • 0032907674 scopus 로고    scopus 로고
    • Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
    • Shibata R., Igarashi T., Haigwood N., et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med 1999, 5:204-210.
    • (1999) Nat Med , vol.5 , pp. 204-210
    • Shibata, R.1    Igarashi, T.2    Haigwood, N.3
  • 343
    • 0033952103 scopus 로고    scopus 로고
    • Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    • Baba T.W., Liska V., Hofmann-Lehmann R., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000, 6:200-206.
    • (2000) Nat Med , vol.6 , pp. 200-206
    • Baba, T.W.1    Liska, V.2    Hofmann-Lehmann, R.3
  • 344
    • 0037029924 scopus 로고    scopus 로고
    • Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1
    • Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002, 20:1922-1925.
    • (2002) Vaccine , vol.20 , pp. 1922-1925
    • Mascola, J.R.1
  • 345
    • 0033951746 scopus 로고    scopus 로고
    • Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
    • Mascola J.R., Stiegler G., VanCott T.C., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
    • (2000) Nat Med , vol.6 , pp. 207-210
    • Mascola, J.R.1    Stiegler, G.2    VanCott, T.C.3
  • 346
    • 38449097264 scopus 로고    scopus 로고
    • Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region
    • Mantis N.J., Palaia J., Hessell A.J., et al. Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region. J Immunol 2007, 179:3144-3152.
    • (2007) J Immunol , vol.179 , pp. 3144-3152
    • Mantis, N.J.1    Palaia, J.2    Hessell, A.J.3
  • 347
    • 68349160853 scopus 로고    scopus 로고
    • Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
    • Hessell A.J., Poignard P., Hunter M., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009, 15:951-954.
    • (2009) Nat Med , vol.15 , pp. 951-954
    • Hessell, A.J.1    Poignard, P.2    Hunter, M.3
  • 348
    • 67249131966 scopus 로고    scopus 로고
    • Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers
    • Hessell A.J., Rakasz E.G., Poignard P., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:e1000433.
    • (2009) PLoS Pathog , vol.5
    • Hessell, A.J.1    Rakasz, E.G.2    Poignard, P.3
  • 349
    • 68349150945 scopus 로고    scopus 로고
    • Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys
    • Johnson P.R., Schnepp B.C., Zhang J., et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-906.
    • (2009) Nat Med , vol.15 , pp. 901-906
    • Johnson, P.R.1    Schnepp, B.C.2    Zhang, J.3
  • 350
    • 0032947286 scopus 로고    scopus 로고
    • Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    • Mascola J.R., Lewis M.G., Stiegler G., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
    • (1999) J Virol , vol.73 , pp. 4009-4018
    • Mascola, J.R.1    Lewis, M.G.2    Stiegler, G.3
  • 351
    • 73949154006 scopus 로고    scopus 로고
    • Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
    • Hessell A.J., Rakasz E.G., Tehrani D.M., et al. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 2010, 84:1302-1313.
    • (2010) J Virol , vol.84 , pp. 1302-1313
    • Hessell, A.J.1    Rakasz, E.G.2    Tehrani, D.M.3
  • 352
    • 0034904087 scopus 로고    scopus 로고
    • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge
    • Hofmann-Lehmann R., Vlasak J., Rasmussen R.A., et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001, 75:7470-7480.
    • (2001) J Virol , vol.75 , pp. 7470-7480
    • Hofmann-Lehmann, R.1    Vlasak, J.2    Rasmussen, R.A.3
  • 353
    • 0033119374 scopus 로고    scopus 로고
    • Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
    • Poignard P., Sabbe R., Picchio G.R., et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999, 10:431-438.
    • (1999) Immunity , vol.10 , pp. 431-438
    • Poignard, P.1    Sabbe, R.2    Picchio, G.R.3
  • 354
    • 34249940652 scopus 로고    scopus 로고
    • Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection
    • Gray E.S., Moore P.L., Choge I.A., et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 2007, 81:6187-6196.
    • (2007) J Virol , vol.81 , pp. 6187-6196
    • Gray, E.S.1    Moore, P.L.2    Choge, I.A.3
  • 355
    • 77749306129 scopus 로고    scopus 로고
    • Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression
    • Euler Z., van Gils M.J., Bunnik E.M., et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis 2010, 201:1045-1053.
    • (2010) J Infect Dis , vol.201 , pp. 1045-1053
    • Euler, Z.1    van Gils, M.J.2    Bunnik, E.M.3
  • 356
    • 1542317452 scopus 로고    scopus 로고
    • HIV vaccine design and the neutralizing antibody problem
    • Burton D.R., Desrosiers R.C., Doms R.W., et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004, 5:233-236.
    • (2004) Nat Immunol , vol.5 , pp. 233-236
    • Burton, D.R.1    Desrosiers, R.C.2    Doms, R.W.3
  • 358
    • 77955630528 scopus 로고    scopus 로고
    • AIDS/HIV: a boost for HIV vaccine design
    • Burton D.R., Weiss R.A. AIDS/HIV: a boost for HIV vaccine design. Science 2010, 329:770-773.
    • (2010) Science , vol.329 , pp. 770-773
    • Burton, D.R.1    Weiss, R.A.2
  • 359
    • 34347256384 scopus 로고    scopus 로고
    • Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets
    • Phogat S., Wyatt R.T., Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007, 262:26-43.
    • (2007) J Intern Med , vol.262 , pp. 26-43
    • Phogat, S.1    Wyatt, R.T.2    Karlsson Hedestam, G.B.3
  • 360
    • 77956689545 scopus 로고    scopus 로고
    • Pushing the envelope on HIV-1 neutralization
    • Joyce J.G., ter Meulen J. Pushing the envelope on HIV-1 neutralization. Nat Biotechnol 2010, 28:929-931.
    • (2010) Nat Biotechnol , vol.28 , pp. 929-931
    • Joyce, J.G.1    Ter Meulen, J.2
  • 361
    • 77951882041 scopus 로고    scopus 로고
    • Toward an antibody-based HIV-1 vaccine
    • Hoxie J.A. Toward an antibody-based HIV-1 vaccine. Annu Rev Med 2010, 61:135-152.
    • (2010) Annu Rev Med , vol.61 , pp. 135-152
    • Hoxie, J.A.1
  • 362
    • 69549091674 scopus 로고    scopus 로고
    • Challenges for structure-based HIV vaccine design
    • Schief W.R., Ban Y.E., Stamatatos L. Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS 2009, 4:431-440.
    • (2009) Curr Opin HIV AIDS , vol.4 , pp. 431-440
    • Schief, W.R.1    Ban, Y.E.2    Stamatatos, L.3
  • 363
    • 0033524838 scopus 로고    scopus 로고
    • Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
    • Schmitz J.E., Kuroda M.J., Santra S., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
    • (1999) Science , vol.283 , pp. 857-860
    • Schmitz, J.E.1    Kuroda, M.J.2    Santra, S.3
  • 364
    • 33744902339 scopus 로고    scopus 로고
    • Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239
    • Wilson N.A., Reed J., Napoe G.S., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006, 80:5875-5885.
    • (2006) J Virol , vol.80 , pp. 5875-5885
    • Wilson, N.A.1    Reed, J.2    Napoe, G.S.3
  • 365
    • 58149267963 scopus 로고    scopus 로고
    • Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys
    • Liu J., O'Brien K.L., Lynch D.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
    • (2009) Nature , vol.457 , pp. 87-91
    • Liu, J.1    O'Brien, K.L.2    Lynch, D.M.3
  • 366
    • 61949216736 scopus 로고    scopus 로고
    • Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge
    • Hansen S.G., Vieville C., Whizin N., et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009, 15:293-299.
    • (2009) Nat Med , vol.15 , pp. 293-299
    • Hansen, S.G.1    Vieville, C.2    Whizin, N.3
  • 367
    • 41949088384 scopus 로고    scopus 로고
    • Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques
    • Sadagopal S., Amara R.R., Kannanganat S., et al. Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques. J Virol 2008, 82:4149-4153.
    • (2008) J Virol , vol.82 , pp. 4149-4153
    • Sadagopal, S.1    Amara, R.R.2    Kannanganat, S.3
  • 368
    • 33947385340 scopus 로고    scopus 로고
    • Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication
    • Friedrich T.C., Valentine L.E., Yant L.J., et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol 2007, 81:3465-3476.
    • (2007) J Virol , vol.81 , pp. 3465-3476
    • Friedrich, T.C.1    Valentine, L.E.2    Yant, L.J.3
  • 369
    • 55549145769 scopus 로고    scopus 로고
    • With minimal systemic T-cell expansion, CD8+ T cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus
    • Genesca M., Skinner P.J., Hong J.J., et al. With minimal systemic T-cell expansion, CD8+ T cells mediate protection of rhesus macaques immunized with attenuated simian-human immunodeficiency virus SHIV89.6 from vaginal challenge with simian immunodeficiency virus. J Virol 2008, 82:11181-11196.
    • (2008) J Virol , vol.82 , pp. 11181-11196
    • Genesca, M.1    Skinner, P.J.2    Hong, J.J.3
  • 370
    • 57449114534 scopus 로고    scopus 로고
    • Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6
    • Genesca M., McChesney M.B., Miller C.J. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J Intern Med 2009, 265:67-77.
    • (2009) J Intern Med , vol.265 , pp. 67-77
    • Genesca, M.1    McChesney, M.B.2    Miller, C.J.3
  • 371
    • 78049423723 scopus 로고    scopus 로고
    • Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations
    • Horton R.E., McLaren P.J., Fowke K., et al. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis 2010, 202(suppl. 3):S377-S381.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 3
    • Horton, R.E.1    McLaren, P.J.2    Fowke, K.3
  • 372
    • 78049445926 scopus 로고    scopus 로고
    • Determinants of protection among HIV-exposed seronegative persons: an overview
    • Lederman M.M., Alter G., Daskalakis D.C., et al. Determinants of protection among HIV-exposed seronegative persons: an overview. J Infect Dis 2010, 202(suppl. 3):S333-S338.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 3
    • Lederman, M.M.1    Alter, G.2    Daskalakis, D.C.3
  • 373
    • 77953701383 scopus 로고    scopus 로고
    • Control of HIV-1 replication in elite suppressors
    • Blankson J.N. Control of HIV-1 replication in elite suppressors. Discov Med 2010, 9:261-266.
    • (2010) Discov Med , vol.9 , pp. 261-266
    • Blankson, J.N.1
  • 374
    • 58149375456 scopus 로고    scopus 로고
    • Elite control of HIV infection: implications for vaccine design
    • Baker B.M., Block B.L., Rothchild A.C., et al. Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther 2009, 9:55-69.
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 55-69
    • Baker, B.M.1    Block, B.L.2    Rothchild, A.C.3
  • 375
    • 33646453478 scopus 로고    scopus 로고
    • Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy
    • Bailey J.R., Lassen K.G., Yang H.C., et al. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 2006, 80:4758-4770.
    • (2006) J Virol , vol.80 , pp. 4758-4770
    • Bailey, J.R.1    Lassen, K.G.2    Yang, H.C.3
  • 376
    • 33646869319 scopus 로고    scopus 로고
    • Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection
    • Duvall M.G., Jaye A., Dong T., et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006, 176:6973-6981.
    • (2006) J Immunol , vol.176 , pp. 6973-6981
    • Duvall, M.G.1    Jaye, A.2    Dong, T.3
  • 377
    • 42049115065 scopus 로고    scopus 로고
    • Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection
    • Leligdowicz A., Rowland-Jones S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines 2008, 7:319-331.
    • (2008) Expert Rev Vaccines , vol.7 , pp. 319-331
    • Leligdowicz, A.1    Rowland-Jones, S.2
  • 378
    • 0030997137 scopus 로고    scopus 로고
    • Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms
    • Yang O.O., Kalams S.A., Trocha A., et al. Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997, 71:3120-3128.
    • (1997) J Virol , vol.71 , pp. 3120-3128
    • Yang, O.O.1    Kalams, S.A.2    Trocha, A.3
  • 379
    • 0034646143 scopus 로고    scopus 로고
    • HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
    • Migueles S.A., Sabbaghian M.S., Shupert W.L., et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000, 97:2709-2714.
    • (2000) Proc Natl Acad Sci U S A , vol.97 , pp. 2709-2714
    • Migueles, S.A.1    Sabbaghian, M.S.2    Shupert, W.L.3
  • 380
    • 33750822983 scopus 로고    scopus 로고
    • Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection
    • Horton H., Frank I., Baydo R., et al. Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection. J Immunol 2006, 177:7406-7415.
    • (2006) J Immunol , vol.177 , pp. 7406-7415
    • Horton, H.1    Frank, I.2    Baydo, R.3
  • 381
    • 33646472100 scopus 로고    scopus 로고
    • HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently
    • Turnbull E.L., Lopes A.R., Jones N.A., et al. HIV-1 epitope-specific CD8+ T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J Immunol 2006, 176:6130-6146.
    • (2006) J Immunol , vol.176 , pp. 6130-6146
    • Turnbull, E.L.1    Lopes, A.R.2    Jones, N.A.3
  • 382
    • 33644755541 scopus 로고    scopus 로고
    • Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control
    • Zuniga R., Lucchetti A., Galvan P., et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 2006, 80:3122-3125.
    • (2006) J Virol , vol.80 , pp. 3122-3125
    • Zuniga, R.1    Lucchetti, A.2    Galvan, P.3
  • 383
    • 38949168855 scopus 로고    scopus 로고
    • Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads
    • Rolland M., Heckerman D., Deng W., et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS One 2008, 3:e1424.
    • (2008) PLoS One , vol.3
    • Rolland, M.1    Heckerman, D.2    Deng, W.3
  • 384
    • 78650165514 scopus 로고    scopus 로고
    • Genetics: first-class control of HIV-1
    • McMichael A.J., Jones E.Y. Genetics: first-class control of HIV-1. Science 2010, 330:1488-1490.
    • (2010) Science , vol.330 , pp. 1488-1490
    • McMichael, A.J.1    Jones, E.Y.2
  • 385
    • 79952452307 scopus 로고    scopus 로고
    • An additive effect of protective host genetic factors correlates with HIV nonprogression status
    • Salgado M., Simon A., Sanz-Minguela B., et al. An additive effect of protective host genetic factors correlates with HIV nonprogression status. J Acquir Immune Defic Syndr 2011, 56:300-305.
    • (2011) J Acquir Immune Defic Syndr , vol.56 , pp. 300-305
    • Salgado, M.1    Simon, A.2    Sanz-Minguela, B.3
  • 386
    • 0036171258 scopus 로고    scopus 로고
    • Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma
    • Edwards B.H., Bansal A., Sabbaj S., et al. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 2002, 76:2298-2305.
    • (2002) J Virol , vol.76 , pp. 2298-2305
    • Edwards, B.H.1    Bansal, A.2    Sabbaj, S.3
  • 387
    • 34249852256 scopus 로고    scopus 로고
    • HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype
    • Saez-Cirion A., Lacabaratz C., Lambotte O., et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 2007, 104:6776-6781.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 6776-6781
    • Saez-Cirion, A.1    Lacabaratz, C.2    Lambotte, O.3
  • 388
    • 34249774014 scopus 로고    scopus 로고
    • Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection
    • Critchfield J.W., Lemongello D., Walker D.H., et al. Multifunctional human immunodeficiency virus (HIV) gag-specific CD8+ T-cell responses in rectal mucosa and peripheral blood mononuclear cells during chronic HIV type 1 infection. J Virol 2007, 81:5460-5471.
    • (2007) J Virol , vol.81 , pp. 5460-5471
    • Critchfield, J.W.1    Lemongello, D.2    Walker, D.H.3
  • 389
    • 33646686040 scopus 로고    scopus 로고
    • HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    • Betts M.R., Nason M.C., West S.M., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
    • (2006) Blood , vol.107 , pp. 4781-4789
    • Betts, M.R.1    Nason, M.C.2    West, S.M.3
  • 390
    • 0036852179 scopus 로고    scopus 로고
    • HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors
    • Migueles S.A., Laborico A.C., Shupert W.L., et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061-1068.
    • (2002) Nat Immunol , vol.3 , pp. 1061-1068
    • Migueles, S.A.1    Laborico, A.C.2    Shupert, W.L.3
  • 391
    • 33845761848 scopus 로고    scopus 로고
    • Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection
    • Day C.L., Kiepiela P., Leslie A.J., et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007, 81:434-438.
    • (2007) J Virol , vol.81 , pp. 434-438
    • Day, C.L.1    Kiepiela, P.2    Leslie, A.J.3
  • 392
    • 57449109484 scopus 로고    scopus 로고
    • Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control
    • Migueles S.A., Osborne C.M., Royce C., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29:1009-1021.
    • (2008) Immunity , vol.29 , pp. 1009-1021
    • Migueles, S.A.1    Osborne, C.M.2    Royce, C.3
  • 393
    • 70350322293 scopus 로고    scopus 로고
    • Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy
    • Migueles S.A., Weeks K.A., Nou E., et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009, 83:11876-11889.
    • (2009) J Virol , vol.83 , pp. 11876-11889
    • Migueles, S.A.1    Weeks, K.A.2    Nou, E.3
  • 394
    • 77954080011 scopus 로고    scopus 로고
    • Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control
    • Hersperger A.R., Pereyra F., Nason M., et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog 2010, 6:e1000917.
    • (2010) PLoS Pathog , vol.6
    • Hersperger, A.R.1    Pereyra, F.2    Nason, M.3
  • 395
    • 67649213034 scopus 로고    scopus 로고
    • Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses
    • Saez-Cirion A., Sinet M., Shin S.Y., et al. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol 2009, 182:7828-7837.
    • (2009) J Immunol , vol.182 , pp. 7828-7837
    • Saez-Cirion, A.1    Sinet, M.2    Shin, S.Y.3
  • 396
    • 77956793480 scopus 로고    scopus 로고
    • Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers
    • Ferre A.L., Lemongello D., Hunt P.W., et al. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J Virol 2010, 84:10354-10365.
    • (2010) J Virol , vol.84 , pp. 10354-10365
    • Ferre, A.L.1    Lemongello, D.2    Hunt, P.W.3
  • 397
    • 65449126294 scopus 로고    scopus 로고
    • Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control
    • Ferre A.L., Hunt P.W., Critchfield J.W., et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978-3989.
    • (2009) Blood , vol.113 , pp. 3978-3989
    • Ferre, A.L.1    Hunt, P.W.2    Critchfield, J.W.3
  • 398
    • 78651397483 scopus 로고    scopus 로고
    • Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function
    • Richmond M., McKinnon L.R., Kiazyk S.A., et al. Epitope mapping of HIV-specific CD8+ T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J Virol 2011, 85:1275-1286.
    • (2011) J Virol , vol.85 , pp. 1275-1286
    • Richmond, M.1    McKinnon, L.R.2    Kiazyk, S.A.3
  • 399
    • 18344418801 scopus 로고    scopus 로고
    • Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
    • Rowland-Jones S.L., Dong T., Fowke K.R., et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998, 102:1758-1765.
    • (1998) J Clin Invest , vol.102 , pp. 1758-1765
    • Rowland-Jones, S.L.1    Dong, T.2    Fowke, K.R.3
  • 400
    • 0026534763 scopus 로고
    • Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
    • Clerici M., Giorgi J.V., Chou C.C., et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012-1019.
    • (1992) J Infect Dis , vol.165 , pp. 1012-1019
    • Clerici, M.1    Giorgi, J.V.2    Chou, C.C.3
  • 401
    • 0035134669 scopus 로고    scopus 로고
    • Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses
    • Kaul R., Rowland-Jones S.L., Kimani J., et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001, 107:341-349.
    • (2001) J Clin Invest , vol.107 , pp. 341-349
    • Kaul, R.1    Rowland-Jones, S.L.2    Kimani, J.3
  • 402
    • 34249786561 scopus 로고    scopus 로고
    • A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells
    • Belyakov I.M., Isakov D., Zhu Q., et al. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 2007, 178:7211-7221.
    • (2007) J Immunol , vol.178 , pp. 7211-7221
    • Belyakov, I.M.1    Isakov, D.2    Zhu, Q.3
  • 403
    • 33645748846 scopus 로고    scopus 로고
    • Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa
    • Belyakov I.M., Kuznetsov V.A., Kelsall B., et al. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 2006, 107:3258-3264.
    • (2006) Blood , vol.107 , pp. 3258-3264
    • Belyakov, I.M.1    Kuznetsov, V.A.2    Kelsall, B.3
  • 404
    • 44949154503 scopus 로고    scopus 로고
    • CD8+ T cell efficacy in vaccination and disease
    • Appay V., Douek D.C., Price D.A. CD8+ T cell efficacy in vaccination and disease. Nat Med 2008, 14:623-628.
    • (2008) Nat Med , vol.14 , pp. 623-628
    • Appay, V.1    Douek, D.C.2    Price, D.A.3
  • 405
    • 60049098638 scopus 로고    scopus 로고
    • Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination
    • Kong W.P., Wu L., Wallstrom T.C., et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol 2009, 83:2201-2215.
    • (2009) J Virol , vol.83 , pp. 2201-2215
    • Kong, W.P.1    Wu, L.2    Wallstrom, T.C.3
  • 406
    • 77749242569 scopus 로고    scopus 로고
    • Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS
    • Ahlers J.D., Belyakov I.M. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Trends Immunol 2010, 31:120-130.
    • (2010) Trends Immunol , vol.31 , pp. 120-130
    • Ahlers, J.D.1    Belyakov, I.M.2
  • 407
    • 0034958413 scopus 로고    scopus 로고
    • Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells
    • Forthal D.N., Landucci G., Daar E.S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001, 75:6953-6961.
    • (2001) J Virol , vol.75 , pp. 6953-6961
    • Forthal, D.N.1    Landucci, G.2    Daar, E.S.3
  • 408
    • 69549103041 scopus 로고    scopus 로고
    • Fc receptor-mediated antiviral antibodies
    • Forthal D.N., Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 2009, 4:388-393.
    • (2009) Curr Opin HIV AIDS , vol.4 , pp. 388-393
    • Forthal, D.N.1    Moog, C.2
  • 409
    • 17344370858 scopus 로고    scopus 로고
    • Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection
    • Van Rompay K.K., Berardi C.J., Dillard-Telm S., et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 1998, 177:1247-1259.
    • (1998) J Infect Dis , vol.177 , pp. 1247-1259
    • Van Rompay, K.K.1    Berardi, C.J.2    Dillard-Telm, S.3
  • 410
    • 0042709478 scopus 로고    scopus 로고
    • Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120
    • Patterson L.J., Malkevitch N., Pinczewski J., et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 2003, 77:8607-8620.
    • (2003) J Virol , vol.77 , pp. 8607-8620
    • Patterson, L.J.1    Malkevitch, N.2    Pinczewski, J.3
  • 411
    • 10744220328 scopus 로고    scopus 로고
    • Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting
    • Patterson L.J., Malkevitch N., Venzon D., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004, 78:2212-2221.
    • (2004) J Virol , vol.78 , pp. 2212-2221
    • Patterson, L.J.1    Malkevitch, N.2    Venzon, D.3
  • 412
    • 13544277161 scopus 로고    scopus 로고
    • Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251
    • Gomez-Roman V.R., Patterson L.J., Venzon D., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005, 174:2185-2189.
    • (2005) J Immunol , vol.174 , pp. 2185-2189
    • Gomez-Roman, V.R.1    Patterson, L.J.2    Venzon, D.3
  • 413
    • 58149526770 scopus 로고    scopus 로고
    • Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques
    • Hidajat R., Xiao P., Zhou Q., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009, 83:791-801.
    • (2009) J Virol , vol.83 , pp. 791-801
    • Hidajat, R.1    Xiao, P.2    Zhou, Q.3
  • 414
    • 77953756732 scopus 로고    scopus 로고
    • Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques
    • Xiao P., Zhao J., Patterson L.J., et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010, 84:7161-7173.
    • (2010) J Virol , vol.84 , pp. 7161-7173
    • Xiao, P.1    Zhao, J.2    Patterson, L.J.3
  • 415
    • 42649138896 scopus 로고    scopus 로고
    • Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques
    • Patterson L.J., Beal J., Demberg T., et al. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 2008, 374:322-337.
    • (2008) Virology , vol.374 , pp. 322-337
    • Patterson, L.J.1    Beal, J.2    Demberg, T.3
  • 416
    • 0031974863 scopus 로고    scopus 로고
    • Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities
    • Alsmadi O., Tilley S.A. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities. J Virol 1998, 72:286-293.
    • (1998) J Virol , vol.72 , pp. 286-293
    • Alsmadi, O.1    Tilley, S.A.2
  • 417
    • 0025238850 scopus 로고
    • Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects
    • Tyler D.S., Stanley S.D., Nastala C.A., et al. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990, 144:3375-3384.
    • (1990) J Immunol , vol.144 , pp. 3375-3384
    • Tyler, D.S.1    Stanley, S.D.2    Nastala, C.A.3
  • 418
    • 33744916994 scopus 로고    scopus 로고
    • Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells
    • Holl V., Peressin M., Decoville T., et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006, 80:6177-6181.
    • (2006) J Virol , vol.80 , pp. 6177-6181
    • Holl, V.1    Peressin, M.2    Decoville, T.3
  • 419
    • 77951480441 scopus 로고    scopus 로고
    • Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity
    • Pietzsch J., Scheid J.F., Mouquet H., et al. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol 2010, 84:5032-5042.
    • (2010) J Virol , vol.84 , pp. 5032-5042
    • Pietzsch, J.1    Scheid, J.F.2    Mouquet, H.3
  • 420
    • 33144486096 scopus 로고    scopus 로고
    • Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1
    • Moore P.L., Crooks E.T., Porter L., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006, 80:2515-2528.
    • (2006) J Virol , vol.80 , pp. 2515-2528
    • Moore, P.L.1    Crooks, E.T.2    Porter, L.3
  • 421
    • 78649804618 scopus 로고    scopus 로고
    • Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region
    • Nicely N.I., Dennison S.M., Spicer L., et al. Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane-proximal external region. Nat Struct Mol Biol 2010, 17:1492-1494.
    • (2010) Nat Struct Mol Biol , vol.17 , pp. 1492-1494
    • Nicely, N.I.1    Dennison, S.M.2    Spicer, L.3
  • 422
    • 34548496893 scopus 로고    scopus 로고
    • Fc receptor but not complement binding is important in antibody protection against HIV
    • Hessell A.J., Hangartner L., Hunter M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104.
    • (2007) Nature , vol.449 , pp. 101-104
    • Hessell, A.J.1    Hangartner, L.2    Hunter, M.3
  • 423
    • 78650656127 scopus 로고    scopus 로고
    • Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12
    • Forthal D.N., Gach J.S., Landucci G., et al. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010, 185:6876-6882.
    • (2010) J Immunol , vol.185 , pp. 6876-6882
    • Forthal, D.N.1    Gach, J.S.2    Landucci, G.3
  • 424
    • 33744481004 scopus 로고    scopus 로고
    • Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation
    • Holl V., Peressin M., Schmidt S., et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 2006, 107:4466-4474.
    • (2006) Blood , vol.107 , pp. 4466-4474
    • Holl, V.1    Peressin, M.2    Schmidt, S.3
  • 425
    • 67650882680 scopus 로고    scopus 로고
    • Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41
    • Perez L.G., Costa M.R., Todd C.A., et al. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J Virol 2009, 83:7397-7410.
    • (2009) J Virol , vol.83 , pp. 7397-7410
    • Perez, L.G.1    Costa, M.R.2    Todd, C.A.3
  • 426
    • 79953736960 scopus 로고    scopus 로고
    • The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner
    • Tudor D., Bomsel M. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner. AIDS 2011, 25:751-759.
    • (2011) AIDS , vol.25 , pp. 751-759
    • Tudor, D.1    Bomsel, M.2
  • 427
    • 67149120819 scopus 로고    scopus 로고
    • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers
    • Lambotte O., Ferrari G., Moog C., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906.
    • (2009) AIDS , vol.23 , pp. 897-906
    • Lambotte, O.1    Ferrari, G.2    Moog, C.3
  • 428
    • 0024596133 scopus 로고
    • Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera
    • Koup R.A., Sullivan J.L., Levine P.H., et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol 1989, 63:584-590.
    • (1989) J Virol , vol.63 , pp. 584-590
    • Koup, R.A.1    Sullivan, J.L.2    Levine, P.H.3
  • 429
    • 0031023496 scopus 로고    scopus 로고
    • Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier
    • Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat Med 1997, 3:42-47.
    • (1997) Nat Med , vol.3 , pp. 42-47
    • Bomsel, M.1
  • 430
    • 18844470061 scopus 로고    scopus 로고
    • Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM
    • Bomsel M., Heyman M., Hocini H., et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM. Immunity 1998, 9:277-287.
    • (1998) Immunity , vol.9 , pp. 277-287
    • Bomsel, M.1    Heyman, M.2    Hocini, H.3
  • 431
    • 0034327707 scopus 로고    scopus 로고
    • Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells
    • Devito C., Broliden K., Kaul R., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165:5170-5176.
    • (2000) J Immunol , vol.165 , pp. 5170-5176
    • Devito, C.1    Broliden, K.2    Kaul, R.3
  • 432
    • 0035500882 scopus 로고    scopus 로고
    • Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers
    • Broliden K., Hinkula J., Devito C., et al. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol Lett 2001, 79:29-36.
    • (2001) Immunol Lett , vol.79 , pp. 29-36
    • Broliden, K.1    Hinkula, J.2    Devito, C.3
  • 433
    • 44649098153 scopus 로고    scopus 로고
    • Not just sheer luck! immune correlates of protection against HIV-1 infection
    • Piacentini L., Fenizia C., Naddeo V., et al. Not just sheer luck! immune correlates of protection against HIV-1 infection. Vaccine 2008, 26:3002-3007.
    • (2008) Vaccine , vol.26 , pp. 3002-3007
    • Piacentini, L.1    Fenizia, C.2    Naddeo, V.3
  • 434
    • 72049111744 scopus 로고    scopus 로고
    • Genital and oral mucosal immune response against HIV-1 in exposed uninfected individuals
    • Hasselrot K. Genital and oral mucosal immune response against HIV-1 in exposed uninfected individuals. Crit Rev Immunol 2009, 29:369-377.
    • (2009) Crit Rev Immunol , vol.29 , pp. 369-377
    • Hasselrot, K.1
  • 435
    • 33745906244 scopus 로고    scopus 로고
    • HIV-specific antibodies but not T-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia
    • Nguyen M., Pean P., Lopalco L., et al. HIV-specific antibodies but not T-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 2006, 42:412-419.
    • (2006) J Acquir Immune Defic Syndr , vol.42 , pp. 412-419
    • Nguyen, M.1    Pean, P.2    Lopalco, L.3
  • 436
    • 33646465596 scopus 로고    scopus 로고
    • Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals
    • Shacklett B.L. Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006, 3:26-31.
    • (2006) Curr HIV/AIDS Rep , vol.3 , pp. 26-31
    • Shacklett, B.L.1
  • 437
    • 58949097921 scopus 로고    scopus 로고
    • The "immunologic advantage" of HIV-exposed seronegative individuals
    • Miyazawa M., Lopalco L., Mazzotta F., et al. The "immunologic advantage" of HIV-exposed seronegative individuals. AIDS 2009, 23:161-175.
    • (2009) AIDS , vol.23 , pp. 161-175
    • Miyazawa, M.1    Lopalco, L.2    Mazzotta, F.3
  • 438
    • 0034622980 scopus 로고    scopus 로고
    • Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate
    • Devito C., Hinkula J., Kaul R., et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000, 14:1917-1920.
    • (2000) AIDS , vol.14 , pp. 1917-1920
    • Devito, C.1    Hinkula, J.2    Kaul, R.3
  • 439
    • 13644254926 scopus 로고    scopus 로고
    • Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin
    • Lopalco L., Barassi C., Paolucci C., et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005, 86(pt 2):339-348.
    • (2005) J Gen Virol , vol.86 , Issue.PART 2 , pp. 339-348
    • Lopalco, L.1    Barassi, C.2    Paolucci, C.3
  • 440
    • 41349105330 scopus 로고    scopus 로고
    • HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers
    • Hirbod T., Kaul R., Reichard C., et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008, 22:727-735.
    • (2008) AIDS , vol.22 , pp. 727-735
    • Hirbod, T.1    Kaul, R.2    Reichard, C.3
  • 441
    • 60549116730 scopus 로고    scopus 로고
    • Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV
    • Horton R.E., Ball T.B., Wachichi C., et al. Cervical HIV-specific IgA in a population of commercial sex workers correlates with repeated exposure but not resistance to HIV. AIDS Res Hum Retroviruses 2009, 25:83-92.
    • (2009) AIDS Res Hum Retroviruses , vol.25 , pp. 83-92
    • Horton, R.E.1    Ball, T.B.2    Wachichi, C.3
  • 442
    • 0037067741 scopus 로고    scopus 로고
    • HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide
    • Alfsen A., Bomsel M. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J Biol Chem 2002, 277:25649-25659.
    • (2002) J Biol Chem , vol.277 , pp. 25649-25659
    • Alfsen, A.1    Bomsel, M.2
  • 443
    • 0035873475 scopus 로고    scopus 로고
    • Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1
    • Alfsen A., Iniguez P., Bouguyon E., et al. Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001, 166:6257-6265.
    • (2001) J Immunol , vol.166 , pp. 6257-6265
    • Alfsen, A.1    Iniguez, P.2    Bouguyon, E.3
  • 444
    • 69249086612 scopus 로고    scopus 로고
    • HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis
    • Tudor D., Derrien M., Diomede L., et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009, 2:412-426.
    • (2009) Mucosal Immunol , vol.2 , pp. 412-426
    • Tudor, D.1    Derrien, M.2    Diomede, L.3
  • 445
    • 73649143882 scopus 로고    scopus 로고
    • Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load
    • Hasselrot K., Bratt G., Hirbod T., et al. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. AIDS 2010, 24:35-43.
    • (2010) AIDS , vol.24 , pp. 35-43
    • Hasselrot, K.1    Bratt, G.2    Hirbod, T.3
  • 446
    • 59849117394 scopus 로고    scopus 로고
    • Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men
    • Hasselrot K., Saberg P., Hirbod T., et al. Oral HIV-exposure elicits mucosal HIV-neutralizing antibodies in uninfected men who have sex with men. AIDS 2009, 23:329-333.
    • (2009) AIDS , vol.23 , pp. 329-333
    • Hasselrot, K.1    Saberg, P.2    Hirbod, T.3
  • 447
    • 77649236000 scopus 로고    scopus 로고
    • Innate immunity and chronic immune activation in HCV/HIV-1 co-infection
    • Gonzalez V.D., Landay A.L., Sandberg J.K. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 2010, 135:12-25.
    • (2010) Clin Immunol , vol.135 , pp. 12-25
    • Gonzalez, V.D.1    Landay, A.L.2    Sandberg, J.K.3
  • 448
    • 77957582392 scopus 로고    scopus 로고
    • Innate immune activation in primary HIV-1 infection
    • Chang J.J., Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis 2010, 202(suppl. 2):S297-S301.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 2
    • Chang, J.J.1    Altfeld, M.2
  • 449
    • 72849136282 scopus 로고    scopus 로고
    • Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response
    • Jacquelin B., Mayau V., Targat B., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009, 119:3544-3555.
    • (2009) J Clin Invest , vol.119 , pp. 3544-3555
    • Jacquelin, B.1    Mayau, V.2    Targat, B.3
  • 450
    • 72849132344 scopus 로고    scopus 로고
    • Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys
    • Bosinger S.E., Li Q., Gordon S.N., et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009, 119:3556-3572.
    • (2009) J Clin Invest , vol.119 , pp. 3556-3572
    • Bosinger, S.E.1    Li, Q.2    Gordon, S.N.3
  • 451
    • 34547130280 scopus 로고    scopus 로고
    • MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands
    • Meier A., Alter G., Frahm N., et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J Virol 2007, 81:8180-8191.
    • (2007) J Virol , vol.81 , pp. 8180-8191
    • Meier, A.1    Alter, G.2    Frahm, N.3
  • 452
    • 53549103852 scopus 로고    scopus 로고
    • Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections
    • Mandl J.N., Barry A.P., Vanderford T.H., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087.
    • (2008) Nat Med , vol.14 , pp. 1077-1087
    • Mandl, J.N.1    Barry, A.P.2    Vanderford, T.H.3
  • 453
    • 64049116643 scopus 로고    scopus 로고
    • Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections
    • Stacey A.R., Norris P.J., Qin L., et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009, 83:3719-3733.
    • (2009) J Virol , vol.83 , pp. 3719-3733
    • Stacey, A.R.1    Norris, P.J.2    Qin, L.3
  • 454
    • 33748757742 scopus 로고    scopus 로고
    • Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection
    • Norris P.J., Pappalardo B.L., Custer B., et al. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses 2006, 22:757-762.
    • (2006) AIDS Res Hum Retroviruses , vol.22 , pp. 757-762
    • Norris, P.J.1    Pappalardo, B.L.2    Custer, B.3
  • 455
    • 43949088825 scopus 로고    scopus 로고
    • Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome
    • Diop O.M., Ploquin M.J., Mortara L., et al. Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol 2008, 82:5145-5152.
    • (2008) J Virol , vol.82 , pp. 5145-5152
    • Diop, O.M.1    Ploquin, M.J.2    Mortara, L.3
  • 456
    • 58149380860 scopus 로고    scopus 로고
    • Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression
    • Malleret B., Maneglier B., Karlsson I., et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 2008, 112:4598-4608.
    • (2008) Blood , vol.112 , pp. 4598-4608
    • Malleret, B.1    Maneglier, B.2    Karlsson, I.3
  • 457
    • 78650065600 scopus 로고    scopus 로고
    • Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection
    • Singh R., Gaiha G., Werner L., et al. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol 2011, 85:208-216.
    • (2011) J Virol , vol.85 , pp. 208-216
    • Singh, R.1    Gaiha, G.2    Werner, L.3
  • 458
    • 62849103646 scopus 로고    scopus 로고
    • Human TRIM gene expression in response to interferons
    • Carthagena L., Bergamaschi A., Luna J.M., et al. Human TRIM gene expression in response to interferons. PLoS One 2009, 4:e4894.
    • (2009) PLoS One , vol.4
    • Carthagena, L.1    Bergamaschi, A.2    Luna, J.M.3
  • 459
    • 23844483865 scopus 로고    scopus 로고
    • APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia
    • Jin X., Brooks A., Chen H., et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005, 79:11513-11516.
    • (2005) J Virol , vol.79 , pp. 11513-11516
    • Jin, X.1    Brooks, A.2    Chen, H.3
  • 460
    • 33947654818 scopus 로고    scopus 로고
    • APOBEC3G levels predict rates of progression to AIDS
    • Jin X., Wu H., Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 2007, 4:20.
    • (2007) Retrovirology , vol.4 , pp. 20
    • Jin, X.1    Wu, H.2    Smith, H.3
  • 461
    • 33845906383 scopus 로고    scopus 로고
    • APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection
    • Pion M., Granelli-Piperno A., Mangeat B., et al. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 2006, 203:2887-2893.
    • (2006) J Exp Med , vol.203 , pp. 2887-2893
    • Pion, M.1    Granelli-Piperno, A.2    Mangeat, B.3
  • 462
    • 70349310335 scopus 로고    scopus 로고
    • APOBEC3B deletion and risk of HIV-1 acquisition
    • An P., Johnson R., Phair J., et al. APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 2009, 200:1054-1058.
    • (2009) J Infect Dis , vol.200 , pp. 1054-1058
    • An, P.1    Johnson, R.2    Phair, J.3
  • 463
    • 34248140162 scopus 로고    scopus 로고
    • Evolution of innate and adaptive effector cell functions during acute HIV-1 infection
    • Alter G., Teigen N., Ahern R., et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis 2007, 195:1452-1460.
    • (2007) J Infect Dis , vol.195 , pp. 1452-1460
    • Alter, G.1    Teigen, N.2    Ahern, R.3
  • 464
    • 67449101826 scopus 로고    scopus 로고
    • HLA class I subtype-dependent expansion of KIR3DS1 + and KIR3DL1 + NK cells during acute human immunodeficiency virus type 1 infection
    • Alter G., Rihn S., Walter K., et al. HLA class I subtype-dependent expansion of KIR3DS1 + and KIR3DL1 + NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009, 83:6798-6805.
    • (2009) J Virol , vol.83 , pp. 6798-6805
    • Alter, G.1    Rihn, S.2    Walter, K.3
  • 465
    • 0031019163 scopus 로고    scopus 로고
    • Activation and function of natural killer cell responses during viral infections
    • Biron C.A. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 1997, 9:24-34.
    • (1997) Curr Opin Immunol , vol.9 , pp. 24-34
    • Biron, C.A.1
  • 466
    • 34249802335 scopus 로고    scopus 로고
    • Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1
    • Martin M.P., Qi Y., Gao X., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007, 39:733-740.
    • (2007) Nat Genet , vol.39 , pp. 733-740
    • Martin, M.P.1    Qi, Y.2    Gao, X.3
  • 468
    • 78049445214 scopus 로고    scopus 로고
    • Natural resistance to HIV infection: lessons learned from HIV-exposed uninfected individuals
    • Pancino G., Saez-Cirion A., Scott-Algara D., et al. Natural resistance to HIV infection: lessons learned from HIV-exposed uninfected individuals. J Infect Dis 2010, 202(suppl. 3):S345-S350.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 3
    • Pancino, G.1    Saez-Cirion, A.2    Scott-Algara, D.3
  • 469
    • 67651148089 scopus 로고    scopus 로고
    • HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens
    • Loo C.P., Long B.R., Hecht F.M., et al. HIV-1-specific T Cell-dependent natural killer (NK) cell activation: major contribution by NK cells to interferon-gamma production in response to HIV-1 antigens. AIDS Res Hum Retroviruses 2009, 25:603-605.
    • (2009) AIDS Res Hum Retroviruses , vol.25 , pp. 603-605
    • Loo, C.P.1    Long, B.R.2    Hecht, F.M.3
  • 470
    • 36549019907 scopus 로고    scopus 로고
    • Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes
    • Alter G., Martin M.P., Teigen N., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007, 204:3027-3036.
    • (2007) J Exp Med , vol.204 , pp. 3027-3036
    • Alter, G.1    Martin, M.P.2    Teigen, N.3
  • 471
    • 34248368553 scopus 로고    scopus 로고
    • Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals
    • Ravet S., Scott-Algara D., Bonnet E., et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007, 109:4296-4305.
    • (2007) Blood , vol.109 , pp. 4296-4305
    • Ravet, S.1    Scott-Algara, D.2    Bonnet, E.3
  • 472
    • 33746039265 scopus 로고    scopus 로고
    • Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals
    • Montoya C.J., Velilla P.A., Chougnet C., et al. Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. Clin Immunol 2006, 120:138-146.
    • (2006) Clin Immunol , vol.120 , pp. 138-146
    • Montoya, C.J.1    Velilla, P.A.2    Chougnet, C.3
  • 473
    • 55049083095 scopus 로고    scopus 로고
    • Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection
    • Pereira L.E., Johnson R.P., Ansari A.A. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol 2008, 254:10-19.
    • (2008) Cell Immunol , vol.254 , pp. 10-19
    • Pereira, L.E.1    Johnson, R.P.2    Ansari, A.A.3
  • 474
    • 78649747999 scopus 로고    scopus 로고
    • Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010
    • Bansal G.P., Leitner W.W. Innate immunity in HIV infection and implications for vaccine design: a summary of the workshop held at the National Institute of Allergy and Infectious Diseases, Bethesda on February 25-26, 2010. Vaccine 2010, 28:8229-8235.
    • (2010) Vaccine , vol.28 , pp. 8229-8235
    • Bansal, G.P.1    Leitner, W.W.2
  • 475
    • 78650970845 scopus 로고    scopus 로고
    • Innate or adaptive immunity? the example of natural killer cells
    • Vivier E., Raulet D.H., Moretta A., et al. Innate or adaptive immunity? the example of natural killer cells. Science 2011, 331:44-49.
    • (2011) Science , vol.331 , pp. 44-49
    • Vivier, E.1    Raulet, D.H.2    Moretta, A.3
  • 476
    • 77649282342 scopus 로고    scopus 로고
    • Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination
    • Scott-Algara D., Mancini-Bourgine M., Fontaine H., et al. Changes to the natural killer cell repertoire after therapeutic hepatitis B DNA vaccination. PLoS One 2010, 5:e8761.
    • (2010) PLoS One , vol.5
    • Scott-Algara, D.1    Mancini-Bourgine, M.2    Fontaine, H.3
  • 477
    • 33748501031 scopus 로고    scopus 로고
    • The French Asymptomatiques à Long Terme (ALT) study group. Specific adaptive humoral response against a gp41 motif inhibits CD4 T cell sensitivity to NK lysis during HIV-1 infection
    • Sep 11
    • Vieillard V., Costagliola D., Simon A. The French Asymptomatiques à Long Terme (ALT) study group. Specific adaptive humoral response against a gp41 motif inhibits CD4 T cell sensitivity to NK lysis during HIV-1 infection. AIDS 2006; Sep 11, 20(14):1795-1804.
    • (2006) AIDS , vol.20 , Issue.14 , pp. 1795-1804
    • Vieillard, V.1    Costagliola, D.2    Simon, A.3
  • 478
    • 77957658572 scopus 로고    scopus 로고
    • HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the P1P3/H2O2 pathway
    • Jul 1;6:e1000975.
    • Fausther-Bovendo H., Vieillard V., Sagan S. HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the P1P3/H2O2 pathway. PLoS Pathog 2010, Jul 1;6:e1000975.
    • (2010) PLoS Pathog
    • Fausther-Bovendo, H.1    Vieillard, V.2    Sagan, S.3
  • 479
    • 33846809447 scopus 로고    scopus 로고
    • Primitive hematopoietic cells resist HIV-1 infection via p21
    • Zhang J., Scadden D.T., Crumpacker C.S. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007, 117:473-481.
    • (2007) J Clin Invest , vol.117 , pp. 473-481
    • Zhang, J.1    Scadden, D.T.2    Crumpacker, C.S.3
  • 480
    • 70450193060 scopus 로고    scopus 로고
    • The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages
    • Bergamaschi A., David A., Le Rouzic E., et al. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol 2009, 83:12253-12265.
    • (2009) J Virol , vol.83 , pp. 12253-12265
    • Bergamaschi, A.1    David, A.2    Le Rouzic, E.3
  • 481
    • 77950422606 scopus 로고    scopus 로고
    • Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells
    • Makedonas G., Hutnick N., Haney D., et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 2010, 6:e1000798.
    • (2010) PLoS Pathog , vol.6
    • Makedonas, G.1    Hutnick, N.2    Haney, D.3
  • 482
    • 78650655851 scopus 로고    scopus 로고
    • Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy
    • Palermo R.E., Patterson L.J., Aicher L.D., et al. Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol 2010, 85:1099-1116.
    • (2010) J Virol , vol.85 , pp. 1099-1116
    • Palermo, R.E.1    Patterson, L.J.2    Aicher, L.D.3
  • 483
    • 77954758455 scopus 로고    scopus 로고
    • A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort
    • Price H., Lacap P., Tuff J., et al. A TRIM5alpha exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort. AIDS 2010, 24:1813-1821.
    • (2010) AIDS , vol.24 , pp. 1813-1821
    • Price, H.1    Lacap, P.2    Tuff, J.3
  • 484
    • 79953305839 scopus 로고    scopus 로고
    • CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21
    • Chen H., Li C., Huang J., et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011, 121:1549-1560.
    • (2011) J Clin Invest , vol.121 , pp. 1549-1560
    • Chen, H.1    Li, C.2    Huang, J.3
  • 485
    • 78650542340 scopus 로고    scopus 로고
    • Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21)
    • Mallery D.L., McEwan W.A., Bidgood S.R., et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A 2010, 107:19985-19990.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 19985-19990
    • Mallery, D.L.1    McEwan, W.A.2    Bidgood, S.R.3
  • 486
    • 77949384495 scopus 로고    scopus 로고
    • Immunology and the elusive AIDS vaccine
    • Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464:224-231.
    • (2010) Nature , vol.464 , pp. 224-231
    • Virgin, H.W.1    Walker, B.D.2
  • 487
    • 32944477067 scopus 로고    scopus 로고
    • The rational design of an AIDS vaccine
    • Douek D.C., Kwong P.D., Nabel G.J. The rational design of an AIDS vaccine. Cell 2006, 124:677-681.
    • (2006) Cell , vol.124 , pp. 677-681
    • Douek, D.C.1    Kwong, P.D.2    Nabel, G.J.3
  • 489
    • 33845207660 scopus 로고    scopus 로고
    • Progress and obstacles in the development of an AIDS vaccine
    • Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006, 6:930-939.
    • (2006) Nat Rev Immunol , vol.6 , pp. 930-939
    • Letvin, N.L.1
  • 490
    • 34249068954 scopus 로고    scopus 로고
    • An HIV vaccine--evolving concepts
    • Johnston M.I., Fauci A.S. An HIV vaccine--evolving concepts. N Engl J Med 2007, 356:2073-2081.
    • (2007) N Engl J Med , vol.356 , pp. 2073-2081
    • Johnston, M.I.1    Fauci, A.S.2
  • 491
    • 13944250922 scopus 로고    scopus 로고
    • Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
    • Gilbert P.B., Peterson M.L., Follmann D., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191:666-677.
    • (2005) J Infect Dis , vol.191 , pp. 666-677
    • Gilbert, P.B.1    Peterson, M.L.2    Follmann, D.3
  • 492
    • 13944254982 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    • Flynn N.M., Forthal D.N., Harro C.D., et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005, 191:654-665.
    • (2005) J Infect Dis , vol.191 , pp. 654-665
    • Flynn, N.M.1    Forthal, D.N.2    Harro, C.D.3
  • 493
    • 33845433434 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    • Pitisuttithum P., Gilbert P., Gurwith M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
    • (2006) J Infect Dis , vol.194 , pp. 1661-1671
    • Pitisuttithum, P.1    Gilbert, P.2    Gurwith, M.3
  • 494
    • 56649114351 scopus 로고    scopus 로고
    • HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    • McElrath M.J., De Rosa S.C., Moodie Z., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
    • (2008) Lancet , vol.372 , pp. 1894-1905
    • McElrath, M.J.1    De Rosa, S.C.2    Moodie, Z.3
  • 495
    • 56649105122 scopus 로고    scopus 로고
    • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    • Buchbinder S.P., Mehrotra D.V., Duerr A., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008, 372:1881-1893.
    • (2008) Lancet , vol.372 , pp. 1881-1893
    • Buchbinder, S.P.1    Mehrotra, D.V.2    Duerr, A.3
  • 496
    • 77953543379 scopus 로고    scopus 로고
    • Rational antibody-based HIV-1 vaccine design: current approaches and future directions
    • Walker L.M., Burton D.R. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010, 22:358-366.
    • (2010) Curr Opin Immunol , vol.22 , pp. 358-366
    • Walker, L.M.1    Burton, D.R.2
  • 498
    • 77957226429 scopus 로고    scopus 로고
    • Antiviral immune responses in the genital tract: clues for vaccines
    • Iwasaki A. Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol 2010, 10:699-711.
    • (2010) Nat Rev Immunol , vol.10 , pp. 699-711
    • Iwasaki, A.1
  • 499
    • 77955513465 scopus 로고    scopus 로고
    • The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise
    • Voronin Y., Manrique A., Bernstein A. The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise. Curr Opin HIV AIDS 2010, 5:414-420.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 414-420
    • Voronin, Y.1    Manrique, A.2    Bernstein, A.3
  • 500
    • 77956450707 scopus 로고    scopus 로고
    • The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise
    • Council of the Global HIV Vaccine Enterprise
    • Berkley S., Bertram K., Delfraissy J-F. The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nat Med 2010, 16:981-989. Council of the Global HIV Vaccine Enterprise.
    • (2010) Nat Med , vol.16 , pp. 981-989
    • Berkley, S.1    Bertram, K.2    Delfraissy, J.-F.3
  • 501
    • 0030175426 scopus 로고    scopus 로고
    • Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS
    • Heeney J., Bogers W., Buijs L., et al. Immune strategies utilized by lentivirus infected chimpanzees to resist progression to AIDS. Immunol Lett 1996, 51:45-52.
    • (1996) Immunol Lett , vol.51 , pp. 45-52
    • Heeney, J.1    Bogers, W.2    Buijs, L.3
  • 502
    • 0030801253 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee
    • Fultz P.N., Yue L., Wei Q., et al. Human immunodeficiency virus type 1 intersubtype (B/E) recombination in a superinfected chimpanzee. J Virol 1997, 71:7990-7995.
    • (1997) J Virol , vol.71 , pp. 7990-7995
    • Fultz, P.N.1    Yue, L.2    Wei, Q.3
  • 503
    • 0025907920 scopus 로고
    • Human immunodeficiency virus infection of human-PBL-SCID mice
    • Mosier D.E., Gulizia R.J., Baird S.M., et al. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991, 251:791-794.
    • (1991) Science , vol.251 , pp. 791-794
    • Mosier, D.E.1    Gulizia, R.J.2    Baird, S.M.3
  • 504
    • 57349129555 scopus 로고    scopus 로고
    • RAG2-/- gamma(c)-/- mice transplanted with CD34 + cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus
    • Hofer U., Baenziger S., Heikenwalder M., et al. RAG2-/- gamma(c)-/- mice transplanted with CD34 + cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus. J Virol 2008, 82:12145-12153.
    • (2008) J Virol , vol.82 , pp. 12145-12153
    • Hofer, U.1    Baenziger, S.2    Heikenwalder, M.3
  • 505
    • 67749106469 scopus 로고    scopus 로고
    • Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse
    • Choudhary S.K., Rezk N.L., Ince W.L., et al. Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. J Virol 2009, 83:8254-8258.
    • (2009) J Virol , vol.83 , pp. 8254-8258
    • Choudhary, S.K.1    Rezk, N.L.2    Ince, W.L.3
  • 506
    • 77649099626 scopus 로고    scopus 로고
    • Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model
    • Ince W.L., Zhang L., Jiang Q., et al. Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model. J Virol 2010, 84:2740-2752.
    • (2010) J Virol , vol.84 , pp. 2740-2752
    • Ince, W.L.1    Zhang, L.2    Jiang, Q.3
  • 507
    • 2542490305 scopus 로고    scopus 로고
    • Primate models for AIDS vaccine development
    • Heeney J.L. Primate models for AIDS vaccine development. AIDS 1996, 10(suppl. A):S115-S122.
    • (1996) AIDS , vol.10 , Issue.SUPPL.. A
    • Heeney, J.L.1
  • 508
    • 0037137568 scopus 로고    scopus 로고
    • Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model
    • Franchini G., Nacsa J., Hel Z., et al. Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. Vaccine 2002, 20(suppl. 4):A52-A60.
    • (2002) Vaccine , vol.20 , Issue.SUPPL.. 4
    • Franchini, G.1    Nacsa, J.2    Hel, Z.3
  • 509
    • 25844482131 scopus 로고    scopus 로고
    • Perils at mucosal front lines for HIV and SIV and their hosts
    • Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005, 5:783-792.
    • (2005) Nat Rev Immunol , vol.5 , pp. 783-792
    • Haase, A.T.1
  • 510
    • 50949114906 scopus 로고    scopus 로고
    • The use of nonhuman primate models in HIV vaccine development
    • Morgan C., Marthas M., Miller C., et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008, 5:e173.
    • (2008) PLoS Med , vol.5
    • Morgan, C.1    Marthas, M.2    Miller, C.3
  • 511
    • 66049157864 scopus 로고    scopus 로고
    • Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1
    • Keele B.F., Li H., Learn G.H., et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009, 206:1117-1134.
    • (2009) J Exp Med , vol.206 , pp. 1117-1134
    • Keele, B.F.1    Li, H.2    Learn, G.H.3
  • 512
    • 0032540418 scopus 로고    scopus 로고
    • Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection
    • Veazey R.S., DeMaria M., Chalifoux L.V., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
    • (1998) Science , vol.280 , pp. 427-431
    • Veazey, R.S.1    DeMaria, M.2    Chalifoux, L.V.3
  • 513
    • 4644342929 scopus 로고    scopus 로고
    • CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
    • Brenchley J.M., Schacker T.W., Ruff L.E., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
    • (2004) J Exp Med , vol.200 , pp. 749-759
    • Brenchley, J.M.1    Schacker, T.W.2    Ruff, L.E.3
  • 514
    • 4644289983 scopus 로고    scopus 로고
    • Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract
    • Mehandru S., Poles M.A., Tenner-Racz K., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 2004, 200:761-770.
    • (2004) J Exp Med , vol.200 , pp. 761-770
    • Mehandru, S.1    Poles, M.A.2    Tenner-Racz, K.3
  • 515
    • 17844374605 scopus 로고    scopus 로고
    • Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection
    • Mattapallil J.J., Douek D.C., Hill B., et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
    • (2005) Nature , vol.434 , pp. 1093-1097
    • Mattapallil, J.J.1    Douek, D.C.2    Hill, B.3
  • 516
    • 17844376742 scopus 로고    scopus 로고
    • Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells
    • Li Q., Duan L., Estes J.D., et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
    • (2005) Nature , vol.434 , pp. 1148-1152
    • Li, Q.1    Duan, L.2    Estes, J.D.3
  • 517
    • 18844375363 scopus 로고    scopus 로고
    • HIV swiftly guts the immune system
    • Veazey R.S., Lackner A.A. HIV swiftly guts the immune system. Nat Med 2005, 11:469-470.
    • (2005) Nat Med , vol.11 , pp. 469-470
    • Veazey, R.S.1    Lackner, A.A.2
  • 518
    • 0034756397 scopus 로고    scopus 로고
    • Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics
    • Parker R.A., Regan M.M., Reimann K.A. Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeutics. J Virol 2001, 75:11234-11238.
    • (2001) J Virol , vol.75 , pp. 11234-11238
    • Parker, R.A.1    Regan, M.M.2    Reimann, K.A.3
  • 519
    • 34548689151 scopus 로고    scopus 로고
    • Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy
    • Deeks S.G., Walker B.D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007, 27:406-416.
    • (2007) Immunity , vol.27 , pp. 406-416
    • Deeks, S.G.1    Walker, B.D.2
  • 520
    • 34547737913 scopus 로고    scopus 로고
    • Mamu-B*08-positive macaques control simian immunodeficiency virus replication
    • Loffredo J.T., Maxwell J., Qi Y., et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 2007, 81:8827-8832.
    • (2007) J Virol , vol.81 , pp. 8827-8832
    • Loffredo, J.T.1    Maxwell, J.2    Qi, Y.3
  • 521
    • 21244495175 scopus 로고    scopus 로고
    • Rhesus macaque MHC class I molecules present HLA-B-like peptides
    • Hickman-Miller H.D., Bardet W., Gilb A., et al. Rhesus macaque MHC class I molecules present HLA-B-like peptides. J Immunol 2005, 175:367-375.
    • (2005) J Immunol , vol.175 , pp. 367-375
    • Hickman-Miller, H.D.1    Bardet, W.2    Gilb, A.3
  • 522
    • 12144287434 scopus 로고    scopus 로고
    • Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection
    • Altfeld M., Addo M.M., Rosenberg E.S., et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS 2003, 17:2581-2591.
    • (2003) AIDS , vol.17 , pp. 2581-2591
    • Altfeld, M.1    Addo, M.M.2    Rosenberg, E.S.3
  • 524
    • 10644267588 scopus 로고    scopus 로고
    • Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA
    • Kiepiela P., Leslie A.J., Honeyborne I., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004, 432:769-775.
    • (2004) Nature , vol.432 , pp. 769-775
    • Kiepiela, P.1    Leslie, A.J.2    Honeyborne, I.3
  • 525
    • 23244463622 scopus 로고    scopus 로고
    • HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load
    • Frahm N., Adams S., Kiepiela P., et al. HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 2005, 79:10218-10225.
    • (2005) J Virol , vol.79 , pp. 10218-10225
    • Frahm, N.1    Adams, S.2    Kiepiela, P.3
  • 526
    • 40949093660 scopus 로고    scopus 로고
    • A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef
    • Navis M., Schellens I.M., van Swieten P., et al. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. J Infect Dis 2008, 197:871-879.
    • (2008) J Infect Dis , vol.197 , pp. 871-879
    • Navis, M.1    Schellens, I.M.2    van Swieten, P.3
  • 527
    • 77956827161 scopus 로고    scopus 로고
    • Additive contribution of HLA class I alleles in the immune control of HIV-1 infection
    • Leslie A., Matthews P.C., Listgarten J., et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol 2010, 84:9879-9888.
    • (2010) J Virol , vol.84 , pp. 9879-9888
    • Leslie, A.1    Matthews, P.C.2    Listgarten, J.3
  • 528
    • 77950229250 scopus 로고    scopus 로고
    • Host determinants of HIV-1 control in African Americans
    • Pelak K., Goldstein D.B., Walley N.M., et al. Host determinants of HIV-1 control in African Americans. J Infect Dis 2010, 201:1141-1149.
    • (2010) J Infect Dis , vol.201 , pp. 1141-1149
    • Pelak, K.1    Goldstein, D.B.2    Walley, N.M.3
  • 529
    • 3042626395 scopus 로고    scopus 로고
    • The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines
    • Staprans S.I., Feinberg M.B. The roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines. Expert Rev Vaccines 2004, 3(suppl. 4):S5-32.
    • (2004) Expert Rev Vaccines , vol.3 , Issue.SUPPL.. 4
    • Staprans, S.I.1    Feinberg, M.B.2
  • 530
    • 0028826088 scopus 로고
    • Persistent infection of macaques with simian-human immunodeficiency viruses
    • Li J.T., Halloran M., Lord C.I., et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J Virol 1995, 69:7061-7067.
    • (1995) J Virol , vol.69 , pp. 7061-7067
    • Li, J.T.1    Halloran, M.2    Lord, C.I.3
  • 531
    • 9244224075 scopus 로고    scopus 로고
    • An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
    • Reimann K.A., Li J.T., Voss G., et al. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys. J Virol 1996, 70:3198-3206.
    • (1996) J Virol , vol.70 , pp. 3198-3206
    • Reimann, K.A.1    Li, J.T.2    Voss, G.3
  • 532
    • 0029794529 scopus 로고    scopus 로고
    • A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
    • Reimann K.A., Li J.T., Veazey R., et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996, 70:6922-6928.
    • (1996) J Virol , vol.70 , pp. 6922-6928
    • Reimann, K.A.1    Li, J.T.2    Veazey, R.3
  • 533
    • 0030944595 scopus 로고    scopus 로고
    • Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS
    • Joag S.V., Adany I., Li Z., et al. Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS. J Virol 1997, 71:4016-4023.
    • (1997) J Virol , vol.71 , pp. 4016-4023
    • Joag, S.V.1    Adany, I.2    Li, Z.3
  • 534
    • 0037227768 scopus 로고    scopus 로고
    • Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120
    • Hsu M., Harouse J.M., Gettie A., et al. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol 2003, 77:989-998.
    • (2003) J Virol , vol.77 , pp. 989-998
    • Hsu, M.1    Harouse, J.M.2    Gettie, A.3
  • 535
    • 77950196210 scopus 로고    scopus 로고
    • Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes
    • Chenine A.L., Siddappa N.B., Kramer V.G., et al. Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 2010, 201:1155-1163.
    • (2010) J Infect Dis , vol.201 , pp. 1155-1163
    • Chenine, A.L.1    Siddappa, N.B.2    Kramer, V.G.3
  • 536
    • 33745937684 scopus 로고    scopus 로고
    • Differential mucosal susceptibility in HIV-1 transmission and infection
    • Moutsopoulos N.M., Greenwell-Wild T., Wahl S.M. Differential mucosal susceptibility in HIV-1 transmission and infection. Adv Dent Res 2006, 19:52-56.
    • (2006) Adv Dent Res , vol.19 , pp. 52-56
    • Moutsopoulos, N.M.1    Greenwell-Wild, T.2    Wahl, S.M.3
  • 537
    • 57349175481 scopus 로고    scopus 로고
    • Systematic review of orogenital HIV-1 transmission probabilities
    • Baggaley R.F., White R.G., Boily M.C. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol 2008, 37:1255-1265.
    • (2008) Int J Epidemiol , vol.37 , pp. 1255-1265
    • Baggaley, R.F.1    White, R.G.2    Boily, M.C.3
  • 538
    • 44349159423 scopus 로고    scopus 로고
    • Setting the stage: host invasion by HIV
    • Hladik F., McElrath M.J. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008, 8:447-457.
    • (2008) Nat Rev Immunol , vol.8 , pp. 447-457
    • Hladik, F.1    McElrath, M.J.2
  • 539
    • 61449159825 scopus 로고    scopus 로고
    • HIV infection of the genital mucosa in women
    • Hladik F., Hope T.J. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009, 6:20-28.
    • (2009) Curr HIV/AIDS Rep , vol.6 , pp. 20-28
    • Hladik, F.1    Hope, T.J.2
  • 540
    • 70349470783 scopus 로고    scopus 로고
    • Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials
    • Shedlock D.J., Silvestri G., Weiner D.B. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol 2009, 9:717-728.
    • (2009) Nat Rev Immunol , vol.9 , pp. 717-728
    • Shedlock, D.J.1    Silvestri, G.2    Weiner, D.B.3
  • 541
    • 0035970644 scopus 로고    scopus 로고
    • Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model
    • Chakraborty H., Sen P.K., Helms R.W., et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001, 15:621-627.
    • (2001) AIDS , vol.15 , pp. 621-627
    • Chakraborty, H.1    Sen, P.K.2    Helms, R.W.3
  • 542
    • 0035857959 scopus 로고    scopus 로고
    • Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai
    • Gray R.H., Wawer M.J., Brookmeyer R., et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai. Uganda. Lancet 2001, 357:1149-1153.
    • (2001) Uganda. Lancet , vol.357 , pp. 1149-1153
    • Gray, R.H.1    Wawer, M.J.2    Brookmeyer, R.3
  • 543
    • 1542287436 scopus 로고    scopus 로고
    • Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates
    • McDermott A.B., Mitchen J., Piaskowski S., et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol 2004, 78:3140-3144.
    • (2004) J Virol , vol.78 , pp. 3140-3144
    • McDermott, A.B.1    Mitchen, J.2    Piaskowski, S.3
  • 544
    • 3543148237 scopus 로고    scopus 로고
    • Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
    • Joag S.V., Liu Z.Q., Stephens E.B., et al. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS. J Virol 1998, 72:9069-9078.
    • (1998) J Virol , vol.72 , pp. 9069-9078
    • Joag, S.V.1    Liu, Z.Q.2    Stephens, E.B.3
  • 545
    • 0029951823 scopus 로고    scopus 로고
    • Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
    • Wyand M.S., Manson K.H., Garcia-Moll M., et al. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996, 70:3724-3733.
    • (1996) J Virol , vol.70 , pp. 3724-3733
    • Wyand, M.S.1    Manson, K.H.2    Garcia-Moll, M.3
  • 546
    • 0030806029 scopus 로고    scopus 로고
    • Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus
    • Johnson R.P., Glickman R.L., Yang J.Q., et al. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997, 71:7711-7718.
    • (1997) J Virol , vol.71 , pp. 7711-7718
    • Johnson, R.P.1    Glickman, R.L.2    Yang, J.Q.3
  • 547
    • 0033598706 scopus 로고    scopus 로고
    • Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production
    • Gauduin M.C., Glickman R.L., Ahmad S., et al. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production. Proc Natl Acad Sci U S A 1999, 96:14031-14036.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 14031-14036
    • Gauduin, M.C.1    Glickman, R.L.2    Ahmad, S.3
  • 548
    • 1842415425 scopus 로고    scopus 로고
    • Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission
    • Putkonen P., Makitalo B., Bottiger D., et al. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol 1997, 71:4981-4984.
    • (1997) J Virol , vol.71 , pp. 4981-4984
    • Putkonen, P.1    Makitalo, B.2    Bottiger, D.3
  • 549
    • 0032905068 scopus 로고    scopus 로고
    • Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
    • Baba T.W., Liska V., Khimani A.H., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5:194-203.
    • (1999) Nat Med , vol.5 , pp. 194-203
    • Baba, T.W.1    Liska, V.2    Khimani, A.H.3
  • 550
    • 0029031494 scopus 로고
    • Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence
    • Whatmore A.M., Cook N., Hall G.A., et al. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 1995, 69:5117-5123.
    • (1995) J Virol , vol.69 , pp. 5117-5123
    • Whatmore, A.M.1    Cook, N.2    Hall, G.A.3
  • 551
    • 0031023570 scopus 로고    scopus 로고
    • Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques
    • Giavedoni L., Ahmad S., Jones L., et al. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J Virol 1997, 71:866-872.
    • (1997) J Virol , vol.71 , pp. 866-872
    • Giavedoni, L.1    Ahmad, S.2    Jones, L.3
  • 552
    • 0029824662 scopus 로고    scopus 로고
    • A candidate live inactivatable attenuated vaccine for AIDS
    • Chakrabarti B.K., Maitra R.K., Ma X.Z., et al. A candidate live inactivatable attenuated vaccine for AIDS. Proc Natl Acad Sci U S A 1996, 93:9810-9815.
    • (1996) Proc Natl Acad Sci U S A , vol.93 , pp. 9810-9815
    • Chakrabarti, B.K.1    Maitra, R.K.2    Ma, X.Z.3
  • 553
    • 0028804160 scopus 로고
    • Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients
    • Deacon N.J., Tsykin A., Solomon A., et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
    • (1995) Science , vol.270 , pp. 988-991
    • Deacon, N.J.1    Tsykin, A.2    Solomon, A.3
  • 554
    • 0029846223 scopus 로고    scopus 로고
    • High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection
    • Mariani R., Kirchhoff F., Greenough T.C., et al. High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol 1996, 70:7752-7764.
    • (1996) J Virol , vol.70 , pp. 7752-7764
    • Mariani, R.1    Kirchhoff, F.2    Greenough, T.C.3
  • 555
    • 0033590405 scopus 로고    scopus 로고
    • Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1
    • Greenough T.C., Sullivan J.L., Desrosiers R.C. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med 1999, 340:236-237.
    • (1999) N Engl J Med , vol.340 , pp. 236-237
    • Greenough, T.C.1    Sullivan, J.L.2    Desrosiers, R.C.3
  • 556
    • 0033519616 scopus 로고    scopus 로고
    • Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney Blood Bank Cohort
    • Learmont J.C., Geczy A.F., Mills J., et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1: a report from the Sydney Blood Bank Cohort. N Engl J Med 1999, 340:1715-1722.
    • (1999) N Engl J Med , vol.340 , pp. 1715-1722
    • Learmont, J.C.1    Geczy, A.F.2    Mills, J.3
  • 557
    • 0036633807 scopus 로고    scopus 로고
    • Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence
    • Jekle A., Schramm B., Jayakumar P., et al. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol 2002, 76:6966-6973.
    • (2002) J Virol , vol.76 , pp. 6966-6973
    • Jekle, A.1    Schramm, B.2    Jayakumar, P.3
  • 558
    • 0031694872 scopus 로고    scopus 로고
    • Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
    • Rossio J.L., Esser M.T., Suryanarayana K., et al. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 1998, 72:7992-8001.
    • (1998) J Virol , vol.72 , pp. 7992-8001
    • Rossio, J.L.1    Esser, M.T.2    Suryanarayana, K.3
  • 559
    • 0030895045 scopus 로고    scopus 로고
    • Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
    • Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997, 37:423-435.
    • (1997) Transfusion , vol.37 , pp. 423-435
    • Lin, L.1    Cook, D.N.2    Wiesehahn, G.P.3
  • 560
    • 3843059028 scopus 로고    scopus 로고
    • Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins
    • Lifson J.D., Rossio J.L., Piatak M., et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 2004, 20:772-787.
    • (2004) AIDS Res Hum Retroviruses , vol.20 , pp. 772-787
    • Lifson, J.D.1    Rossio, J.L.2    Piatak, M.3
  • 561
    • 14844300825 scopus 로고    scopus 로고
    • Virus-like particles as HIV-1 vaccines
    • Doan L.X., Li M., Chen C., et al. Virus-like particles as HIV-1 vaccines. Rev Med Virol 2005, 15:75-88.
    • (2005) Rev Med Virol , vol.15 , pp. 75-88
    • Doan, L.X.1    Li, M.2    Chen, C.3
  • 562
    • 25144495663 scopus 로고    scopus 로고
    • Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses
    • Zanotto C., Paganini M., Elli V., et al. Molecular and biological characterization of simian-human immunodeficiency virus-like particles produced by recombinant fowlpox viruses. Vaccine 2005, 23:4745-4753.
    • (2005) Vaccine , vol.23 , pp. 4745-4753
    • Zanotto, C.1    Paganini, M.2    Elli, V.3
  • 563
    • 0037333412 scopus 로고    scopus 로고
    • Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus
    • Kang S.M., Compans R.W. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol 2003, 77:3615-3623.
    • (2003) J Virol , vol.77 , pp. 3615-3623
    • Kang, S.M.1    Compans, R.W.2
  • 564
    • 34249950861 scopus 로고    scopus 로고
    • Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
    • Kim M., Qiao Z., Yu J., et al. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 2007, 25:5102-5114.
    • (2007) Vaccine , vol.25 , pp. 5102-5114
    • Kim, M.1    Qiao, Z.2    Yu, J.3
  • 565
    • 40649095248 scopus 로고    scopus 로고
    • Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles
    • Phogat S., Svehla K., Tang M., et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008, 373:72-84.
    • (2008) Virology , vol.373 , pp. 72-84
    • Phogat, S.1    Svehla, K.2    Tang, M.3
  • 566
    • 3242660762 scopus 로고    scopus 로고
    • Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles
    • Zhang H., Huang Y., Fayad R., et al. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 2004, 78:8342-8348.
    • (2004) J Virol , vol.78 , pp. 8342-8348
    • Zhang, H.1    Huang, Y.2    Fayad, R.3
  • 567
    • 0036239831 scopus 로고    scopus 로고
    • Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses
    • Liu X.S., Liu W.J., Zhao K.N., et al. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol 2002, 80:21-29.
    • (2002) Immunol Cell Biol , vol.80 , pp. 21-29
    • Liu, X.S.1    Liu, W.J.2    Zhao, K.N.3
  • 568
    • 0025331727 scopus 로고
    • Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
    • Berman P.W., Gregory T.J., Riddle L., et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345:622-625.
    • (1990) Nature , vol.345 , pp. 622-625
    • Berman, P.W.1    Gregory, T.J.2    Riddle, L.3
  • 569
    • 0025965050 scopus 로고
    • Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus
    • Girard M., Kieny M.P., Pinter A., et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A 1991, 88:542-546.
    • (1991) Proc Natl Acad Sci U S A , vol.88 , pp. 542-546
    • Girard, M.1    Kieny, M.P.2    Pinter, A.3
  • 570
    • 0026752976 scopus 로고
    • Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells
    • Fultz P.N., Nara P., Barre-Sinoussi F., et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992, 256:1687-1690.
    • (1992) Science , vol.256 , pp. 1687-1690
    • Fultz, P.N.1    Nara, P.2    Barre-Sinoussi, F.3
  • 571
    • 0028169641 scopus 로고
    • HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees
    • Bruck C., Thiriart C., Fabry L., et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 1994, 12:1141-1148.
    • (1994) Vaccine , vol.12 , pp. 1141-1148
    • Bruck, C.1    Thiriart, C.2    Fabry, L.3
  • 572
    • 0029154345 scopus 로고
    • Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
    • Girard M., Meignier B., Barre-Sinoussi F., et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J Virol 1995, 69:6239-6248.
    • (1995) J Virol , vol.69 , pp. 6239-6248
    • Girard, M.1    Meignier, B.2    Barre-Sinoussi, F.3
  • 573
    • 19144370387 scopus 로고    scopus 로고
    • Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
    • Berman P.W., Murthy K.K., Wrin T., et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996, 173:52-59.
    • (1996) J Infect Dis , vol.173 , pp. 52-59
    • Berman, P.W.1    Murthy, K.K.2    Wrin, T.3
  • 574
    • 0025284794 scopus 로고
    • Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees
    • Emini E.A., Nara P.L., Schleif W.A., et al. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990, 64:3674-3678.
    • (1990) J Virol , vol.64 , pp. 3674-3678
    • Emini, E.A.1    Nara, P.L.2    Schleif, W.A.3
  • 575
    • 15444345624 scopus 로고    scopus 로고
    • A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection
    • Mooij P., van der Kolk M., Bogers W.M., et al. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 1998, 12:F15-F22.
    • (1998) AIDS , vol.12
    • Mooij, P.1    van der Kolk, M.2    Bogers, W.M.3
  • 576
    • 15444349408 scopus 로고    scopus 로고
    • Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus
    • Stott E.J., Almond N., Kent K., et al. Evaluation of a candidate human immunodeficiency virus type 1 (HIV-1) vaccine in macaques: effect of vaccination with HIV-1 gp120 on subsequent challenge with heterologous simian immunodeficiency virus-HIV-1 chimeric virus. J Gen Virol 1998, 79(pt 3):423-432.
    • (1998) J Gen Virol , vol.79 , Issue.PART 3 , pp. 423-432
    • Stott, E.J.1    Almond, N.2    Kent, K.3
  • 577
    • 0026689113 scopus 로고
    • Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies
    • Browning M., Reid G., Osborne R., Jarrett O. Incorporation of soluble antigens into ISCOMs: HIV gp120 ISCOMs induce virus neutralizing antibodies. Vaccine 1992, 10:585-590.
    • (1992) Vaccine , vol.10 , pp. 585-590
    • Browning, M.1    Reid, G.2    Osborne, R.3    Jarrett, O.4
  • 578
    • 0029151884 scopus 로고
    • Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5)
    • Hulskotte E.G., Geretti A.M., Siebelink K.H., et al. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 1995, 69:6289-6296.
    • (1995) J Virol , vol.69 , pp. 6289-6296
    • Hulskotte, E.G.1    Geretti, A.M.2    Siebelink, K.H.3
  • 579
    • 78649725224 scopus 로고    scopus 로고
    • Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies
    • Vaine M., Wang S., Liu Q., et al. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 2010, 5:e13916.
    • (2010) PLoS One , vol.5
    • Vaine, M.1    Wang, S.2    Liu, Q.3
  • 580
    • 0036231093 scopus 로고    scopus 로고
    • Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin
    • Yang X., Lee J., Mahony E.M., et al. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 2002, 76:4634-4642.
    • (2002) J Virol , vol.76 , pp. 4634-4642
    • Yang, X.1    Lee, J.2    Mahony, E.M.3
  • 581
    • 23844451664 scopus 로고    scopus 로고
    • Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus
    • Forsell M.N., Li Y., Sundback M., et al. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol 2005, 79:10902-10914.
    • (2005) J Virol , vol.79 , pp. 10902-10914
    • Forsell, M.N.1    Li, Y.2    Sundback, M.3
  • 582
    • 0035000679 scopus 로고    scopus 로고
    • The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    • Barnett S.W., Lu S., Srivastava I., et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001, 75:5526-5540.
    • (2001) J Virol , vol.75 , pp. 5526-5540
    • Barnett, S.W.1    Lu, S.2    Srivastava, I.3
  • 583
    • 0037321708 scopus 로고    scopus 로고
    • Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
    • Srivastava I.K., VanDorsten K., Vojtech L., et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003, 77:2310-2320.
    • (2003) J Virol , vol.77 , pp. 2310-2320
    • Srivastava, I.K.1    VanDorsten, K.2    Vojtech, L.3
  • 584
    • 38149096202 scopus 로고    scopus 로고
    • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope
    • Barnett S.W., Srivastava I.K., Kan E., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22:339-348.
    • (2008) AIDS , vol.22 , pp. 339-348
    • Barnett, S.W.1    Srivastava, I.K.2    Kan, E.3
  • 585
    • 0036333661 scopus 로고    scopus 로고
    • Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
    • Sanders R.W., Vesanen M., Schuelke N., et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002, 76:8875-8889.
    • (2002) J Virol , vol.76 , pp. 8875-8889
    • Sanders, R.W.1    Vesanen, M.2    Schuelke, N.3
  • 586
    • 21644445378 scopus 로고    scopus 로고
    • Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
    • Beddows S., Schulke N., Kirschner M., et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005, 79:8812-8827.
    • (2005) J Virol , vol.79 , pp. 8812-8827
    • Beddows, S.1    Schulke, N.2    Kirschner, M.3
  • 587
    • 0029927680 scopus 로고    scopus 로고
    • Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates
    • Devico A., Silver A., Thronton A.M., et al. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 1996, 218:258-263.
    • (1996) Virology , vol.218 , pp. 258-263
    • Devico, A.1    Silver, A.2    Thronton, A.M.3
  • 588
    • 0034467954 scopus 로고    scopus 로고
    • Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex
    • Fouts T.R., Tuskan R., Godfrey K., et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol 2000, 74:11427-11436.
    • (2000) J Virol , vol.74 , pp. 11427-11436
    • Fouts, T.R.1    Tuskan, R.2    Godfrey, K.3
  • 589
    • 0037015043 scopus 로고    scopus 로고
    • Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
    • Fouts T., Godfrey K., Bobb K., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 2002, 99:11842-11847.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 11842-11847
    • Fouts, T.1    Godfrey, K.2    Bobb, K.3
  • 590
    • 36849031146 scopus 로고    scopus 로고
    • Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens
    • DeVico A., Fouts T., Lewis G.K., et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A 2007, 104:17477-17482.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 17477-17482
    • DeVico, A.1    Fouts, T.2    Lewis, G.K.3
  • 591
    • 21744447837 scopus 로고    scopus 로고
    • Immunology: close to the edge: neutralizing the HIV-1 envelope
    • Nabel G.J. Immunology: close to the edge: neutralizing the HIV-1 envelope. Science 2005, 308:1878-1879.
    • (2005) Science , vol.308 , pp. 1878-1879
    • Nabel, G.J.1
  • 592
    • 22144431896 scopus 로고    scopus 로고
    • Application of the polyvalent approach to HIV-1 vaccine development
    • Hurwitz J.L., Slobod K.S., Lockey T.D., et al. Application of the polyvalent approach to HIV-1 vaccine development. Curr Drug Targets Infect Disord 2005, 5:143-156.
    • (2005) Curr Drug Targets Infect Disord , vol.5 , pp. 143-156
    • Hurwitz, J.L.1    Slobod, K.S.2    Lockey, T.D.3
  • 593
    • 13944277994 scopus 로고    scopus 로고
    • Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
    • Seaman M.S., Xu L., Beaudry K., et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005, 79:2956-2963.
    • (2005) J Virol , vol.79 , pp. 2956-2963
    • Seaman, M.S.1    Xu, L.2    Beaudry, K.3
  • 594
    • 34447262868 scopus 로고    scopus 로고
    • Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines
    • McBurney S.P., Ross T.M. Developing broadly reactive HIV-1/AIDS vaccines: a review of polyvalent and centralized HIV-1 vaccines. Curr Pharm Des 2007, 13:1957-1964.
    • (2007) Curr Pharm Des , vol.13 , pp. 1957-1964
    • McBurney, S.P.1    Ross, T.M.2
  • 596
    • 33747041588 scopus 로고    scopus 로고
    • Ancestral and consensus envelope immunogens for HIV-1 subtype C
    • Kothe D.L., Li Y., Decker J.M., et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006, 352:438-449.
    • (2006) Virology , vol.352 , pp. 438-449
    • Kothe, D.L.1    Li, Y.2    Decker, J.M.3
  • 597
    • 33847266930 scopus 로고    scopus 로고
    • Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins
    • Kothe D.L., Decker J.M., Li Y., et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007, 360:218-234.
    • (2007) Virology , vol.360 , pp. 218-234
    • Kothe, D.L.1    Decker, J.M.2    Li, Y.3
  • 598
    • 77954662179 scopus 로고    scopus 로고
    • Challenges of antibody-mediated protection against HIV-1
    • Lewis G.K. Challenges of antibody-mediated protection against HIV-1. Expert Rev Vaccines 2010, 9:683-687.
    • (2010) Expert Rev Vaccines , vol.9 , pp. 683-687
    • Lewis, G.K.1
  • 599
    • 0030975067 scopus 로고    scopus 로고
    • Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160
    • VanCott T.C., Mascola J.R., Kaminski R.W., et al. Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol 1997, 71:4319-4330.
    • (1997) J Virol , vol.71 , pp. 4319-4330
    • VanCott, T.C.1    Mascola, J.R.2    Kaminski, R.W.3
  • 600
    • 0034663142 scopus 로고    scopus 로고
    • Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
    • Kumar A., Lifson J.D., Silverstein P.S., et al. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses. Virology 2000, 274:149-164.
    • (2000) Virology , vol.274 , pp. 149-164
    • Kumar, A.1    Lifson, J.D.2    Silverstein, P.S.3
  • 601
    • 27144524041 scopus 로고    scopus 로고
    • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain
    • Lian Y., Srivastava I., Gomez-Roman V.R., et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005, 79:13338-13349.
    • (2005) J Virol , vol.79 , pp. 13338-13349
    • Lian, Y.1    Srivastava, I.2    Gomez-Roman, V.R.3
  • 602
    • 31144451337 scopus 로고    scopus 로고
    • Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants
    • Li Y., Svehla K., Mathy N.L., et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006, 80:1414-1426.
    • (2006) J Virol , vol.80 , pp. 1414-1426
    • Li, Y.1    Svehla, K.2    Mathy, N.L.3
  • 603
    • 0037195784 scopus 로고    scopus 로고
    • Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro: implications for vaccine design
    • Joyce J.G., Hurni W.M., Bogusky M.J., et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro: implications for vaccine design. J Biol Chem 2002, 277:45811-45820.
    • (2002) J Biol Chem , vol.277 , pp. 45811-45820
    • Joyce, J.G.1    Hurni, W.M.2    Bogusky, M.J.3
  • 604
    • 13444280027 scopus 로고    scopus 로고
    • Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response
    • Ho J., Uger R.A., Zwick M.B., et al. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005, 23:1559-1573.
    • (2005) Vaccine , vol.23 , pp. 1559-1573
    • Ho, J.1    Uger, R.A.2    Zwick, M.B.3
  • 605
    • 77954892934 scopus 로고    scopus 로고
    • Structural characterization of HIV gp41 with the membrane-proximal external region
    • Shi W., Bohon J., Han D.P., et al. Structural characterization of HIV gp41 with the membrane-proximal external region. J Biol Chem 2010, 285:24290-24298.
    • (2010) J Biol Chem , vol.285 , pp. 24290-24298
    • Shi, W.1    Bohon, J.2    Han, D.P.3
  • 606
    • 78649613568 scopus 로고    scopus 로고
    • Synthesis and analysis of the membrane proximal external region epitopes of HIV-1
    • Ingale S., Gach J.S., Zwick M.B., et al. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. J Pept Sci 2010, 16:716-722.
    • (2010) J Pept Sci , vol.16 , pp. 716-722
    • Ingale, S.1    Gach, J.S.2    Zwick, M.B.3
  • 607
    • 14244264413 scopus 로고    scopus 로고
    • Trimeric membrane-anchored gp41 inhibits HIV membrane fusion
    • Lenz O., Dittmar M.T., Wagner A., et al. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J Biol Chem 2005, 280:4095-4101.
    • (2005) J Biol Chem , vol.280 , pp. 4095-4101
    • Lenz, O.1    Dittmar, M.T.2    Wagner, A.3
  • 608
    • 78650126176 scopus 로고    scopus 로고
    • Autonomous folding in the membrane proximal HIV peptide gp41(659-671): pH tuneability at micelle interfaces
    • Gregor C.R., Cerasoli E., Tulip P.R., et al. Autonomous folding in the membrane proximal HIV peptide gp41(659-671): pH tuneability at micelle interfaces. Phys Chem Chem Phys 2010, 13:127-135.
    • (2010) Phys Chem Chem Phys , vol.13 , pp. 127-135
    • Gregor, C.R.1    Cerasoli, E.2    Tulip, P.R.3
  • 609
    • 67649506170 scopus 로고    scopus 로고
    • Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41
    • Watson D.S., Szoka F.C. Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41. Vaccine 2009, 27:4672-4683.
    • (2009) Vaccine , vol.27 , pp. 4672-4683
    • Watson, D.S.1    Szoka, F.C.2
  • 610
    • 0029840636 scopus 로고    scopus 로고
    • HIV-1 Tat protein as a potential AIDS vaccine
    • Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996, 2:960-964.
    • (1996) Nat Med , vol.2 , pp. 960-964
    • Goldstein, G.1
  • 611
    • 4544301217 scopus 로고    scopus 로고
    • Recent advances in the development of HIV-1 Tat-based vaccines
    • Caputo A., Gavioli R., Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2004, 2:357-376.
    • (2004) Curr HIV Res , vol.2 , pp. 357-376
    • Caputo, A.1    Gavioli, R.2    Ensoli, B.3
  • 612
    • 73949092256 scopus 로고    scopus 로고
    • A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting
    • Goldstein G., Chicca J.J. A universal anti-HIV-1 Tat epitope vaccine that is fully synthetic and self-adjuvanting. Vaccine 2010, 28:1008-1014.
    • (2010) Vaccine , vol.28 , pp. 1008-1014
    • Goldstein, G.1    Chicca, J.J.2
  • 613
    • 0032057349 scopus 로고    scopus 로고
    • Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine
    • Zagury J.F., Sill A., Blattner W., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998, 1:282-292.
    • (1998) J Hum Virol , vol.1 , pp. 282-292
    • Zagury, J.F.1    Sill, A.2    Blattner, W.3
  • 614
    • 0035114575 scopus 로고    scopus 로고
    • Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients
    • Re M.C., Vignoli M., Furlini G., et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001, 21:81-89.
    • (2001) J Clin Virol , vol.21 , pp. 81-89
    • Re, M.C.1    Vignoli, M.2    Furlini, G.3
  • 615
    • 12944273609 scopus 로고    scopus 로고
    • Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
    • Pauza C.D., Trivedi P., Wallace M., et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci U S A 2000, 97:3515-3519.
    • (2000) Proc Natl Acad Sci U S A , vol.97 , pp. 3515-3519
    • Pauza, C.D.1    Trivedi, P.2    Wallace, M.3
  • 616
    • 0034660318 scopus 로고    scopus 로고
    • Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33)
    • Goldstein G., Manson K., Tribbick G., et al. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 2000, 18:2789-2795.
    • (2000) Vaccine , vol.18 , pp. 2789-2795
    • Goldstein, G.1    Manson, K.2    Tribbick, G.3
  • 617
    • 0036194524 scopus 로고    scopus 로고
    • Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication
    • Allen T.M., Mortara L., Mothe B.R., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002, 76:4108-4112.
    • (2002) J Virol , vol.76 , pp. 4108-4112
    • Allen, T.M.1    Mortara, L.2    Mothe, B.R.3
  • 618
    • 25144485385 scopus 로고    scopus 로고
    • Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
    • Liang X., Casimiro D.R., Schleif W.A., et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79:12321-12331.
    • (2005) J Virol , vol.79 , pp. 12321-12331
    • Liang, X.1    Casimiro, D.R.2    Schleif, W.A.3
  • 619
    • 0033026062 scopus 로고    scopus 로고
    • Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
    • Cafaro A., Caputo A., Fracasso C., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999, 5:643-650.
    • (1999) Nat Med , vol.5 , pp. 643-650
    • Cafaro, A.1    Caputo, A.2    Fracasso, C.3
  • 620
    • 0035815501 scopus 로고    scopus 로고
    • Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)
    • Cafaro A., Titti F., Fracasso C., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001, 19:2862-2877.
    • (2001) Vaccine , vol.19 , pp. 2862-2877
    • Cafaro, A.1    Titti, F.2    Fracasso, C.3
  • 621
    • 4043096335 scopus 로고    scopus 로고
    • Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys
    • Maggiorella M.T., Baroncelli S., Michelini Z., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004, 22:3258-3269.
    • (2004) Vaccine , vol.22 , pp. 3258-3269
    • Maggiorella, M.T.1    Baroncelli, S.2    Michelini, Z.3
  • 622
    • 65249088382 scopus 로고    scopus 로고
    • Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243)
    • Borsetti A., Baroncelli S., Maggiorella M.T., et al. Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). Viral Immunol 2009, 22:117-124.
    • (2009) Viral Immunol , vol.22 , pp. 117-124
    • Borsetti, A.1    Baroncelli, S.2    Maggiorella, M.T.3
  • 623
    • 0037223760 scopus 로고    scopus 로고
    • Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
    • Voss G., Manson K., Montefiori D., et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003, 77:1049-1058.
    • (2003) J Virol , vol.77 , pp. 1049-1058
    • Voss, G.1    Manson, K.2    Montefiori, D.3
  • 624
    • 41649098046 scopus 로고    scopus 로고
    • Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination
    • Koopman G., Mortier D., Hofman S., et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 2008, 89(pt 2):540-553.
    • (2008) J Gen Virol , vol.89 , Issue.PART 2 , pp. 540-553
    • Koopman, G.1    Mortier, D.2    Hofman, S.3
  • 625
    • 29644446139 scopus 로고    scopus 로고
    • Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes
    • Hel Z., Tsai W.P., Tryniszewska E., et al. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 2006, 176:85-96.
    • (2006) J Immunol , vol.176 , pp. 85-96
    • Hel, Z.1    Tsai, W.P.2    Tryniszewska, E.3
  • 626
    • 33947380960 scopus 로고    scopus 로고
    • A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques
    • Demberg T., Florese R.H., Heath M.J., et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007, 81:3414-3427.
    • (2007) J Virol , vol.81 , pp. 3414-3427
    • Demberg, T.1    Florese, R.H.2    Heath, M.J.3
  • 627
    • 44749092729 scopus 로고    scopus 로고
    • Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection
    • Florese R.H., Wiseman R.W., Venzon D., et al. Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection. Vaccine 2008, 26:3312-3321.
    • (2008) Vaccine , vol.26 , pp. 3312-3321
    • Florese, R.H.1    Wiseman, R.W.2    Venzon, D.3
  • 628
    • 65449179917 scopus 로고    scopus 로고
    • Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines
    • Florese R.H., Demberg T., Xiao P., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009, 182:3718-3727.
    • (2009) J Immunol , vol.182 , pp. 3718-3727
    • Florese, R.H.1    Demberg, T.2    Xiao, P.3
  • 629
    • 73349086222 scopus 로고    scopus 로고
    • HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development
    • Caputo A., Gavioli R., Bellino S., et al. HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol 2009, 28:285-334.
    • (2009) Int Rev Immunol , vol.28 , pp. 285-334
    • Caputo, A.1    Gavioli, R.2    Bellino, S.3
  • 630
    • 77957584418 scopus 로고    scopus 로고
    • T cell immunity in acute HIV-1 infection
    • Streeck H., Nixon D.F. T cell immunity in acute HIV-1 infection. J Infect Dis 2010, 202(suppl. 2):S302-S308.
    • (2010) J Infect Dis , vol.202 , Issue.SUPPL.. 2
    • Streeck, H.1    Nixon, D.F.2
  • 631
    • 18844459354 scopus 로고    scopus 로고
    • AIDS vaccine development: perspectives, challenges & hopes
    • Excler J.L. AIDS vaccine development: perspectives, challenges & hopes. Indian J Med Res 2005, 121:568-581.
    • (2005) Indian J Med Res , vol.121 , pp. 568-581
    • Excler, J.L.1
  • 632
    • 0027284896 scopus 로고
    • Gene inoculation generates immune responses against human immunodeficiency virus type 1
    • Wang B., Ugen K.E., Srikantan V., et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993, 90:4156-4160.
    • (1993) Proc Natl Acad Sci U S A , vol.90 , pp. 4156-4160
    • Wang, B.1    Ugen, K.E.2    Srikantan, V.3
  • 633
    • 0029131261 scopus 로고
    • Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation
    • Wang B., Boyer J., Srikantan V., et al. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 1995, 211:102-112.
    • (1995) Virology , vol.211 , pp. 102-112
    • Wang, B.1    Boyer, J.2    Srikantan, V.3
  • 634
    • 0029655928 scopus 로고    scopus 로고
    • Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys
    • Yasutomi Y., Robinson H.L., Lu S., et al. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 1996, 70:678-681.
    • (1996) J Virol , vol.70 , pp. 678-681
    • Yasutomi, Y.1    Robinson, H.L.2    Lu, S.3
  • 635
    • 2042522699 scopus 로고    scopus 로고
    • DNA vaccines against human immunodeficiency virus type 1 in the past decade
    • Giri M., Ugen K.E., Weiner D.B. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004, 17:370-389.
    • (2004) Clin Microbiol Rev , vol.17 , pp. 370-389
    • Giri, M.1    Ugen, K.E.2    Weiner, D.B.3
  • 636
    • 0005457558 scopus 로고    scopus 로고
    • First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response
    • MacGregor R.R., Boyer J.D., Ugen K.E., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178:92-100.
    • (1998) J Infect Dis , vol.178 , pp. 92-100
    • MacGregor, R.R.1    Boyer, J.D.2    Ugen, K.E.3
  • 638
    • 0030111265 scopus 로고    scopus 로고
    • Codon usage limitation in the expression of HIV-1 envelope glycoprotein
    • Haas J., Park E.C., Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996, 6:315-324.
    • (1996) Curr Biol , vol.6 , pp. 315-324
    • Haas, J.1    Park, E.C.2    Seed, B.3
  • 639
    • 0033766645 scopus 로고    scopus 로고
    • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
    • Barouch D.H., Santra S., Schmitz J.E., et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000, 290:486-492.
    • (2000) Science , vol.290 , pp. 486-492
    • Barouch, D.H.1    Santra, S.2    Schmitz, J.E.3
  • 640
    • 21244447927 scopus 로고    scopus 로고
    • Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help
    • Kutzler M.A., Robinson T.M., Chattergoon M.A., et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005, 175:112-123.
    • (2005) J Immunol , vol.175 , pp. 112-123
    • Kutzler, M.A.1    Robinson, T.M.2    Chattergoon, M.A.3
  • 641
    • 33646835940 scopus 로고    scopus 로고
    • A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques
    • Schadeck E.B., Sidhu M., Egan M.A., et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006, 24:4677-4687.
    • (2006) Vaccine , vol.24 , pp. 4677-4687
    • Schadeck, E.B.1    Sidhu, M.2    Egan, M.A.3
  • 642
    • 36749042670 scopus 로고    scopus 로고
    • Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid
    • Boyer J.D., Robinson T.M., Kutzler M.A., et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007, 104:18648-18653.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 18648-18653
    • Boyer, J.D.1    Robinson, T.M.2    Kutzler, M.A.3
  • 643
    • 49549106212 scopus 로고    scopus 로고
    • Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines
    • Xu R., Megati S., Roopchand V., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 2008, 26:4819-4829.
    • (2008) Vaccine , vol.26 , pp. 4819-4829
    • Xu, R.1    Megati, S.2    Roopchand, V.3
  • 644
    • 41149180540 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business"
    • Schoenly K.A., Weiner D.B. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". J Virol 2008, 82:3166-3180.
    • (2008) J Virol , vol.82 , pp. 3166-3180
    • Schoenly, K.A.1    Weiner, D.B.2
  • 645
    • 28444497720 scopus 로고    scopus 로고
    • Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery
    • Brave A., Ljungberg K., Boberg A., et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005, 12:1197-1205.
    • (2005) Mol Ther , vol.12 , pp. 1197-1205
    • Brave, A.1    Ljungberg, K.2    Boberg, A.3
  • 646
    • 29044440477 scopus 로고    scopus 로고
    • Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model
    • Rao S.S., Gomez P., Mascola J.R., et al. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine 2006, 24:367-373.
    • (2006) Vaccine , vol.24 , pp. 367-373
    • Rao, S.S.1    Gomez, P.2    Mascola, J.R.3
  • 647
    • 0034849493 scopus 로고    scopus 로고
    • Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
    • O'Hagan D., Singh M., Ugozzoli M., et al. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol 2001, 75:9037-9043.
    • (2001) J Virol , vol.75 , pp. 9037-9043
    • O'Hagan, D.1    Singh, M.2    Ugozzoli, M.3
  • 648
    • 0033228367 scopus 로고    scopus 로고
    • DNA vaccines: basic mechanism and immune responses (review)
    • Robinson H.L. DNA vaccines: basic mechanism and immune responses (review). Int J Mol Med 1999, 4:549-555.
    • (1999) Int J Mol Med , vol.4 , pp. 549-555
    • Robinson, H.L.1
  • 649
    • 12244263558 scopus 로고    scopus 로고
    • Gene transfer to subdermal tissues via a new gene gun design
    • Dileo J., Miller T.E., Chesnoy S., et al. Gene transfer to subdermal tissues via a new gene gun design. Hum Gene Ther 2003, 14:79-87.
    • (2003) Hum Gene Ther , vol.14 , pp. 79-87
    • Dileo, J.1    Miller, T.E.2    Chesnoy, S.3
  • 650
    • 77958163907 scopus 로고    scopus 로고
    • DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge
    • Kask A.S., Chen X., Marshak J.O., et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 2010, 28:7483-7491.
    • (2010) Vaccine , vol.28 , pp. 7483-7491
    • Kask, A.S.1    Chen, X.2    Marshak, J.O.3
  • 651
    • 78649802326 scopus 로고    scopus 로고
    • Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays
    • Chen X., Kask A.S., Crichton M.L., et al. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J Control Release 2010, 148:327-333.
    • (2010) J Control Release , vol.148 , pp. 327-333
    • Chen, X.1    Kask, A.S.2    Crichton, M.L.3
  • 652
    • 77955624546 scopus 로고    scopus 로고
    • Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice
    • Prow T.W., Chen X., Prow N.A., et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small 2010, 6:1776-1784.
    • (2010) Small , vol.6 , pp. 1776-1784
    • Prow, T.W.1    Chen, X.2    Prow, N.A.3
  • 653
    • 34248382494 scopus 로고    scopus 로고
    • Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques
    • Luckay A., Sidhu M.K., Kjeken R., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81:5257-5269.
    • (2007) J Virol , vol.81 , pp. 5257-5269
    • Luckay, A.1    Sidhu, M.K.2    Kjeken, R.3
  • 654
    • 37549037877 scopus 로고    scopus 로고
    • Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques
    • Hirao L.A., Wu L., Khan A.S., et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008, 26:440-448.
    • (2008) Vaccine , vol.26 , pp. 440-448
    • Hirao, L.A.1    Wu, L.2    Khan, A.S.3
  • 655
    • 77950957345 scopus 로고    scopus 로고
    • Basic principles and clinical advancements of muscle electrotransfer
    • Hojman P. Basic principles and clinical advancements of muscle electrotransfer. Curr Gene Ther 2010, 10:128-138.
    • (2010) Curr Gene Ther , vol.10 , pp. 128-138
    • Hojman, P.1
  • 656
    • 78649658963 scopus 로고    scopus 로고
    • Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation
    • Brave A., Gudmundsdotter L., Sandstrom E., et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 2010, 28:8203-8209.
    • (2010) Vaccine , vol.28 , pp. 8203-8209
    • Brave, A.1    Gudmundsdotter, L.2    Sandstrom, E.3
  • 658
    • 70349471292 scopus 로고    scopus 로고
    • DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge
    • Rosati M., Bergamaschi C., Valentin A., et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009, 106:15831-15836.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 15831-15836
    • Rosati, M.1    Bergamaschi, C.2    Valentin, A.3
  • 659
    • 80052285787 scopus 로고    scopus 로고
    • High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation
    • Yin J., Dai A., Lecureux J., et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011, 29:6763-6770.
    • (2011) Vaccine , vol.29 , pp. 6763-6770
    • Yin, J.1    Dai, A.2    Lecureux, J.3
  • 660
    • 14844322130 scopus 로고    scopus 로고
    • DermaVir, a novel HIV immunisation technology
    • Lori F., Trocio J., Bakare N., et al. DermaVir, a novel HIV immunisation technology. Vaccine 2005, 23:2030-2034.
    • (2005) Vaccine , vol.23 , pp. 2030-2034
    • Lori, F.1    Trocio, J.2    Bakare, N.3
  • 661
    • 34547668503 scopus 로고    scopus 로고
    • Nanochemistry-based immunotherapy for HIV-1
    • Lori F., Calarota S.A., Lisziewicz J. Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem 2007, 14:1911-1919.
    • (2007) Curr Med Chem , vol.14 , pp. 1911-1919
    • Lori, F.1    Calarota, S.A.2    Lisziewicz, J.3
  • 662
    • 50849133565 scopus 로고    scopus 로고
    • IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine
    • Calarota S.A., Dai A., Trocio J.N., et al. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 2008, 26:5188-5195.
    • (2008) Vaccine , vol.26 , pp. 5188-5195
    • Calarota, S.A.1    Dai, A.2    Trocio, J.N.3
  • 663
    • 0034176364 scopus 로고    scopus 로고
    • The prime-boost strategy: exciting prospects for improved vaccination
    • Ramshaw I.A., Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today 2000, 21:163-165.
    • (2000) Immunol Today , vol.21 , pp. 163-165
    • Ramshaw, I.A.1    Ramsay, A.J.2
  • 664
    • 0036113771 scopus 로고    scopus 로고
    • Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine
    • Amara R.R., Smith J.M., Staprans S.I., et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002, 76:6138-6146.
    • (2002) J Virol , vol.76 , pp. 6138-6146
    • Amara, R.R.1    Smith, J.M.2    Staprans, S.I.3
  • 665
    • 14544290129 scopus 로고    scopus 로고
    • Progress toward an HIV vaccine
    • Letvin N.L. Progress toward an HIV vaccine. Annu Rev Med 2005, 56:213-223.
    • (2005) Annu Rev Med , vol.56 , pp. 213-223
    • Letvin, N.L.1
  • 666
    • 0035948229 scopus 로고    scopus 로고
    • Viral vectors as potential HIV-1 vaccines
    • Schnell M.J. Viral vectors as potential HIV-1 vaccines. FEMS Microbiol Lett 2001, 200:123-129.
    • (2001) FEMS Microbiol Lett , vol.200 , pp. 123-129
    • Schnell, M.J.1
  • 667
    • 18144386590 scopus 로고    scopus 로고
    • Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system
    • Sauter S.L., Rahman A., Muralidhar G. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system. Curr HIV Res 2005, 3:157-181.
    • (2005) Curr HIV Res , vol.3 , pp. 157-181
    • Sauter, S.L.1    Rahman, A.2    Muralidhar, G.3
  • 668
    • 0028786661 scopus 로고
    • Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals
    • Honda M., Matsuo K., Nakasone T., et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guerin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci U S A 1995, 92:10693-10697.
    • (1995) Proc Natl Acad Sci U S A , vol.92 , pp. 10693-10697
    • Honda, M.1    Matsuo, K.2    Nakasone, T.3
  • 669
    • 26444589093 scopus 로고    scopus 로고
    • Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity
    • Ami Y., Izumi Y., Matsuo K., et al. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 2005, 79:12871-12879.
    • (2005) J Virol , vol.79 , pp. 12871-12879
    • Ami, Y.1    Izumi, Y.2    Matsuo, K.3
  • 670
    • 0037029902 scopus 로고    scopus 로고
    • Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1
    • Devico A.L., Fouts T.R., Shata M.T., et al. Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. Vaccine 2002, 20:1968-1974.
    • (2002) Vaccine , vol.20 , pp. 1968-1974
    • Devico, A.L.1    Fouts, T.R.2    Shata, M.T.3
  • 671
    • 0038771229 scopus 로고    scopus 로고
    • Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1
    • Fouts T.R., DeVico A.L., Onyabe D.Y., et al. Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1. FEMS Immunol Med Microbiol 2003, 37:129-134.
    • (2003) FEMS Immunol Med Microbiol , vol.37 , pp. 129-134
    • Fouts, T.R.1    DeVico, A.L.2    Onyabe, D.Y.3
  • 672
    • 4344573008 scopus 로고    scopus 로고
    • Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens
    • Paterson Y., Johnson R.S. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004, 3(suppl. 4):S119-S134.
    • (2004) Expert Rev Vaccines , vol.3 , Issue.SUPPL.. 4
    • Paterson, Y.1    Johnson, R.S.2
  • 674
    • 0037771077 scopus 로고    scopus 로고
    • Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity
    • Vogels R., Zuijdgeest D., van Rijnsoever R., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003, 77:8263-8271.
    • (2003) J Virol , vol.77 , pp. 8263-8271
    • Vogels, R.1    Zuijdgeest, D.2    van Rijnsoever, R.3
  • 675
    • 2442611810 scopus 로고    scopus 로고
    • Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity
    • Barouch D.H., Pau M.G., Custers J.H., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172:6290-6297.
    • (2004) J Immunol , vol.172 , pp. 6290-6297
    • Barouch, D.H.1    Pau, M.G.2    Custers, J.H.3
  • 676
    • 34247585475 scopus 로고    scopus 로고
    • Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D
    • Abbink P., Lemckert A.A., Ewald B.A., et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007, 81:4654-4663.
    • (2007) J Virol , vol.81 , pp. 4654-4663
    • Abbink, P.1    Lemckert, A.A.2    Ewald, B.A.3
  • 677
    • 0037310512 scopus 로고    scopus 로고
    • A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag
    • Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol 2003, 170:1416-1422.
    • (2003) J Immunol , vol.170 , pp. 1416-1422
    • Fitzgerald, J.C.1    Gao, G.P.2    Reyes-Sandoval, A.3
  • 678
    • 34249930119 scopus 로고    scopus 로고
    • Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors
    • McCoy K., Tatsis N., Korioth-Schmitz B., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007, 81:6594-6604.
    • (2007) J Virol , vol.81 , pp. 6594-6604
    • McCoy, K.1    Tatsis, N.2    Korioth-Schmitz, B.3
  • 679
    • 33847222746 scopus 로고    scopus 로고
    • A CD46-binding chimpanzee adenovirus vector as a vaccine carrier
    • Tatsis N., Blejer A., Lasaro M.O., et al. A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 2007, 15:608-617.
    • (2007) Mol Ther , vol.15 , pp. 608-617
    • Tatsis, N.1    Blejer, A.2    Lasaro, M.O.3
  • 680
    • 0031012007 scopus 로고    scopus 로고
    • Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins
    • Anderson M.J., Porter D.C., Moldoveanu Z., et al. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins. AIDS Res Hum Retroviruses 1997, 13:53-62.
    • (1997) AIDS Res Hum Retroviruses , vol.13 , pp. 53-62
    • Anderson, M.J.1    Porter, D.C.2    Moldoveanu, Z.3
  • 681
    • 65349118744 scopus 로고    scopus 로고
    • Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope
    • Arnold G.F., Velasco P.K., Holmes A.K., et al. Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 2009, 83:5087-5100.
    • (2009) J Virol , vol.83 , pp. 5087-5100
    • Arnold, G.F.1    Velasco, P.K.2    Holmes, A.K.3
  • 682
    • 0141521625 scopus 로고    scopus 로고
    • An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector
    • Perri S., Greer C.E., Thudium K., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003, 77:10394-10403.
    • (2003) J Virol , vol.77 , pp. 10394-10403
    • Perri, S.1    Greer, C.E.2    Thudium, K.3
  • 683
    • 19944425988 scopus 로고    scopus 로고
    • Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques
    • Johnson P.R., Schnepp B.C., Connell M.J., et al. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005, 79:955-965.
    • (2005) J Virol , vol.79 , pp. 955-965
    • Johnson, P.R.1    Schnepp, B.C.2    Connell, M.J.3
  • 684
    • 0042389496 scopus 로고    scopus 로고
    • Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model
    • Takeda A., Igarashi H., Nakamura H., et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J Virol 2003, 77:9710-9715.
    • (2003) J Virol , vol.77 , pp. 9710-9715
    • Takeda, A.1    Igarashi, H.2    Nakamura, H.3
  • 685
    • 3042545965 scopus 로고    scopus 로고
    • Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial
    • Matano T., Kobayashi M., Igarashi H., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004, 199:1709-1718.
    • (2004) J Exp Med , vol.199 , pp. 1709-1718
    • Matano, T.1    Kobayashi, M.2    Igarashi, H.3
  • 686
    • 0034467097 scopus 로고    scopus 로고
    • Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
    • Rose N.F., Roberts A., Buonocore L., et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 2000, 74:10903-10910.
    • (2000) J Virol , vol.74 , pp. 10903-10910
    • Rose, N.F.1    Roberts, A.2    Buonocore, L.3
  • 687
    • 27144515268 scopus 로고    scopus 로고
    • A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector
    • Publicover J., Ramsburg E., Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005, 79:13231-13238.
    • (2005) J Virol , vol.79 , pp. 13231-13238
    • Publicover, J.1    Ramsburg, E.2    Rose, J.K.3
  • 688
    • 58149526762 scopus 로고    scopus 로고
    • Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses
    • Carnero E., Li W., Borderia A.V., et al. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009, 83:584-597.
    • (2009) J Virol , vol.83 , pp. 584-597
    • Carnero, E.1    Li, W.2    Borderia, A.V.3
  • 689
    • 0345734199 scopus 로고    scopus 로고
    • A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV
    • Lorin C., Mollet L., Delebecque F., et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004, 78:146-157.
    • (2004) J Virol , vol.78 , pp. 146-157
    • Lorin, C.1    Mollet, L.2    Delebecque, F.3
  • 690
    • 70149088017 scopus 로고    scopus 로고
    • Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity
    • Honda M., Wang R., Kong W.P., et al. Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J Immunol 2009, 183:2425-2434.
    • (2009) J Immunol , vol.183 , pp. 2425-2434
    • Honda, M.1    Wang, R.2    Kong, W.P.3
  • 691
    • 78650041204 scopus 로고    scopus 로고
    • Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors
    • Rhee E.G., Blattman J.N., Kasturi S.P., et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol 2011, 85:315-323.
    • (2011) J Virol , vol.85 , pp. 315-323
    • Rhee, E.G.1    Blattman, J.N.2    Kasturi, S.P.3
  • 692
    • 0029940996 scopus 로고    scopus 로고
    • Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara
    • Hirsch V.M., Fuerst T.R., Sutter G., et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996, 70:3741-3752.
    • (1996) J Virol , vol.70 , pp. 3741-3752
    • Hirsch, V.M.1    Fuerst, T.R.2    Sutter, G.3
  • 693
    • 0034093217 scopus 로고    scopus 로고
    • Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
    • Ourmanov I., Brown C.R., Moss B., et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000, 74:2740-2751.
    • (2000) J Virol , vol.74 , pp. 2740-2751
    • Ourmanov, I.1    Brown, C.R.2    Moss, B.3
  • 694
    • 0035025623 scopus 로고    scopus 로고
    • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
    • Barouch D.H., Santra S., Kuroda M.J., et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001, 75:5151-5158.
    • (2001) J Virol , vol.75 , pp. 5151-5158
    • Barouch, D.H.1    Santra, S.2    Kuroda, M.J.3
  • 695
    • 18344405225 scopus 로고    scopus 로고
    • Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure
    • Benson J., Chougnet C., Robert-Guroff M., et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol 1998, 72:4170-4182.
    • (1998) J Virol , vol.72 , pp. 4170-4182
    • Benson, J.1    Chougnet, C.2    Robert-Guroff, M.3
  • 696
    • 0037122719 scopus 로고    scopus 로고
    • Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    • Shiver J.W., Fu T.M., Chen L., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
    • (2002) Nature , vol.415 , pp. 331-335
    • Shiver, J.W.1    Fu, T.M.2    Chen, L.3
  • 697
    • 29244455769 scopus 로고    scopus 로고
    • Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag
    • Casimiro D.R., Wang F., Schleif W.A., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005, 79:15547-15555.
    • (2005) J Virol , vol.79 , pp. 15547-15555
    • Casimiro, D.R.1    Wang, F.2    Schleif, W.A.3
  • 698
    • 29744438821 scopus 로고    scopus 로고
    • Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques
    • McDermott A.B., O'Connor D.H., Fuenger S., et al. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques. J Virol 2005, 79:15556-15566.
    • (2005) J Virol , vol.79 , pp. 15556-15566
    • McDermott, A.B.1    O'Connor, D.H.2    Fuenger, S.3
  • 699
    • 0033988633 scopus 로고    scopus 로고
    • Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
    • Davis N.L., Caley I.J., Brown K.W., et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000, 74:371-378.
    • (2000) J Virol , vol.74 , pp. 371-378
    • Davis, N.L.1    Caley, I.J.2    Brown, K.W.3
  • 700
    • 24644447713 scopus 로고    scopus 로고
    • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660
    • Johnston R.E., Johnson P.R., Connell M.J., et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005, 23:4969-4979.
    • (2005) Vaccine , vol.23 , pp. 4969-4979
    • Johnston, R.E.1    Johnson, P.R.2    Connell, M.J.3
  • 701
    • 33644866612 scopus 로고    scopus 로고
    • Mucosal and systemic adjuvant activity of alphavirus replicon particles
    • Thompson J.M., Whitmore A.C., Konopka J.L., et al. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc Natl Acad Sci U S A 2006, 103:3722-3727.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 3722-3727
    • Thompson, J.M.1    Whitmore, A.C.2    Konopka, J.L.3
  • 702
    • 77649339799 scopus 로고    scopus 로고
    • Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]
    • Lapelosa M., Arnold G.F., Gallicchio E., et al. Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]. J Mol Biol 2010, 397:752-766.
    • (2010) J Mol Biol , vol.397 , pp. 752-766
    • Lapelosa, M.1    Arnold, G.F.2    Gallicchio, E.3
  • 703
    • 0036547263 scopus 로고    scopus 로고
    • New hope for an AIDS vaccine
    • Robinson H.L. New hope for an AIDS vaccine. Nat Rev Immunol 2002, 2:239-250.
    • (2002) Nat Rev Immunol , vol.2 , pp. 239-250
    • Robinson, H.L.1
  • 704
    • 19944425960 scopus 로고    scopus 로고
    • Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
    • Mascola J.R., Sambor A., Beaudry K., et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005, 79:771-779.
    • (2005) J Virol , vol.79 , pp. 771-779
    • Mascola, J.R.1    Sambor, A.2    Beaudry, K.3
  • 705
    • 20744452323 scopus 로고    scopus 로고
    • Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens
    • Wu L., Kong W.P., Nabel G.J. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 2005, 79:8024-8031.
    • (2005) J Virol , vol.79 , pp. 8024-8031
    • Wu, L.1    Kong, W.P.2    Nabel, G.J.3
  • 706
    • 67049086871 scopus 로고    scopus 로고
    • Heterologous prime-boost vaccination
    • Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009, 21:346-351.
    • (2009) Curr Opin Immunol , vol.21 , pp. 346-351
    • Lu, S.1
  • 707
    • 77749322238 scopus 로고    scopus 로고
    • Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses
    • Koup R.A., Roederer M., Lamoreaux L., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5:e9015.
    • (2010) PLoS One , vol.5
    • Koup, R.A.1    Roederer, M.2    Lamoreaux, L.3
  • 708
    • 12144289214 scopus 로고    scopus 로고
    • Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates
    • Bertley F.M., Kozlowski P.A., Wang S.W., et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 2004, 172:3745-3757.
    • (2004) J Immunol , vol.172 , pp. 3745-3757
    • Bertley, F.M.1    Kozlowski, P.A.2    Wang, S.W.3
  • 709
    • 41449096780 scopus 로고    scopus 로고
    • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory
    • Manrique M., Micewicz E., Kozlowski P.A., et al. DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. AIDS Res Hum Retroviruses 2008, 24:505-519.
    • (2008) AIDS Res Hum Retroviruses , vol.24 , pp. 505-519
    • Manrique, M.1    Micewicz, E.2    Kozlowski, P.A.3
  • 710
    • 0036839574 scopus 로고    scopus 로고
    • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses
    • Hel Z., Nacsa J., Tryniszewska E., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 2002, 169:4778-4787.
    • (2002) J Immunol , vol.169 , pp. 4778-4787
    • Hel, Z.1    Nacsa, J.2    Tryniszewska, E.3
  • 711
    • 58549099671 scopus 로고    scopus 로고
    • Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89. 6P challenge
    • Schell J., Rose N.F., Fazo N., et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89. 6P challenge. Vaccine 2009, 27:979-986.
    • (2009) Vaccine , vol.27 , pp. 979-986
    • Schell, J.1    Rose, N.F.2    Fazo, N.3
  • 712
    • 32544446124 scopus 로고    scopus 로고
    • Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
    • Suh Y.S., Park K.S., Sauermann U., et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 2006, 24:1811-1820.
    • (2006) Vaccine , vol.24 , pp. 1811-1820
    • Suh, Y.S.1    Park, K.S.2    Sauermann, U.3
  • 713
    • 33745015013 scopus 로고    scopus 로고
    • Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge
    • Mattapallil J.J., Douek D.C., Buckler-White A., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006, 203:1533-1541.
    • (2006) J Exp Med , vol.203 , pp. 1533-1541
    • Mattapallil, J.J.1    Douek, D.C.2    Buckler-White, A.3
  • 714
    • 48749130188 scopus 로고    scopus 로고
    • A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys
    • Santra S., Korber B.T., Muldoon M., et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 2008, 105:10489-10494.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 10489-10494
    • Santra, S.1    Korber, B.T.2    Muldoon, M.3
  • 715
    • 67449101823 scopus 로고    scopus 로고
    • Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge
    • Wilson N.A., Keele B.F., Reed J.S., et al. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J Virol 2009, 83:6508-6521.
    • (2009) J Virol , vol.83 , pp. 6508-6521
    • Wilson, N.A.1    Keele, B.F.2    Reed, J.S.3
  • 716
    • 71949122352 scopus 로고    scopus 로고
    • Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens
    • Asmuth D.M., Brown E.L., DiNubile M.J., et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J Infect Dis 2010, 201:132-141.
    • (2010) J Infect Dis , vol.201 , pp. 132-141
    • Asmuth, D.M.1    Brown, E.L.2    DiNubile, M.J.3
  • 717
    • 77950819099 scopus 로고    scopus 로고
    • T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge
    • Martins M.A., Wilson N.A., Reed J.S., et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol 2010, 84:4352-4365.
    • (2010) J Virol , vol.84 , pp. 4352-4365
    • Martins, M.A.1    Wilson, N.A.2    Reed, J.S.3
  • 718
    • 34248373768 scopus 로고    scopus 로고
    • Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine
    • Kawada M., Tsukamoto T., Yamamoto H., et al. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 2007, 81:5202-5211.
    • (2007) J Virol , vol.81 , pp. 5202-5211
    • Kawada, M.1    Tsukamoto, T.2    Yamamoto, H.3
  • 719
    • 32444446673 scopus 로고    scopus 로고
    • Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques
    • Kawada M., Igarashi H., Takeda A., et al. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J Virol 2006, 80:1949-1958.
    • (2006) J Virol , vol.80 , pp. 1949-1958
    • Kawada, M.1    Igarashi, H.2    Takeda, A.3
  • 720
    • 69449108369 scopus 로고    scopus 로고
    • Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys
    • Barouch D.H., Liu J., Lynch D.M., et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol 2009, 83:9584-9590.
    • (2009) J Virol , vol.83 , pp. 9584-9590
    • Barouch, D.H.1    Liu, J.2    Lynch, D.M.3
  • 721
    • 34548182353 scopus 로고    scopus 로고
    • HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3
    • Cristillo A.D., Lisziewicz J., He L., et al. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007, 366:197-211.
    • (2007) Virology , vol.366 , pp. 197-211
    • Cristillo, A.D.1    Lisziewicz, J.2    He, L.3
  • 722
    • 0032920019 scopus 로고    scopus 로고
    • Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
    • Robinson H.L., Montefiori D.C., Johnson R.P., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999, 5:526-534.
    • (1999) Nat Med , vol.5 , pp. 526-534
    • Robinson, H.L.1    Montefiori, D.C.2    Johnson, R.P.3
  • 723
    • 0035815437 scopus 로고    scopus 로고
    • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    • Amara R.R., Villinger F., Altman J.D., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
    • (2001) Science , vol.292 , pp. 69-74
    • Amara, R.R.1    Villinger, F.2    Altman, J.D.3
  • 724
    • 4344714042 scopus 로고    scopus 로고
    • MVA as a vector for vaccines against HIV-1
    • Im E.J., Hanke T. MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 2004, 3(suppl. 4):S89-S97.
    • (2004) Expert Rev Vaccines , vol.3 , Issue.SUPPL.. 4
    • Im, E.J.1    Hanke, T.2
  • 725
    • 34548070699 scopus 로고    scopus 로고
    • A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice
    • Brave A., Boberg A., Gudmundsdotter L., et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther 2007, 15:1724-1733.
    • (2007) Mol Ther , vol.15 , pp. 1724-1733
    • Brave, A.1    Boberg, A.2    Gudmundsdotter, L.3
  • 726
    • 37549023073 scopus 로고    scopus 로고
    • Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells
    • Robinson H.L., Sharma S., Zhao J., et al. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells. AIDS Res Hum Retroviruses 2007, 23:1555-1562.
    • (2007) AIDS Res Hum Retroviruses , vol.23 , pp. 1555-1562
    • Robinson, H.L.1    Sharma, S.2    Zhao, J.3
  • 727
    • 35649027418 scopus 로고    scopus 로고
    • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine
    • Lai L., Vodros D., Kozlowski P.A., et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007, 369:153-167.
    • (2007) Virology , vol.369 , pp. 153-167
    • Lai, L.1    Vodros, D.2    Kozlowski, P.A.3
  • 728
    • 66149097337 scopus 로고    scopus 로고
    • Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia
    • Zhao J., Lai L., Amara R.R., et al. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J Virol 2009, 83:4102-4111.
    • (2009) J Virol , vol.83 , pp. 4102-4111
    • Zhao, J.1    Lai, L.2    Amara, R.R.3
  • 729
    • 77956177746 scopus 로고    scopus 로고
    • Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys
    • Sun Y., Santra S., Buzby A.P., et al. Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys. Virology 2010, 406:48-55.
    • (2010) Virology , vol.406 , pp. 48-55
    • Sun, Y.1    Santra, S.2    Buzby, A.P.3
  • 730
    • 33750701498 scopus 로고    scopus 로고
    • Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge
    • Sun Y., Schmitz J.E., Buzby A.P., et al. Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge. J Virol 2006, 80:10950-10956.
    • (2006) J Virol , vol.80 , pp. 10950-10956
    • Sun, Y.1    Schmitz, J.E.2    Buzby, A.P.3
  • 731
    • 4644225721 scopus 로고    scopus 로고
    • Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors
    • Casimiro D.R., Bett A.J., Fu T.M., et al. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004, 78:11434-11438.
    • (2004) J Virol , vol.78 , pp. 11434-11438
    • Casimiro, D.R.1    Bett, A.J.2    Fu, T.M.3
  • 732
    • 22544467274 scopus 로고    scopus 로고
    • Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity
    • Lemckert A.A., Sumida S.M., Holterman L., et al. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 2005, 79:9694-9701.
    • (2005) J Virol , vol.79 , pp. 9694-9701
    • Lemckert, A.A.1    Sumida, S.M.2    Holterman, L.3
  • 733
    • 66149141072 scopus 로고    scopus 로고
    • Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses
    • Cayabyab M.J., Korioth-Schmitz B., Sun Y., et al. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 2009, 83:5505-5513.
    • (2009) J Virol , vol.83 , pp. 5505-5513
    • Cayabyab, M.J.1    Korioth-Schmitz, B.2    Sun, Y.3
  • 735
    • 0036133208 scopus 로고    scopus 로고
    • ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency
    • Pal R., Venzon D., Letvin N.L., et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002, 76:292-302.
    • (2002) J Virol , vol.76 , pp. 292-302
    • Pal, R.1    Venzon, D.2    Letvin, N.L.3
  • 736
    • 33645793093 scopus 로고    scopus 로고
    • + T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels
    • + T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 2006, 80:3732-3742.
    • (2006) J Virol , vol.80 , pp. 3732-3742
    • Pal, R.1    Venzon, D.2    Santra, S.3
  • 737
    • 0038784862 scopus 로고    scopus 로고
    • Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen
    • Zhao J., Pinczewski J., Gomez-Roman V.R., et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 2003, 77:8354-8365.
    • (2003) J Virol , vol.77 , pp. 8354-8365
    • Zhao, J.1    Pinczewski, J.2    Gomez-Roman, V.R.3
  • 738
    • 12644271200 scopus 로고    scopus 로고
    • Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
    • Letvin N.L., Montefiori D.C., Yasutomi Y., et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997, 94:9378-9383.
    • (1997) Proc Natl Acad Sci U S A , vol.94 , pp. 9378-9383
    • Letvin, N.L.1    Montefiori, D.C.2    Yasutomi, Y.3
  • 739
    • 0030872511 scopus 로고    scopus 로고
    • Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
    • Barnett S.W., Rajasekar S., Legg H., et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997, 15:869-873.
    • (1997) Vaccine , vol.15 , pp. 869-873
    • Barnett, S.W.1    Rajasekar, S.2    Legg, H.3
  • 740
    • 40549094977 scopus 로고    scopus 로고
    • Human versus HIV: round 2 defeat in AIDS vaccine development
    • Lu S. Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev Vaccines 2008, 7:151-153.
    • (2008) Expert Rev Vaccines , vol.7 , pp. 151-153
    • Lu, S.1
  • 741
    • 33746651142 scopus 로고    scopus 로고
    • Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
    • Wang S., Pal R., Mascola J.R., et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006, 350:34-47.
    • (2006) Virology , vol.350 , pp. 34-47
    • Wang, S.1    Pal, R.2    Mascola, J.R.3
  • 742
    • 0026047610 scopus 로고
    • Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen
    • Wang C.Y., Looney D.J., Li M.L., et al. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991, 254:285-288.
    • (1991) Science , vol.254 , pp. 285-288
    • Wang, C.Y.1    Looney, D.J.2    Li, M.L.3
  • 743
    • 0442292287 scopus 로고    scopus 로고
    • Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy
    • Liu Z., Chen Y.H. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy. J Immunol Methods 2004, 285:93-97.
    • (2004) J Immunol Methods , vol.285 , pp. 93-97
    • Liu, Z.1    Chen, Y.H.2
  • 744
    • 14844302633 scopus 로고    scopus 로고
    • HIV vaccine development by computer assisted design: the GAIA vaccine
    • De Groot A.S., Marcon L., Bishop E.A., et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005, 23:2136-2148.
    • (2005) Vaccine , vol.23 , pp. 2136-2148
    • De Groot, A.S.1    Marcon, L.2    Bishop, E.A.3
  • 745
    • 24944542364 scopus 로고    scopus 로고
    • HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach
    • Gahery H., Choppin J., Bourgault I., et al. HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach. Therapie 2005, 60:243-248.
    • (2005) Therapie , vol.60 , pp. 243-248
    • Gahery, H.1    Choppin, J.2    Bourgault, I.3
  • 746
    • 33646365642 scopus 로고    scopus 로고
    • Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults
    • Durier C., Launay O., Meiffredy V., et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006, 20:1039-1049.
    • (2006) AIDS , vol.20 , pp. 1039-1049
    • Durier, C.1    Launay, O.2    Meiffredy, V.3
  • 747
    • 77953752637 scopus 로고    scopus 로고
    • Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates
    • Bianchi E., Joyce J.G., Miller M.D., et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A 2010, 107:10655-10660.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 10655-10660
    • Bianchi, E.1    Joyce, J.G.2    Miller, M.D.3
  • 748
    • 0030012266 scopus 로고    scopus 로고
    • Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL
    • Deprez B., Sauzet J.P., Boutillon C., et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996, 14:375-382.
    • (1996) Vaccine , vol.14 , pp. 375-382
    • Deprez, B.1    Sauzet, J.P.2    Boutillon, C.3
  • 749
    • 0342647378 scopus 로고    scopus 로고
    • Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
    • Gahery-Segard H., Pialoux G., Charmeteau B., et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000, 74:1694-1703.
    • (2000) J Virol , vol.74 , pp. 1694-1703
    • Gahery-Segard, H.1    Pialoux, G.2    Charmeteau, B.3
  • 750
    • 38849188390 scopus 로고    scopus 로고
    • Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
    • Launay O., Durier C., Desaint C., et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One 2007, 2:e725.
    • (2007) PLoS One , vol.2
    • Launay, O.1    Durier, C.2    Desaint, C.3
  • 751
    • 42049102863 scopus 로고    scopus 로고
    • Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA Study
    • Pialoux G., Quercia R.P., Gahery H., et al. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA Study. Clin Vaccine Immunol 2008, 15:562-568.
    • (2008) Clin Vaccine Immunol , vol.15 , pp. 562-568
    • Pialoux, G.1    Quercia, R.P.2    Gahery, H.3
  • 752
    • 77952581247 scopus 로고    scopus 로고
    • Mucosal HIV vaccines: a holy grail or a dud?
    • Azizi A., Ghunaim H., Diaz-Mitoma F., et al. Mucosal HIV vaccines: a holy grail or a dud?. Vaccine 2010, 28:4015-4026.
    • (2010) Vaccine , vol.28 , pp. 4015-4026
    • Azizi, A.1    Ghunaim, H.2    Diaz-Mitoma, F.3
  • 753
    • 77958452906 scopus 로고    scopus 로고
    • Vaccination strategies to promote mucosal antibody responses
    • Chen K., Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010, 33:479-491.
    • (2010) Immunity , vol.33 , pp. 479-491
    • Chen, K.1    Cerutti, A.2
  • 754
    • 77954672442 scopus 로고    scopus 로고
    • Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes
    • Yu M., Vajdy M. Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes. Expert Opin Biol Ther 2010, 10:1181-1195.
    • (2010) Expert Opin Biol Ther , vol.10 , pp. 1181-1195
    • Yu, M.1    Vajdy, M.2
  • 755
    • 57449084255 scopus 로고    scopus 로고
    • The great barrier
    • Von Bubnoff A. The great barrier. IAVI Rep 2008, 12:10-14.
    • (2008) IAVI Rep , vol.12 , pp. 10-14
    • Von Bubnoff, A.1
  • 756
    • 41149163239 scopus 로고    scopus 로고
    • Conquering sexually transmitted diseases
    • Starnbach M.N., Roan N.R. Conquering sexually transmitted diseases. Nat Rev Immunol 2008, 8:313-317.
    • (2008) Nat Rev Immunol , vol.8 , pp. 313-317
    • Starnbach, M.N.1    Roan, N.R.2
  • 757
    • 2442517281 scopus 로고    scopus 로고
    • Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule
    • Gherardi M.M., Perez-Jimenez E., Najera J.L., et al. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol 2004, 172:6209-6220.
    • (2004) J Immunol , vol.172 , pp. 6209-6220
    • Gherardi, M.M.1    Perez-Jimenez, E.2    Najera, J.L.3
  • 758
    • 17844394454 scopus 로고    scopus 로고
    • Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE
    • Pinczewski J., Zhao J., Malkevitch N., et al. Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol 2005, 18:236-243.
    • (2005) Viral Immunol , vol.18 , pp. 236-243
    • Pinczewski, J.1    Zhao, J.2    Malkevitch, N.3
  • 759
    • 35449000608 scopus 로고    scopus 로고
    • Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251)
    • Zhou Q., Hidajat R., Peng B., et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). Vaccine 2007, 25:8021-8035.
    • (2007) Vaccine , vol.25 , pp. 8021-8035
    • Zhou, Q.1    Hidajat, R.2    Peng, B.3
  • 760
    • 79951754740 scopus 로고    scopus 로고
    • Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
    • Bomsel M., Tudor D., Drillet A.S., et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011, 34:269-280.
    • (2011) Immunity , vol.34 , pp. 269-280
    • Bomsel, M.1    Tudor, D.2    Drillet, A.S.3
  • 761
    • 79951745043 scopus 로고    scopus 로고
    • Standing guard at the mucosa
    • McElrath M.J. Standing guard at the mucosa. Immunity 2011, 34:146-148.
    • (2011) Immunity , vol.34 , pp. 146-148
    • McElrath, M.J.1
  • 762
    • 33646872613 scopus 로고    scopus 로고
    • Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate
    • Matoba N., Geyer B.C., Kilbourne J., et al. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006, 24:5047-5055.
    • (2006) Vaccine , vol.24 , pp. 5047-5055
    • Matoba, N.1    Geyer, B.C.2    Kilbourne, J.3
  • 763
    • 34447509610 scopus 로고    scopus 로고
    • DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity
    • Buonaguro L., Devito C., Tornesello M.L., et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 2007, 25:5968-5977.
    • (2007) Vaccine , vol.25 , pp. 5968-5977
    • Buonaguro, L.1    Devito, C.2    Tornesello, M.L.3
  • 764
    • 77952001983 scopus 로고    scopus 로고
    • Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
    • Binley J.M., Ban Y.E., Crooks E.T., et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J Virol 2010, 84:5637-5655.
    • (2010) J Virol , vol.84 , pp. 5637-5655
    • Binley, J.M.1    Ban, Y.E.2    Crooks, E.T.3
  • 765
    • 41649090223 scopus 로고    scopus 로고
    • A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
    • Frey G., Peng H., Rits-Volloch S., et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2008, 105:3739-3744.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 3739-3744
    • Frey, G.1    Peng, H.2    Rits-Volloch, S.3
  • 766
    • 21344434534 scopus 로고    scopus 로고
    • Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    • Haynes B.F., Fleming J., St Clair E.W., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
    • (2005) Science , vol.308 , pp. 1906-1908
    • Haynes, B.F.1    Fleming, J.2    St Clair, E.W.3
  • 767
    • 76249083814 scopus 로고    scopus 로고
    • Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance
    • Verkoczy L., Diaz M., Holl T.M., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010, 107:181-186.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 181-186
    • Verkoczy, L.1    Diaz, M.2    Holl, T.M.3
  • 768
    • 0027985431 scopus 로고
    • Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
    • Burton D.R., Pyati J., Koduri R., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1047.
    • (1994) Science , vol.266 , pp. 1024-1047
    • Burton, D.R.1    Pyati, J.2    Koduri, R.3
  • 769
    • 0028291731 scopus 로고
    • Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
    • Roben P., Moore J.P., Thali M., et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994, 68:4821-4828.
    • (1994) J Virol , vol.68 , pp. 4821-4828
    • Roben, P.1    Moore, J.P.2    Thali, M.3
  • 770
    • 34249950588 scopus 로고    scopus 로고
    • Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors
    • Dhillon A.K., Donners H., Pantophlet R., et al. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007, 81:6548-6562.
    • (2007) J Virol , vol.81 , pp. 6548-6562
    • Dhillon, A.K.1    Donners, H.2    Pantophlet, R.3
  • 771
    • 70450182950 scopus 로고    scopus 로고
    • Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120
    • Chen L., Do Kwon Y., Zhou T., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123-1127.
    • (2009) Science , vol.326 , pp. 1123-1127
    • Chen, L.1    Do Kwon, Y.2    Zhou, T.3
  • 772
    • 33847101745 scopus 로고    scopus 로고
    • Structural definition of a conserved neutralization epitope on HIV-1 gp120
    • Zhou T., Xu L., Dey B., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
    • (2007) Nature , vol.445 , pp. 732-737
    • Zhou, T.1    Xu, L.2    Dey, B.3
  • 773
    • 0028208268 scopus 로고
    • Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
    • Conley A.J., Kessler J.A., Boots L.J., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A 1994, 91:3348-3352.
    • (1994) Proc Natl Acad Sci U S A , vol.91 , pp. 3348-3352
    • Conley, A.J.1    Kessler, J.A.2    Boots, L.J.3
  • 774
    • 0028865465 scopus 로고
    • Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
    • Trkola A., Pomales A.B., Yuan H., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995, 69:6609-6617.
    • (1995) J Virol , vol.69 , pp. 6609-6617
    • Trkola, A.1    Pomales, A.B.2    Yuan, H.3
  • 775
    • 0035701421 scopus 로고    scopus 로고
    • A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
    • Stiegler G., Kunert R., Purtscher M., et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
    • (2001) AIDS Res Hum Retroviruses , vol.17 , pp. 1757-1765
    • Stiegler, G.1    Kunert, R.2    Purtscher, M.3
  • 776
    • 0034759882 scopus 로고    scopus 로고
    • Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
    • Zwick M.B., Labrijn A.F., Wang M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.
    • (2001) J Virol , vol.75 , pp. 10892-10905
    • Zwick, M.B.1    Labrijn, A.F.2    Wang, M.3
  • 777
    • 34247106331 scopus 로고    scopus 로고
    • An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10
    • Nelson J.D., Brunel F.M., Jensen R., et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol 2007, 81:4033-4043.
    • (2007) J Virol , vol.81 , pp. 4033-4043
    • Nelson, J.D.1    Brunel, F.M.2    Jensen, R.3
  • 778
    • 13844255333 scopus 로고    scopus 로고
    • Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
    • Cardoso R.M., Zwick M.B., Stanfield R.L., et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
    • (2005) Immunity , vol.22 , pp. 163-173
    • Cardoso, R.M.1    Zwick, M.B.2    Stanfield, R.L.3
  • 779
    • 4544379899 scopus 로고    scopus 로고
    • Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
    • Ofek G., Tang M., Sambor A., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004, 78:10724-10737.
    • (2004) J Virol , vol.78 , pp. 10724-10737
    • Ofek, G.1    Tang, M.2    Sambor, A.3
  • 780
    • 73949133588 scopus 로고    scopus 로고
    • Role of HIV membrane in neutralization by two broadly neutralizing antibodies
    • Alam S.M., Morelli M., Dennison S.M., et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A 2009, 106:20234-20239.
    • (2009) Proc Natl Acad Sci U S A , vol.106 , pp. 20234-20239
    • Alam, S.M.1    Morelli, M.2    Dennison, S.M.3
  • 781
    • 77649132440 scopus 로고    scopus 로고
    • Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region
    • Ofek G., McKee K., Yang Y., et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J Virol 2010, 84:2955-2962.
    • (2010) J Virol , vol.84 , pp. 2955-2962
    • Ofek, G.1    McKee, K.2    Yang, Y.3
  • 782
    • 0036637385 scopus 로고    scopus 로고
    • The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120
    • Sanders R.W., Venturi M., Schiffner L., et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002, 76:7293-7305.
    • (2002) J Virol , vol.76 , pp. 7293-7305
    • Sanders, R.W.1    Venturi, M.2    Schiffner, L.3
  • 783
    • 18244422922 scopus 로고    scopus 로고
    • The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120
    • Scanlan C.N., Pantophlet R., Wormald M.R., et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J Virol 2002, 76:7306-7321.
    • (2002) J Virol , vol.76 , pp. 7306-7321
    • Scanlan, C.N.1    Pantophlet, R.2    Wormald, M.R.3
  • 784
    • 77957189612 scopus 로고    scopus 로고
    • Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged
    • Doores K.J., Fulton Z., Huber M., et al. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged. J Virol 2010, 84:10690-10699.
    • (2010) J Virol , vol.84 , pp. 10690-10699
    • Doores, K.J.1    Fulton, Z.2    Huber, M.3
  • 785
    • 77954920017 scopus 로고    scopus 로고
    • Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    • Wu X., Yang Z.Y., Li Y., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
    • (2010) Science , vol.329 , pp. 856-861
    • Wu, X.1    Yang, Z.Y.2    Li, Y.3
  • 786
    • 77649318846 scopus 로고    scopus 로고
    • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    • Corti D., Langedijk J.P., Hinz A., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.
    • (2010) PLoS One , vol.5
    • Corti, D.1    Langedijk, J.P.2    Hinz, A.3
  • 787
    • 77958115264 scopus 로고    scopus 로고
    • A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    • Walker L.M., Simek M.D., Priddy F., et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog 2010, 6:e1001028.
    • (2010) PLoS Pathog , vol.6
    • Walker, L.M.1    Simek, M.D.2    Priddy, F.3
  • 788
    • 80052470370 scopus 로고    scopus 로고
    • High through-put functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies
    • Walker L., Chan-Hui P., Ramos A., et al. High through-put functional screening of activated B cells from 4 African elite neutralizers yields a panel of novel broadly neutralizing antibodies. AIDS Res Hum Retroviruses 2010, 26:A149-A150.
    • (2010) AIDS Res Hum Retroviruses , vol.26
    • Walker, L.1    Chan-Hui, P.2    Ramos, A.3
  • 789
    • 0034823216 scopus 로고    scopus 로고
    • Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development
    • Meffre E., Milili M., Blanco-Betancourt C., et al. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 2001, 108:879-886.
    • (2001) J Clin Invest , vol.108 , pp. 879-886
    • Meffre, E.1    Milili, M.2    Blanco-Betancourt, C.3
  • 790
    • 0033563012 scopus 로고    scopus 로고
    • IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth
    • Shiokawa S., Mortari F., Lima J.O., et al. IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J Immunol 1999, 162:6060-6070.
    • (1999) J Immunol , vol.162 , pp. 6060-6070
    • Shiokawa, S.1    Mortari, F.2    Lima, J.O.3
  • 791
    • 69549091679 scopus 로고    scopus 로고
    • Immunogenicity of HIV-1 envelope glycoprotein oligomers
    • Forsell M.N.E., Schief W.R., Wyatt R.T. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 2009, 4:380-387.
    • (2009) Curr Opin HIV AIDS , vol.4 , pp. 380-387
    • Forsell, M.N.E.1    Schief, W.R.2    Wyatt, R.T.3
  • 792
    • 44049108744 scopus 로고    scopus 로고
    • Toward an AIDS vaccine
    • Walker B.D., Burton D.R. Toward an AIDS vaccine. Science 2008, 320:760-764.
    • (2008) Science , vol.320 , pp. 760-764
    • Walker, B.D.1    Burton, D.R.2
  • 793
    • 77956247505 scopus 로고    scopus 로고
    • Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies
    • Bhattacharyya S., Rajan R.E., Swarupa Y., et al. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. J Biol Chem 2010, 285:27100-27110.
    • (2010) J Biol Chem , vol.285 , pp. 27100-27110
    • Bhattacharyya, S.1    Rajan, R.E.2    Swarupa, Y.3
  • 794
    • 69549095803 scopus 로고    scopus 로고
    • The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility
    • Korber B., Gnanakaran S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr Opin HIV AIDS 2009, 4:408-417.
    • (2009) Curr Opin HIV AIDS , vol.4 , pp. 408-417
    • Korber, B.1    Gnanakaran, S.2
  • 795
    • 78349299783 scopus 로고    scopus 로고
    • Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies
    • Gnanakaran S., Daniels M.G., Bhattacharya T., et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol 2010, 6:e1000955.
    • (2010) PLoS Comput Biol , vol.6
    • Gnanakaran, S.1    Daniels, M.G.2    Bhattacharya, T.3
  • 796
    • 80051558293 scopus 로고    scopus 로고
    • Quantitative assessment of masking of neutralization epitopes in HIV-1
    • Agarwal A., Hioe C.E., Swetnam J., et al. Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine 2011, 29:6736-6741.
    • (2011) Vaccine , vol.29 , pp. 6736-6741
    • Agarwal, A.1    Hioe, C.E.2    Swetnam, J.3
  • 797
    • 54849437925 scopus 로고    scopus 로고
    • Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site
    • Burioni R., Mancini N., De Marco D., et al. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS One 2008, 3:e3423.
    • (2008) PLoS One , vol.3
    • Burioni, R.1    Mancini, N.2    De Marco, D.3
  • 798
    • 77956385205 scopus 로고    scopus 로고
    • Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
    • Doores K.J., Bonomelli C., Harvey D.J., et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 2010, 107:13800-13805.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 13800-13805
    • Doores, K.J.1    Bonomelli, C.2    Harvey, D.J.3
  • 799
    • 35248867927 scopus 로고    scopus 로고
    • A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006
    • Bansal G.P. A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006. Biologicals 2007, 35:367-371.
    • (2007) Biologicals , vol.35 , pp. 367-371
    • Bansal, G.P.1
  • 800
    • 78349286286 scopus 로고    scopus 로고
    • Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization
    • Lohman-Payne B., Slyker J., Rowland-Jones S.L. Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization. Clin Perinatol 2010, 37:787-805.
    • (2010) Clin Perinatol , vol.37 , pp. 787-805
    • Lohman-Payne, B.1    Slyker, J.2    Rowland-Jones, S.L.3
  • 802
    • 33645218704 scopus 로고    scopus 로고
    • Engineered antibody Fc variants with enhanced effector function
    • Lazar G.A., Dang W., Karki S., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006, 103:4005-4010.
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 4005-4010
    • Lazar, G.A.1    Dang, W.2    Karki, S.3
  • 803
    • 76349123565 scopus 로고    scopus 로고
    • Enhanced antibody half-life improves in vivo activity
    • Zalevsky J., Chamberlain A.K., Horton H.M., et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
    • (2010) Nat Biotechnol , vol.28 , pp. 157-159
    • Zalevsky, J.1    Chamberlain, A.K.2    Horton, H.M.3
  • 804
    • 61649087668 scopus 로고    scopus 로고
    • Glycosylation as a strategy to improve antibody-based therapeutics
    • Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009, 8:226-234.
    • (2009) Nat Rev Drug Discov , vol.8 , pp. 226-234
    • Jefferis, R.1
  • 805
    • 0036340378 scopus 로고    scopus 로고
    • Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer
    • Lewis A.D., Chen R., Montefiori D.C., et al. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002, 76:8769-8775.
    • (2002) J Virol , vol.76 , pp. 8769-8775
    • Lewis, A.D.1    Chen, R.2    Montefiori, D.C.3
  • 806
    • 61849122809 scopus 로고    scopus 로고
    • Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes
    • Luo X.M., Maarschalk E., O'Connell R.M., et al. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 2009, 113:1422-1431.
    • (2009) Blood , vol.113 , pp. 1422-1431
    • Luo, X.M.1    Maarschalk, E.2    O'Connell, R.M.3
  • 807
    • 77953311689 scopus 로고    scopus 로고
    • Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody
    • Joseph A., Zheng J.H., Chen K., et al. Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. J Virol 2010, 84:6645-6653.
    • (2010) J Virol , vol.84 , pp. 6645-6653
    • Joseph, A.1    Zheng, J.H.2    Chen, K.3
  • 808
    • 2442689092 scopus 로고    scopus 로고
    • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies
    • Haigwood N.L., Montefiori D.C., Sutton W.F., et al. Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J Virol 2004, 78:5983-5995.
    • (2004) J Virol , vol.78 , pp. 5983-5995
    • Haigwood, N.L.1    Montefiori, D.C.2    Sutton, W.F.3
  • 809
    • 68649084966 scopus 로고    scopus 로고
    • Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue
    • Murakami T., Eda Y., Nakasone T., et al. Postinfection passive transfer of KD-247 protects against simian/human immunodeficiency virus-induced CD4+ T-cell loss in macaque lymphoid tissue. AIDS 2009, 23:1485-1494.
    • (2009) AIDS , vol.23 , pp. 1485-1494
    • Murakami, T.1    Eda, Y.2    Nakasone, T.3
  • 810
    • 20944446452 scopus 로고    scopus 로고
    • Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    • Trkola A., Kuster H., Rusert P., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622.
    • (2005) Nat Med , vol.11 , pp. 615-622
    • Trkola, A.1    Kuster, H.2    Rusert, P.3
  • 811
    • 41949106267 scopus 로고    scopus 로고
    • Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    • Huber M., von Wyl V., Ammann C.G., et al. Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. J Virol 2008, 82:3834-3842.
    • (2008) J Virol , vol.82 , pp. 3834-3842
    • Huber, M.1    von Wyl, V.2    Ammann, C.G.3
  • 812
    • 79951823624 scopus 로고    scopus 로고
    • An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers
    • Van Braeckel E., Bourguignon P., Koutsoukos M., et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis 2011, 52:522-531.
    • (2011) Clin Infect Dis , vol.52 , pp. 522-531
    • Van Braeckel, E.1    Bourguignon, P.2    Koutsoukos, M.3
  • 813
    • 77956231717 scopus 로고    scopus 로고
    • Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
    • Salmon-Ceron D., Durier C., Desaint C., et al. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial. AIDS 2010, 24:2211-2223.
    • (2010) AIDS , vol.24 , pp. 2211-2223
    • Salmon-Ceron, D.1    Durier, C.2    Desaint, C.3
  • 814
    • 33845433434 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    • Pitisuttithum P., Gilbert P., Gurwith M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
    • (2006) J Infect Dis , vol.194 , pp. 1661-1671
    • Pitisuttithum, P.1    Gilbert, P.2    Gurwith, M.3
  • 815
    • 34247201441 scopus 로고    scopus 로고
    • Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    • Catanzaro A.T., Roederer M., Koup R.A., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007, 25:4085-4092.
    • (2007) Vaccine , vol.25 , pp. 4085-4092
    • Catanzaro, A.T.1    Roederer, M.2    Koup, R.A.3
  • 816
    • 78650568204 scopus 로고    scopus 로고
    • Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in electroporation
    • Dolter K.E., Evans C.F., Ellefsen B., et al. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in electroporation. Vaccine 2011, 29:795-803.
    • (2011) Vaccine , vol.29 , pp. 795-803
    • Dolter, K.E.1    Evans, C.F.2    Ellefsen, B.3
  • 817
    • 77955513770 scopus 로고    scopus 로고
    • Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine
    • Gray G., Buchbinder S., Duerr A. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 2010, 5:357-361.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 357-361
    • Gray, G.1    Buchbinder, S.2    Duerr, A.3
  • 818
    • 75749141272 scopus 로고    scopus 로고
    • A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172)
    • Kibuuka H., Kimutai R., Maboko L., et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis 2010, 201:600-607.
    • (2010) J Infect Dis , vol.201 , pp. 600-607
    • Kibuuka, H.1    Kimutai, R.2    Maboko, L.3
  • 819
    • 45749099294 scopus 로고    scopus 로고
    • Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration
    • Bansal A., Jackson B., West K., et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 2008, 82:6458-6469.
    • (2008) J Virol , vol.82 , pp. 6458-6469
    • Bansal, A.1    Jackson, B.2    West, K.3
  • 820
    • 38749132973 scopus 로고    scopus 로고
    • An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
    • Harari A., Bart P.A., Stohr W., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205:63-77.
    • (2008) J Exp Med , vol.205 , pp. 63-77
    • Harari, A.1    Bart, P.A.2    Stohr, W.3
  • 821
    • 79751487021 scopus 로고    scopus 로고
    • Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
    • Goepfert P.A., Elizaga M.L., Sato A., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203:610-619.
    • (2011) J Infect Dis , vol.203 , pp. 610-619
    • Goepfert, P.A.1    Elizaga, M.L.2    Sato, A.3
  • 822
    • 85158966553 scopus 로고    scopus 로고
    • Human immunodeficiency virus
    • Saunders/Elsevier, Philadelphia, PA, S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.)
    • Girard M., Koff W. Human immunodeficiency virus. Vaccines 2008, 1213-1251. Saunders/Elsevier, Philadelphia, PA. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
    • (2008) Vaccines , pp. 1213-1251
    • Girard, M.1    Koff, W.2
  • 823
    • 24644479045 scopus 로고    scopus 로고
    • HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine
    • Gilbert P.B., Ackers M.L., Berman P.W., et al. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine. J Infect Dis 2005, 192:974-983.
    • (2005) J Infect Dis , vol.192 , pp. 974-983
    • Gilbert, P.B.1    Ackers, M.L.2    Berman, P.W.3
  • 824
    • 37349036786 scopus 로고    scopus 로고
    • Lessons from the AIDSVAX B/B′ Vaccine Efficacy Trial
    • Horizon Press, Norkfolk, UK, W. Koff, P. Kahn, I. Gust (Eds.)
    • Buchbinder S.P., Fuchs J.D. Lessons from the AIDSVAX B/B′ Vaccine Efficacy Trial. AIDS Vaccine Development: Challenges and Opportunities 2007, 105-110. Horizon Press, Norkfolk, UK. W. Koff, P. Kahn, I. Gust (Eds.).
    • (2007) AIDS Vaccine Development: Challenges and Opportunities , pp. 105-110
    • Buchbinder, S.P.1    Fuchs, J.D.2
  • 825
    • 77954722964 scopus 로고    scopus 로고
    • Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine
    • Gilbert P., Wang M., Wrin T., et al. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 2010, 202:595-605.
    • (2010) J Infect Dis , vol.202 , pp. 595-605
    • Gilbert, P.1    Wang, M.2    Wrin, T.3
  • 826
    • 69749121344 scopus 로고    scopus 로고
    • Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors
    • Sep 25
    • Santra S., Sun Y., Korioth-Schmitz B., et al. Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 2009 Sep 25, 27(42):5837-5845.
    • (2009) Vaccine , vol.27 , Issue.42 , pp. 5837-5845
    • Santra, S.1    Sun, Y.2    Korioth-Schmitz, B.3
  • 827
    • 84856880087 scopus 로고    scopus 로고
    • Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector
    • O'Hara G.A., Duncan C.J.A., Ewer K.J., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205:772-781.
    • (2012) J Infect Dis , vol.205 , pp. 772-781
    • O'Hara, G.A.1    Duncan, C.J.A.2    Ewer, K.J.3
  • 828
    • 84902046259 scopus 로고    scopus 로고
    • The Thai VaxGen Trial: What have we learned?
    • Horizon Press, Norkfolk, UK, W. Koff, P. Kahn, I. Gust (Eds.)
    • Beyrer C. The Thai VaxGen Trial: What have we learned?. AIDS Vaccine Development: Challenges and Opportunities 2007, 111-116. Horizon Press, Norkfolk, UK. W. Koff, P. Kahn, I. Gust (Eds.).
    • (2007) AIDS Vaccine Development: Challenges and Opportunities , pp. 111-116
    • Beyrer, C.1
  • 829
    • 43949099690 scopus 로고    scopus 로고
    • Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
    • Priddy F.H., Brown D., Kublin J., et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 2008, 46:1769-1781.
    • (2008) Clin Infect Dis , vol.46 , pp. 1769-1781
    • Priddy, F.H.1    Brown, D.2    Kublin, J.3
  • 830
    • 44949100369 scopus 로고    scopus 로고
    • Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans
    • Watkins D.I., Burton D.R., Kallas E.G., et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621.
    • (2008) Nat Med , vol.14 , pp. 617-621
    • Watkins, D.I.1    Burton, D.R.2    Kallas, E.G.3
  • 831
    • 79952445068 scopus 로고    scopus 로고
    • Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial
    • Rolland M., Tovanabutra S., Decamp A.C., et al. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat Med 2011, 17:366-371.
    • (2011) Nat Med , vol.17 , pp. 366-371
    • Rolland, M.1    Tovanabutra, S.2    Decamp, A.C.3
  • 832
    • 68349130410 scopus 로고    scopus 로고
    • Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells
    • Hutnick N.A., Carnathan D.G., Dubey S.A., et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 2009, 15:876-878.
    • (2009) Nat Med , vol.15 , pp. 876-878
    • Hutnick, N.A.1    Carnathan, D.G.2    Dubey, S.A.3
  • 833
    • 68349135329 scopus 로고    scopus 로고
    • Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans
    • O'Brien K.L., Liu J., King S.L., et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med 2009, 15:873-875.
    • (2009) Nat Med , vol.15 , pp. 873-875
    • O'Brien, K.L.1    Liu, J.2    King, S.L.3
  • 834
    • 77955517683 scopus 로고    scopus 로고
    • HIV vaccines: lessons learned and the way forward
    • Kim J.H., Rerks-Ngarm S., Excler J.L., et al. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010, 5:428-434.
    • (2010) Curr Opin HIV AIDS , vol.5 , pp. 428-434
    • Kim, J.H.1    Rerks-Ngarm, S.2    Excler, J.L.3
  • 835
    • 79953019952 scopus 로고    scopus 로고
    • Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials
    • Gilbert P.B., Berger J.O., Stablein D., et al. Statistical interpretation of the RV144 HIV Vaccine Efficacy Trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011, 203:969-975.
    • (2011) J Infect Dis , vol.203 , pp. 969-975
    • Gilbert, P.B.1    Berger, J.O.2    Stablein, D.3
  • 836
    • 84859393693 scopus 로고    scopus 로고
    • Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    • Apr 5
    • Haynes B.F., Gilbert P.B., McElrath M.J., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012 Apr 5, 366(14):1275-1286.
    • (2012) N Engl J Med , vol.366 , Issue.14 , pp. 1275-1286
    • Haynes, B.F.1    Gilbert, P.B.2    McElrath, M.J.3
  • 837
    • 69749111528 scopus 로고    scopus 로고
    • Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults
    • Harro C., Sun X., Stek J.E., et al. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults. Clin Vaccine Immunol 2009, 16:1285-1292.
    • (2009) Clin Vaccine Immunol , vol.16 , pp. 1285-1292
    • Harro, C.1    Sun, X.2    Stek, J.E.3
  • 838
    • 77949263061 scopus 로고    scopus 로고
    • Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
    • Barouch D.H., O'Brien K.L., Simmons N.L., et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 2010, 16:319-323.
    • (2010) Nat Med , vol.16 , pp. 319-323
    • Barouch, D.H.1    O'Brien, K.L.2    Simmons, N.L.3
  • 839
    • 54949106244 scopus 로고    scopus 로고
    • Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara
    • Sandstrom E., Nilsson C., Hejdeman B., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198:1482-1490.
    • (2008) J Infect Dis , vol.198 , pp. 1482-1490
    • Sandstrom, E.1    Nilsson, C.2    Hejdeman, B.3
  • 840
    • 78649733251 scopus 로고    scopus 로고
    • Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate
    • Currier J.R., Ngauy V., de Souza M.S., et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate. PLoS One 2010, 5:e13983.
    • (2010) PLoS One , vol.5
    • Currier, J.R.1    Ngauy, V.2    de Souza, M.S.3
  • 841
    • 67649338409 scopus 로고    scopus 로고
    • Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
    • Gudmundsdotter L., Nilsson C., Brave A., et al. Recombinant modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27:4468-4474.
    • (2009) Vaccine , vol.27 , pp. 4468-4474
    • Gudmundsdotter, L.1    Nilsson, C.2    Brave, A.3
  • 842
    • 44749088148 scopus 로고    scopus 로고
    • EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone
    • McCormack S., Stohr W., Barber T., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26:3162-3174.
    • (2008) Vaccine , vol.26 , pp. 3162-3174
    • McCormack, S.1    Stohr, W.2    Barber, T.3
  • 843
    • 77957871228 scopus 로고    scopus 로고
    • The safety and immunogenicity of the replicative Tiantan Vaccinia HIV vaccine in phase I clinical trial. Presented as a poster at AIDS
    • Cape Town, South Africa; Oct 13-16, 2008. Poster pp., 1
    • Shao Y., Li T., Shen X., et al. the safety and immunogenicity of the replicative Tiantan Vaccinia HIV vaccine in phase I clinical trial. Presented as a poster at AIDS. Vaccine 2008, 13-18. Cape Town, South Africa; Oct 13-16, 2008. Poster pp., 1.
    • (2008) Vaccine , pp. 13-18
    • Shao, Y.1    Li, T.2    Shen, X.3
  • 844
    • 48449105674 scopus 로고    scopus 로고
    • The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
    • Kennedy J.S., Co M., Green S., et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008, 26:4420-4424.
    • (2008) Vaccine , vol.26 , pp. 4420-4424
    • Kennedy, J.S.1    Co, M.2    Green, S.3
  • 845
    • 0030896310 scopus 로고    scopus 로고
    • Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity
    • Tubiana R., Gomard E., Fleury H., et al. Vaccine therapy in early HIV-1 infection using a recombinant canarypox virus expressing gp160MN (ALVAC-HIV): a double-blind controlled randomized study of safety and immunogenicity. AIDS 1997, 11:819-820.
    • (1997) AIDS , vol.11 , pp. 819-820
    • Tubiana, R.1    Gomard, E.2    Fleury, H.3
  • 846
    • 10544220020 scopus 로고    scopus 로고
    • Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
    • Eron J.J., Ashby M.A., Giordano M.F., et al. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection. Lancet 1996, 348:1547-1551.
    • (1996) Lancet , vol.348 , pp. 1547-1551
    • Eron, J.J.1    Ashby, M.A.2    Giordano, M.F.3
  • 847
    • 77958464026 scopus 로고    scopus 로고
    • A tonsillar polyICLC/At-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation
    • Vagenas P., Aravantinou M., Williams V.G., et al. A tonsillar polyICLC/At-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS One 2010, 5:1-13.
    • (2010) PLoS One , vol.5 , pp. 1-13
    • Vagenas, P.1    Aravantinou, M.2    Williams, V.G.3
  • 848
    • 50849140177 scopus 로고    scopus 로고
    • + central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization
    • + central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. Vaccine 2008, 26:5107-5110.
    • (2008) Vaccine , vol.26 , pp. 5107-5110
    • Gudmundsdotter, L.1    Boström, A.C.2    Burton, C.3
  • 849
    • 73349096659 scopus 로고    scopus 로고
    • Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate
    • Bellino S., Francavilla V., Longo O., et al. Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009, 4:195-204.
    • (2009) Rev Recent Clin Trials , vol.4 , pp. 195-204
    • Bellino, S.1    Francavilla, V.2    Longo, O.3
  • 850
    • 67349268940 scopus 로고    scopus 로고
    • Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up
    • Longo O., Tripiciano A., Fiorelli V., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27:3306-3312.
    • (2009) Vaccine , vol.27 , pp. 3306-3312
    • Longo, O.1    Tripiciano, A.2    Fiorelli, V.3
  • 851
    • 79952706286 scopus 로고    scopus 로고
    • Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a phase I safety study
    • Kityo C., Bousheri S., Akao J., et al. Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a phase I safety study. Vaccine 2011, 29:1617-1623.
    • (2011) Vaccine , vol.29 , pp. 1617-1623
    • Kityo, C.1    Bousheri, S.2    Akao, J.3
  • 852
    • 77954962865 scopus 로고    scopus 로고
    • Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection
    • Jones T. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. Curr Opin Invest Drugs 2010, 11:964-970.
    • (2010) Curr Opin Invest Drugs , vol.11 , pp. 964-970
    • Jones, T.1
  • 853
    • 78349309046 scopus 로고    scopus 로고
    • Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides
    • Kran A.M., Jonassen T.O., Sommerfelt M.A., et al. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides. AIDS 2010, 24:2609-2618.
    • (2010) AIDS , vol.24 , pp. 2609-2618
    • Kran, A.M.1    Jonassen, T.O.2    Sommerfelt, M.A.3
  • 854
    • 70449713593 scopus 로고    scopus 로고
    • Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
    • Cobb A.J., Mead H., Montes M., et al. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens. Retrovirology 2009, 6(suppl. 3):19-45.
    • (2009) Retrovirology , vol.6 , Issue.SUPPL.. 3 , pp. 19-45
    • Cobb, A.J.1    Mead, H.2    Montes, M.3
  • 855
    • 40449119721 scopus 로고    scopus 로고
    • Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
    • Connolly N.C., Whiteside T.L., Wilson C., et al. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15:284-292.
    • (2008) Clin Vaccine Immunol , vol.15 , pp. 284-292
    • Connolly, N.C.1    Whiteside, T.L.2    Wilson, C.3
  • 856
    • 70349299844 scopus 로고    scopus 로고
    • A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy
    • Gandhi R.T., O'Neill D., Bosch R.J., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27:6088-6094.
    • (2009) Vaccine , vol.27 , pp. 6088-6094
    • Gandhi, R.T.1    O'Neill, D.2    Bosch, R.J.3
  • 857
    • 77954990423 scopus 로고    scopus 로고
    • Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART
    • Macatangay B.J., Szajnik M.E., Whiteside T.L., et al. Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One 2010, 5:e9852.
    • (2010) PLoS One , vol.5
    • Macatangay, B.J.1    Szajnik, M.E.2    Whiteside, T.L.3
  • 858
    • 70349784438 scopus 로고    scopus 로고
    • Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine
    • Lopez A., van der Lubbe N., Sanchez-Palomino S., et al. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine 2009, 27:6166-6178.
    • (2009) Vaccine , vol.27 , pp. 6166-6178
    • Lopez, A.1    van der Lubbe, N.2    Sanchez-Palomino, S.3
  • 859
    • 73549125003 scopus 로고    scopus 로고
    • Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
    • Routy J.P., Boulassel M.R., Yassine-Diab B., et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010, 134:140-147.
    • (2010) Clin Immunol , vol.134 , pp. 140-147
    • Routy, J.P.1    Boulassel, M.R.2    Yassine-Diab, B.3
  • 860
    • 77954973455 scopus 로고    scopus 로고
    • Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
    • Routy J.P., Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2010, 2:467-476.
    • (2010) Immunotherapy , vol.2 , pp. 467-476
    • Routy, J.P.1    Nicolette, C.2
  • 861
    • 77955671541 scopus 로고    scopus 로고
    • AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein
    • Schooley R.T., Spritzler J., Wang H., et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010, 202:705-716.
    • (2010) J Infect Dis , vol.202 , pp. 705-716
    • Schooley, R.T.1    Spritzler, J.2    Wang, H.3
  • 862
    • 56649097350 scopus 로고    scopus 로고
    • Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy
    • Greenough T.C., Cunningham C.K., Muresan P., et al. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine 2008, 26:6883-6893.
    • (2008) Vaccine , vol.26 , pp. 6883-6893
    • Greenough, T.C.1    Cunningham, C.K.2    Muresan, P.3
  • 863
    • 38949098104 scopus 로고    scopus 로고
    • Therapeutic vaccination reduces HIV sequence variability
    • Hoffmann D., Seebach J., Cosma A., et al. Therapeutic vaccination reduces HIV sequence variability. FASEB J 2008, 22:437-444.
    • (2008) FASEB J , vol.22 , pp. 437-444
    • Hoffmann, D.1    Seebach, J.2    Cosma, A.3
  • 864
    • 78650311033 scopus 로고    scopus 로고
    • Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine
    • Papagno L., Alter G., Assoumou L., et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011, 25:27-36.
    • (2011) AIDS , vol.25 , pp. 27-36
    • Papagno, L.1    Alter, G.2    Assoumou, L.3
  • 865
    • 79955523128 scopus 로고    scopus 로고
    • The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children
    • Palma P., Romiti M.L., Li Pira G., et al. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children. Vaccine 2011, 29:6810-6816.
    • (2011) Vaccine , vol.29 , pp. 6810-6816
    • Palma, P.1    Romiti, M.L.2    Li Pira, G.3
  • 866
    • 77954637904 scopus 로고    scopus 로고
    • Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
    • Rosenberg E.S., Graham B.S., Chan E.S., et al. Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 2010, 5:e10555.
    • (2010) PLoS One , vol.5
    • Rosenberg, E.S.1    Graham, B.S.2    Chan, E.S.3
  • 867
    • 77955067596 scopus 로고    scopus 로고
    • The renaissance in HIV vaccine development: future directions
    • Koff W.C., Berkley S.F. The renaissance in HIV vaccine development: future directions. N Engl J Med 2010, 363:e7.
    • (2010) N Engl J Med , vol.363
    • Koff, W.C.1    Berkley, S.F.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.